<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open-access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6426199</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0212785</article-id><article-id pub-id-type="publisher-id">PONE-D-18-27034</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Headaches</subject><subj-group><subject>Migraine</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Headaches</subject><subj-group><subject>Migraine</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Headaches</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Headaches</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Headaches</subject><subj-group><subject>Tension-Type Headache</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Headaches</subject><subj-group><subject>Tension-Type Headache</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Complementary and Alternative Medicine</subject><subj-group><subject>Acupuncture</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pain Management</subject><subj-group><subject>Acupuncture</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Research Design</subject><subj-group><subject>Clinical Research Design</subject><subj-group><subject>Comparative Effectiveness Research</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Mathematical and Statistical Techniques</subject><subj-group><subject>Statistical Methods</subject><subj-group><subject>Metaanalysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics</subject><subj-group><subject>Statistical Methods</subject><subj-group><subject>Metaanalysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Headaches</subject><subj-group><subject>Secondary Headaches</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Headaches</subject><subj-group><subject>Secondary Headaches</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drugs</subject><subj-group><subject>Analgesics</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pain Management</subject><subj-group><subject>Analgesics</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis</article-title><alt-title alt-title-type="running-head">Beta-blockers for preventing headaches</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9820-5834</contrib-id><name><surname>Jackson</surname><given-names>Jeffrey L.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Kuriyama</surname><given-names>Akira</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Kuwatsuka</surname><given-names>Yachiyo</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Nickoloff</surname><given-names>Sarah</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Storch</surname><given-names>Derek</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Jackson</surname><given-names>Wilkins</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhang</surname><given-names>Zhi-Jiang</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Hayashino</surname><given-names>Yasuaki</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Medicine, Zablocki VA Medical Center, Milwaukee, WI, United States of America</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of General Medicine, Kurashiki Central Hospital, Okayama, Japan</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Medicine, Nagoya University Hospital, Nagoya, Japan</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Department of Biology, University of Wisconsin-Milwaukee, Milwaukee, WI, United States of America</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Department of Epidemiology and Biostatistics, School of Health Sciences, Wuhan University, Wuhan, China</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>Department of Endocrinology, Tenri Hospital, Nara, Japan</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Kwok</surname><given-names>Chun Shing</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Keele University, UNITED KINGDOM</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>jjackson@mcw.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>3</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>14</volume><issue>3</issue><elocation-id>e0212785</elocation-id><history><date date-type="received"><day>18</day><month>9</month><year>2018</year></date><date date-type="accepted"><day>10</day><month>2</month><year>2019</year></date></history><permissions><license xlink:href="https://creativecommons.org/publicdomain/zero/1.0/"><license-p>This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0</ext-link> public domain dedication.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0212785.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Headaches are a common source of pain and suffering. The study&#x02019;s purpose was to assess beta-blockers efficacy in preventing migraine and tension-type headache.</p></sec><sec id="sec002"><title>Methods</title><p>Cochrane Register of Controlled Trials; MEDLINE; EMBASE; ISI Web of Science, clinical trial registries, CNKI, Wanfang and CQVIP were searched through 21 August 2018, for randomized trials in which at least one comparison was a beta-blocker for the prevention of migraine or tension-type headache in adults. The primary outcome, headache frequency per month, was extracted in duplicate and pooled using random effects models.</p></sec><sec id="sec003"><title>Data synthesis</title><p>This study included 108 randomized controlled trials, 50 placebo-controlled and 58 comparative effectiveness trials. Compared to placebo, propranolol reduced episodic migraine headaches by 1.5 headaches/month at 8 weeks (95% CI: -2.3 to -0.65) and was more likely to reduce headaches by 50% (RR: 1.4, 95% CI: 1.1&#x02013;1.7). Trial Sequential Analysis (TSA) found that these outcomes were unlikely to be due to a Type I error. A network analysis suggested that beta-blocker&#x02019;s benefit for episodic migraines may be a class effect. Trials comparing beta-blockers to other interventions were largely single, underpowered trials. Propranolol was comparable to other medications known to be effective including flunarizine, topiramate and valproate. For chronic migraine, propranolol was more likely to reduce headaches by at least 50% (RR: 2.0, 95% CI: 1.0&#x02013;4.3). There was only one trial of beta-blockers for tension-type headache.</p></sec><sec id="sec004"><title>Conclusions</title><p>There is high quality evidence that propranolol is better than placebo for episodic migraine headache. Other comparisons were underpowered, rated as low-quality based on only including single trials, making definitive conclusions about comparative effectiveness impossible. There were few trials examining beta-blocker effectiveness for chronic migraine or tension-type headache though there was limited evidence of benefit.</p></sec><sec id="sec005"><title>Registration</title><p>Prospero (ID: <ext-link ext-link-type="uri" xlink:href="https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=50335">CRD42017050335</ext-link>).</p></sec></abstract><funding-group><funding-statement>The authors received no specific funding for this work.</funding-statement></funding-group><counts><fig-count count="6"/><table-count count="6"/><page-count count="38"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>Dara are available at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.6084/m9.figshare.7674092">https://doi.org/10.6084/m9.figshare.7674092</ext-link>.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>Dara are available at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.6084/m9.figshare.7674092">https://doi.org/10.6084/m9.figshare.7674092</ext-link>.</p></notes></front><body><sec sec-type="intro" id="sec006"><title>Introduction</title><p>Headaches are a common problem, world-wide. The two most common types of headaches are migraine and tension-type. Migraines have a prevalence of 6&#x02013;8% [<xref rid="pone.0212785.ref001" ref-type="bibr">1</xref>&#x02013;<xref rid="pone.0212785.ref009" ref-type="bibr">9</xref>], and cause significant disability [<xref rid="pone.0212785.ref010" ref-type="bibr">10</xref>&#x02013;<xref rid="pone.0212785.ref013" ref-type="bibr">13</xref>], even during periods between attacks [<xref rid="pone.0212785.ref014" ref-type="bibr">14</xref>]. Migraines are responsible for $1 billion in medical costs and $16 billion in lost productivity per year [<xref rid="pone.0212785.ref015" ref-type="bibr">15</xref>;<xref rid="pone.0212785.ref016" ref-type="bibr">16</xref>] in the US alone. While episodic migraine is more common than chronic migraine, chronic migraine has greater disability as well as financial and occupational consequences [8;9] and has received much greater research attention [<xref rid="pone.0212785.ref017" ref-type="bibr">17</xref>].</p><p>Tension-type headache is more common than migraine; up to 90% of adults experience one at some time in their life [<xref rid="pone.0212785.ref018" ref-type="bibr">18</xref>&#x02013;<xref rid="pone.0212785.ref022" ref-type="bibr">22</xref>]. In any given month, a tension-type headache occurs in 46% of adults [<xref rid="pone.0212785.ref022" ref-type="bibr">22</xref>]. Most tension-type headaches are managed with over the counter medications, consequently most do not seek medical attention. However, tension-type headache reduces the quality of life [<xref rid="pone.0212785.ref023" ref-type="bibr">23</xref>], results in up to a fifth of all missed work days [<xref rid="pone.0212785.ref024" ref-type="bibr">24</xref>], and costs EUR 21 billion annually in Europe [<xref rid="pone.0212785.ref025" ref-type="bibr">25</xref>].</p><p>There are several options available for preventing migraines including alpha antagonists, antiepileptics [<xref rid="pone.0212785.ref026" ref-type="bibr">26</xref>], beta-blockers [<xref rid="pone.0212785.ref027" ref-type="bibr">27</xref>], botulinum toxin-A [<xref rid="pone.0212785.ref028" ref-type="bibr">28</xref>], calcium channel blockers [<xref rid="pone.0212785.ref029" ref-type="bibr">29</xref>], flunarizine [<xref rid="pone.0212785.ref017" ref-type="bibr">17</xref>], pizotifen [<xref rid="pone.0212785.ref017" ref-type="bibr">17</xref>], serotonin agonists [<xref rid="pone.0212785.ref030" ref-type="bibr">30</xref>], serotonin reuptake inhibitors (SSRIs) [<xref rid="pone.0212785.ref031" ref-type="bibr">31</xref>] and tricyclic antidepressants (TCAs) [<xref rid="pone.0212785.ref032" ref-type="bibr">32</xref>]. Nearly half of males and a third of females who are candidates for prophylactic therapy do not receive it [<xref rid="pone.0212785.ref033" ref-type="bibr">33</xref>]. Selection of prophylactic treatment is tailored on individual patient characteristics, costs, perceived efficacy of the intervention and side effects of the available options.</p><p>The 2012 American Academy of Neurology guideline recommends beta-blockers, specifically propranolol and metoprolol, as first line therapy for preventing migraines [<xref rid="pone.0212785.ref034" ref-type="bibr">34</xref>]. Specific medications commonly used in prophylaxis has not been well described. In Europe, commonly prescribed prophylactic agents include antiepileptics, beta-blockers, flunarizine, pizotifen and TCAs [<xref rid="pone.0212785.ref035" ref-type="bibr">35</xref>]. Other studies found that specialists are twice as likely to prescribe antiepileptics than primary care providers [<xref rid="pone.0212785.ref036" ref-type="bibr">36</xref>], that treatment persistence is low [<xref rid="pone.0212785.ref037" ref-type="bibr">37</xref>] and that use of prophylactic medications has increased [<xref rid="pone.0212785.ref038" ref-type="bibr">38</xref>], though none of these three characterized the specific medications used.</p><p>The purpose of this study is to assess the efficacy of beta-blockers in the prophylaxis of migraine and tension-type headache. Two previous systematic reviews focused on the use of beta-blockers in migraine headaches, both are more than 15 years old [<xref rid="pone.0212785.ref039" ref-type="bibr">39</xref>;<xref rid="pone.0212785.ref040" ref-type="bibr">40</xref>], and included limited outcomes, though both suggest benefit of beta-blockers compared to placebo. There are two more recent comparative effectiveness analyses of headache management that included beta-blockers. Shamliyan reviewed pharmacologic treatment for episodic migraine and reported that beta-blockers were effective; their outcome was 50% reduction in headaches, an outcome recommended by the International Headache Society (IHS) as a secondary outcome. They also excluded beta-blockers not approved for headaches in the U.S [<xref rid="pone.0212785.ref041" ref-type="bibr">41</xref>]. In the other meta-analysis, we found that beta-blockers were beneficial for migraine headaches, but did not differentiate between episodic and chronic migraine headaches, did not include all possible outcomes and did not examine beta-blockers for management of tension-type headache [<xref rid="pone.0212785.ref017" ref-type="bibr">17</xref>].</p></sec><sec sec-type="materials|methods" id="sec007"><title>Methods</title><p>This study was conducted in accordance with PRISMA guidelines (<xref ref-type="supplementary-material" rid="pone.0212785.s001">S1 Table</xref>. Prisma Checklist) [<xref rid="pone.0212785.ref042" ref-type="bibr">42</xref>] and was registered in PROSPERO (ID: CRD42017050335). Databases searched (without language restriction) included the Cochrane Central Register of Controlled Clinical Trials, MEDLINE, EMBASE, ISI Web of Science (SCI, SSCI, CPCI-S &#x00026; CPCI-SSH), and three Chinese databases (CNKI, Wanfang and CQVIP) trough 21 August 2018 using the search strategies in supporting information (<xref ref-type="supplementary-material" rid="pone.0212785.s002">S2 Table</xref>. Search Strategy). Randomized controlled studies of adults that were at least four weeks in duration and used a beta-blocker in at least one study arm were included. Articles were assessed for inclusion in duplicate (JLJ, AK). Because the definition of headache has changed over time, articles were reviewed by at least two authors to determine if the headache could be reasonably classified as migraine or tension-type headache and as either frequent episodic or chronic according to the most recent IHS criteria [<xref rid="pone.0212785.ref043" ref-type="bibr">43</xref>]. IHS recommendations were followed by including only patient-reported outcomes [<xref rid="pone.0212785.ref044" ref-type="bibr">44</xref>] and including the monthly headache frequency as the primary outcome. Additional outcomes included headache index, headache days, severity, duration, quality of life, the use of acute analgesic medications, the proportion with at least 50% improvement in headaches, study withdrawal and the occurrence of adverse events. Data were abstracted in duplicate. Because of the large volume of articles, after training on a separate set of pediatric headache articles, the articles were divided among the authors with all authors serving as the primary abstractor for some articles and as the secondary reviewer, assessing for data accuracy in other articles. Disagreements resolved through consensus between the two and if consensus could not be reached, the entire group discussed and made consensual decisions.</p><p>Bias was assessed using the Cochrane risk of bias instrument [<xref rid="pone.0212785.ref045" ref-type="bibr">45</xref>] as well as the JADAD scale [<xref rid="pone.0212785.ref046" ref-type="bibr">46</xref>]. Study size was also included as a risk of bias based on sample size calculations. It was estimated that 60 subjects were required for continuous outcomes and 200 for dichotomous ones (<xref ref-type="supplementary-material" rid="pone.0212785.s003">S3 Table</xref>. Quality Ratings of Included Trials) based on results from our previous review of treatment of migraine headaches [<xref rid="pone.0212785.ref017" ref-type="bibr">17</xref>]. Studies with more than one arm were pooled into a single arm (if the study reported no differences between arms). For crossover trials, several approaches were used, depending on how the data was reported. For trials that provided only pooled data from both time-periods, the sample size was reduced by 50%, to avoid over-weighting the study [<xref rid="pone.0212785.ref045" ref-type="bibr">45</xref>]. For trials that provided data from both time periods separately, if there was no difference between the two-time periods, the average point estimates and variance was used, with reduction of the sample size by 50%.</p><p>The preference was to pool study outcomes in their original unit of analysis. Headache frequency was pooled as headache days per month, headache duration as hours per month, and analgesic use as number of doses per month. Since headache severity and headache index metrics varied, these outcomes were pooled using standardized mean differences [<xref rid="pone.0212785.ref047" ref-type="bibr">47</xref>]. Missing outcome variances were imputed from the reported mean, sample size, and P values [<xref rid="pone.0212785.ref048" ref-type="bibr">48</xref>]. Heterogeneity was assessed using Chi<sup>2</sup> (Cochrane Q), Galbraith plots [<xref rid="pone.0212785.ref049" ref-type="bibr">49</xref>] and the I<sup>2</sup> statistic [<xref rid="pone.0212785.ref050" ref-type="bibr">50</xref>]. Data were pooled at each reported time point using a random-effects model [<xref rid="pone.0212785.ref051" ref-type="bibr">51</xref>] using Stata (V15.1 College Station TX). A priori, the analytic plan was to pool data at 4, 8, 12, 16, 20 and 24 weeks. Studies that reported outcomes at different time points were combined at the closest time point available (for example, 9-week outcomes were pooled with the 8-week group). For comparative effectiveness trials with 2 or fewer studies, outcomes were reported at the last point reported. Small study effects (publication bias) was assessed using the methods of Peters [<xref rid="pone.0212785.ref052" ref-type="bibr">52</xref>] for dichotomous outcomes and Egger [<xref rid="pone.0212785.ref053" ref-type="bibr">53</xref>] for continuous outcomes if there were a sufficient number of studies. Trial sequential analysis was performed for the comparisons of propranolol to placebo for headache frequency (at 8 weeks), using the O&#x02019;Brien-Fleming method of alpha-spending function to robustness of the pooled estimates against type 1 and type 2 error [<xref rid="pone.0212785.ref054" ref-type="bibr">54</xref>], using TSA software (Copenhagen, Denmark).</p><p>A network meta-analysis was performed for beta-blockers that were compared with placebo at 8 and 12 weeks using the residual maximum likelihood with a modification to the coefficients&#x02019; estimated variance using the Kapp and Hartung approach [<xref rid="pone.0212785.ref055" ref-type="bibr">55</xref>] that had a minimum of 2 studies. Both 8- and 12-week results were pooled including all beta-blockers using multivariate random-effects meta-analysis using the network package in STATA [<xref rid="pone.0212785.ref056" ref-type="bibr">56</xref>].</p><p>Finally, the quality of evidence was assessed using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) system to rate the quality of the evidence (GRADEPro GDT 2015) following Cochrane guidelines [<xref rid="pone.0212785.ref045" ref-type="bibr">45</xref>]. Grade assesses quality in four levels: High (further research is unlikely to change estimate of effect); Moderate (further research may impact effect estimate); Low (further research is likely to have important impact on estimate); Very low (any estimate of effect is very uncertain).</p></sec><sec sec-type="results" id="sec008"><title>Results</title><p>The literature search yielded 3513 unique studies after excluding duplicates. Application of inclusion and exclusion criteria (<xref ref-type="fig" rid="pone.0212785.g001">Fig 1</xref>) resulted in 108 randomized controlled trials [<xref rid="pone.0212785.ref057" ref-type="bibr">57</xref>&#x02013;<xref rid="pone.0212785.ref164" ref-type="bibr">164</xref>], of which 50 had a placebo arm [57&#x02013;59;62;68;69;71;72;75;77&#x02013;79;81&#x02013;83;88;94&#x02013;97;99;107;108;113;115;116;118;121&#x02013;124;126;130;133&#x02013;138;141;142;144;145;147;149;151;152;152;154;156;157;162]. Because some placebo-controlled trials included non-placebo comparisons, there were a total of 86 comparative effectiveness arms. Nearly all trials (n = 106) focused on migraine headaches, most (n = 83) could be classified as episodic. Only 4 trials studied chronic migraines [76;105;129;151] and there was only 1 trial of beta-blockers for chronic tension-type headache [<xref rid="pone.0212785.ref057" ref-type="bibr">57</xref>].</p><fig id="pone.0212785.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0212785.g001</object-id><label>Fig 1</label><caption><title>PRISMA flow chart.</title></caption><graphic xlink:href="pone.0212785.g001"/></fig><p>The 108 included studies ranged from 4 to 64 weeks in duration (average: 12.9). Fifty-one were parallel in design and 57 had a crossover design. Among crossover trials, 43 were randomized, with washout periods ranging from zero to four weeks. Twenty-five different countries (<xref rid="pone.0212785.t001" ref-type="table">Table 1</xref>) and four languages (Chinese (n = 15), English (n = 86), German (n = 6), Polish (n = 1) were represented. The average age was 38.6 years and 77% of participants were women. Ten different beta-blockers were studied. Propranolol (n = 74) and metoprolol (n = 21) were the most commonly evaluated beta-blockers. Atenolol, nadolol, pindolol and timolol had two studies each. Several beta-blockers were evaluated in only a single trial (acebutolol, alprenolol, bisoprolol and oxprenolol). Study characteristics for included trials are provided in <xref rid="pone.0212785.t001" ref-type="table">Table 1</xref> and quality ratings are given in <xref ref-type="supplementary-material" rid="pone.0212785.s002">S2 Table</xref>.</p><table-wrap id="pone.0212785.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0212785.t001</object-id><label>Table 1</label><caption><title>Included trial characteristics.</title></caption><alternatives><graphic id="pone.0212785.t001g" xlink:href="pone.0212785.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Study, Year, Country</th><th align="left" rowspan="1" colspan="1">Comparison (mg)</th><th align="left" rowspan="1" colspan="1">Headache Type</th><th align="left" rowspan="1" colspan="1">Classification</th><th align="left" rowspan="1" colspan="1">Design</th><th align="left" rowspan="1" colspan="1">Duration (weeks)</th><th align="left" rowspan="1" colspan="1">Sample Size (dropout %)</th><th align="left" rowspan="1" colspan="1">Age</th><th align="left" rowspan="1" colspan="1">Women</th><th align="left" rowspan="1" colspan="1">Dose titrated</th><th align="left" rowspan="1" colspan="1">Rescue Medication Allowed</th></tr></thead><tbody><tr><td align="left" colspan="11" rowspan="1"><bold>Acebutolol</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Nanda, 1978, Scotland</td><td align="left" rowspan="1" colspan="1">Acebutolol (800) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">43 (23%)</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">74%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" colspan="11" rowspan="1"><bold>Alprenolol</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Ekbom, 1975, Sweden</td><td align="left" rowspan="1" colspan="1">Alprenolol (200) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad-hoc 1962</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">33 (15)</td><td align="left" rowspan="1" colspan="1">41.5</td><td align="left" rowspan="1" colspan="1">82%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" colspan="11" rowspan="1"><bold>Atenolol</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Forssman, 1983, Sweden</td><td align="left" rowspan="1" colspan="1">Atenolol (100) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-unspecified</td><td align="left" rowspan="1" colspan="1">Ad-hoc 1962</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">24 (17)</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">80%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Johannsson, 1987, Sweden</td><td align="left" rowspan="1" colspan="1">Atenolol (100) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad-hoc 1962</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">72 (13)</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">70%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Stensrud, 1980, Norway</td><td align="left" rowspan="1" colspan="1">Propranolol (160) v. Atenolol (100)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad-hoc 1962</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">35 (20)</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">69%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" colspan="11" rowspan="1"><bold>Bisoprolol</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">van de Ven, 1997, Europe</td><td align="left" rowspan="1" colspan="1">Bisoprolol (5) v. Bisoprolol (10) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">IHS1988</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">226 (14)</td><td align="left" rowspan="1" colspan="1">38.7</td><td align="left" rowspan="1" colspan="1">82%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" colspan="11" rowspan="1"><bold>Metoprolol</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Andersson, 1983, Denmark</td><td align="left" rowspan="1" colspan="1">Metoprolol (200) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">WFNRG 1969</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">71 (13)</td><td align="left" rowspan="1" colspan="1">39.7</td><td align="left" rowspan="1" colspan="1">85%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Diener, 2001, Europe</td><td align="left" rowspan="1" colspan="1">Metoprolol (200) v. Aspirin (300)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">IHS 1988</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">270 (15)</td><td align="left" rowspan="1" colspan="1">39.4</td><td align="left" rowspan="1" colspan="1">81%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Gong, 2016, China</td><td align="left" rowspan="1" colspan="1">Metoprolol (25) + Flunarizine (5) v. Flunarizine (5)</td><td align="left" rowspan="1" colspan="1">Migraine-unspecified</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">80 (0)</td><td align="left" rowspan="1" colspan="1">47.5</td><td align="left" rowspan="1" colspan="1">40%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Grotemeyer, 1988, Germany</td><td align="left" rowspan="1" colspan="1">Metoprolol (200) v. Flunarizine (10)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad hoc 1962</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">29 (17)</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">79%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Grotemeyer, 1990, Germany</td><td align="left" rowspan="1" colspan="1">Metoprolol (200) v. Acetylsalicyclic Acid (1500)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">IHS 1988</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">28 (NS)</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">82%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Hesse, 1994, Denmark</td><td align="left" rowspan="1" colspan="1">Metoprolol (100) v. Acupuncture</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">IHS 1988</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">85 (10)</td><td align="left" rowspan="1" colspan="1">44.7</td><td align="left" rowspan="1" colspan="1">84%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Kangasniemi, 1987, Scandinavia</td><td align="left" rowspan="1" colspan="1">Metoprolol (200) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad-hoc 1962</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">77 (11)</td><td align="left" rowspan="1" colspan="1">37.5</td><td align="left" rowspan="1" colspan="1">80%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Langohr, 1985, Germany</td><td align="left" rowspan="1" colspan="1">Metoprolol (100) v. Clomipramine (100) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad-hoc 1962</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">63 (43)</td><td align="left" rowspan="1" colspan="1">44.4</td><td align="left" rowspan="1" colspan="1">67%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Li, 2006, China</td><td align="left" rowspan="1" colspan="1">Metoprolol (125) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-unspecified</td><td align="left" rowspan="1" colspan="1">IHS 1988</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">60 (0)</td><td align="left" rowspan="1" colspan="1">48.5</td><td align="left" rowspan="1" colspan="1">100%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Louis 1985, Europe</td><td align="left" rowspan="1" colspan="1">Metoprolol (100) v. Clonidine (0.1)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">WFNRG 1969</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">31 (26)</td><td align="left" rowspan="1" colspan="1">35.5</td><td align="left" rowspan="1" colspan="1">81%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Ma, 2011, China</td><td align="left" rowspan="1" colspan="1">Metoprolol (50) + Flunarizine (5) v. Flunarizine (5)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">HIS 2004</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">48</td><td align="left" rowspan="1" colspan="1">56 (0)</td><td align="left" rowspan="1" colspan="1">36.3</td><td align="left" rowspan="1" colspan="1">65%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Schellenberg, 2008, Germany</td><td align="left" rowspan="1" colspan="1">Metoprolol (142.5) v. Nebivolol (5)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">IHS 2004</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">30 (7)</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">87%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Siniatchkin, 2007, Germany</td><td align="left" rowspan="1" colspan="1">Metoprolol (200) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-unspecified</td><td align="left" rowspan="1" colspan="1">IHS2004</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">20 (0%)</td><td align="left" rowspan="1" colspan="1">37</td><td align="left" rowspan="1" colspan="1">85%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Sorensen 1991, Denmark</td><td align="left" rowspan="1" colspan="1">Metoprolol (200) v. Flunarizine (10)</td><td align="left" rowspan="1" colspan="1">Migraine</td><td align="left" rowspan="1" colspan="1">IHS 1988</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">149 (1)</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">79%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Steiner, 1988, UK</td><td align="left" rowspan="1" colspan="1">Metoprolol Cr (100) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Vahlquist 1955</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">59 (NS)</td><td align="left" rowspan="1" colspan="1">37.4</td><td align="left" rowspan="1" colspan="1">76%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Streng 2005, Germany</td><td align="left" rowspan="1" colspan="1">Metoprolol (200) v. Acupuncture)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">IHS 1997</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">114 (17)</td><td align="left" rowspan="1" colspan="1">36.6</td><td align="left" rowspan="1" colspan="1">88%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Vilming, 1985, Sweden</td><td align="left" rowspan="1" colspan="1">Metoprolol (100) v. Pizotifen (1.5)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">WFNRG 1969</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">35 (14)</td><td align="left" rowspan="1" colspan="1">37.6</td><td align="left" rowspan="1" colspan="1">83%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Worz 1992, Germany</td><td align="left" rowspan="1" colspan="1">Metoprolol (200) v. Bisoprolol (10)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">IHS1988</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">125 (38)</td><td align="left" rowspan="1" colspan="1">38.5</td><td align="left" rowspan="1" colspan="1">71%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Yang, 2006, China</td><td align="left" rowspan="1" colspan="1">Metoprolol (90) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">IHS 1988</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">60 (0)</td><td align="left" rowspan="1" colspan="1">48.5</td><td align="left" rowspan="1" colspan="1">100%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Yang, 2016, China</td><td align="left" rowspan="1" colspan="1">Metoprolol (95) v. Metoprolol (95) + Fluoxetine</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">120 (0)</td><td align="left" rowspan="1" colspan="1">38.4</td><td align="left" rowspan="1" colspan="1">64%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Zhou, 2015, China</td><td align="left" rowspan="1" colspan="1">Metoprolol (95) v. Metoprolol (95) + Fluoxetine</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">112 (0)</td><td align="left" rowspan="1" colspan="1">37.0</td><td align="left" rowspan="1" colspan="1">63%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" colspan="11" rowspan="1"><bold>Nadolol</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Freitag, 1984, USA</td><td align="left" rowspan="1" colspan="1">Nadolol (80) v. Nadolol (160) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-unspecified</td><td align="left" rowspan="1" colspan="1">Ad-hoc 1962</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">32 (20)</td><td align="left" rowspan="1" colspan="1">36.7</td><td align="left" rowspan="1" colspan="1">81%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Ryan, 1982, USA</td><td align="left" rowspan="1" colspan="1">Nadolol (80) v. Nadolol (160) v Nadolol (240) v Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">80 (1%)</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">78%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" colspan="11" rowspan="1"><bold>Oxprenolol</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Ekbom, 1977, Sweden</td><td align="left" rowspan="1" colspan="1">Oxprenolol (240) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad-hoc 1962</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">34 (12)</td><td align="left" rowspan="1" colspan="1">41.8</td><td align="left" rowspan="1" colspan="1">76%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" colspan="11" rowspan="1"><bold>Pindolol</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Ekbom, 1972, Sweden</td><td align="left" rowspan="1" colspan="1">Pindolol (7.5) v. Pindolol (15) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad-hoc 1962</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">30 (NS)</td><td align="left" rowspan="1" colspan="1">33.7</td><td align="left" rowspan="1" colspan="1">87%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" colspan="11" rowspan="1"><bold>Pindolol + Amitriptyline</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Agius, 2013, Italy</td><td align="left" rowspan="1" colspan="1">Pindolol (10)+ Amitriptyline (10) v. Amitriptyline (10) v. Placebo</td><td align="left" rowspan="1" colspan="1">Tension-chronic</td><td align="left" rowspan="1" colspan="1">IHS 2004</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">64 (3)</td><td align="left" rowspan="1" colspan="1">35.6</td><td align="left" rowspan="1" colspan="1">74%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Streng, 2005, Germany</td><td align="left" rowspan="1" colspan="1">Metoprolol (200) v. Acupuncture</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">IHS 1997</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">114 (17)</td><td align="left" rowspan="1" colspan="1">36.6</td><td align="left" rowspan="1" colspan="1">88%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" colspan="11" rowspan="1"><bold>Propranolol</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Ahuja, 1985, India</td><td align="left" rowspan="1" colspan="1">Propranolol (120) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad-hoc 1962</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">26 (NS)</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">46%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">al-Qassab, 1993, UK</td><td align="left" rowspan="1" colspan="1">Propranolol (80) v. Propranolol (160) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad-hoc 1962</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">45 (33)</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">80%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Albers, 1989, USA</td><td align="left" rowspan="1" colspan="1">Propranolol (180) v. Nifedipine (60)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad hoc 1962</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">40 (37)</td><td align="left" rowspan="1" colspan="1">35.2</td><td align="left" rowspan="1" colspan="1">89%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Andersson, 1981, Denmark</td><td align="left" rowspan="1" colspan="1">Propranolol (160) v. Femoxitine (400)</td><td align="left" rowspan="1" colspan="1">Migraine</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">49 (24)</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">69%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Ashtari, 2008, Iran</td><td align="left" rowspan="1" colspan="1">Propranolol (80) vs. Topiramate (50)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">IHS 2005</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">62 (3)</td><td align="left" rowspan="1" colspan="1">30.8</td><td align="left" rowspan="1" colspan="1">82%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Baldrati, 1983, Italy</td><td align="left" rowspan="1" colspan="1">Propranolol (80) v. Aspirin (1.9 mg/kg)</td><td align="left" rowspan="1" colspan="1">Migraine-not specified</td><td align="left" rowspan="1" colspan="1">Ad hoc 1962</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">18 (33)</td><td align="left" rowspan="1" colspan="1">33.3</td><td align="left" rowspan="1" colspan="1">89%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Behan, 1980, Scotland</td><td align="left" rowspan="1" colspan="1">Propranolol (120) v. Methysergide (3)</td><td align="left" rowspan="1" colspan="1">Migraine-not specified</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">56 (36)</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">66%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">Bonuso, 1998, Italy</td><td align="left" rowspan="1" colspan="1">Propranolol (80) v. Flunarizine (10)</td><td align="left" rowspan="1" colspan="1">Migraine-not specified</td><td align="left" rowspan="1" colspan="1">IHS 1988</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">50 (16)</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">68%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Bordini, 1997, Brazil</td><td align="left" rowspan="1" colspan="1">Propranolol (60) v. Flunarizine (10) v. Combo.</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">IHS 1988</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">52 (13)</td><td align="left" rowspan="1" colspan="1">31.2</td><td align="left" rowspan="1" colspan="1">91%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Borgesen, 1974, Denmark</td><td align="left" rowspan="1" colspan="1">Propranolol (120) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad-hoc 1962</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">12 (33)</td><td align="left" rowspan="1" colspan="1">37.6</td><td align="left" rowspan="1" colspan="1">83%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Carroll, 1990, UK</td><td align="left" rowspan="1" colspan="1">Propranolol (80) v. Propranolol (160)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad hoc 1962</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">51 (27)</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">69%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Chen, 2009, China</td><td align="left" rowspan="1" colspan="1">Propranolol (60) + Flunarizine (10) v. Topoiramate (100)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">IHS 1988</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">82 (0)</td><td align="left" rowspan="1" colspan="1">38.2</td><td align="left" rowspan="1" colspan="1">60%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Dahlof, 1987, Sweden</td><td align="left" rowspan="1" colspan="1">Propranolol (120) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">WFNRG 1969</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">28 (0)</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">93%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Diener, 1996, German</td><td align="left" rowspan="1" colspan="1">Propranolol (120) v. Cylcendalate (1200) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">IHS 1988</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">214 (17)</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">78%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Diener, 2002, Germany</td><td align="left" rowspan="1" colspan="1">Propranolol (160) v. Flunarizine (5) v. Flunarizine (10)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">IHS 1988</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">808 (18)</td><td align="left" rowspan="1" colspan="1">38.8</td><td align="left" rowspan="1" colspan="1">63%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Diener, 2004, Europe</td><td align="left" rowspan="1" colspan="1">Propranolol (160) v. Topiramate (100) v. Topiramate (200) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">IHS 1988</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">575 (37)</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">80%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Domingues, 2009, Brazil</td><td align="left" rowspan="1" colspan="1">Propranolol (80) v. Nortriptyline (40) v. Combo.</td><td align="left" rowspan="1" colspan="1">Migraine-chronic</td><td align="left" rowspan="1" colspan="1">IHS 2004</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">76 (42)</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">DongXiang, 2010, China</td><td align="left" rowspan="1" colspan="1">Propranolol (90) + Amitriptyline (100) v. Amitriptyline (100)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">HIS 1988</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">310 (0)</td><td align="left" rowspan="1" colspan="1">32.5</td><td align="left" rowspan="1" colspan="1">80%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Formisano, 1991, Italy</td><td align="left" rowspan="1" colspan="1">Propranolol (120) v. Nimodipine (120)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">IHS 1988</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">22 (14)</td><td align="left" rowspan="1" colspan="1">39.2</td><td align="left" rowspan="1" colspan="1">55%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Forssman, 1976, Sweden</td><td align="left" rowspan="1" colspan="1">Propranolol (240) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-unspecified</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">40 (20)</td><td align="left" rowspan="1" colspan="1">37.4</td><td align="left" rowspan="1" colspan="1">88%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Gawel, 1992, Canada</td><td align="left" rowspan="1" colspan="1">Propranolol (120) v. Flunarizine (10)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">WFNRG 1970</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">94 (19)</td><td align="left" rowspan="1" colspan="1">35.9</td><td align="left" rowspan="1" colspan="1">89%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Gerber, 1991, Germany</td><td align="left" rowspan="1" colspan="1">Propranolol (120) v. Metoprolol (150) v. Nifedipine (30)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">IHS 1988</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">58 (NS)</td><td align="left" rowspan="1" colspan="1">42.4</td><td align="left" rowspan="1" colspan="1">73%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Gerber, 1995, Germany</td><td align="left" rowspan="1" colspan="1">Propranolol (120/160) v. Cyclandelate (1200/1600)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">IHS 1988</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">84 (26)</td><td align="left" rowspan="1" colspan="1">40.9</td><td align="left" rowspan="1" colspan="1">90%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Ghobadi, 2013, Iran</td><td align="left" rowspan="1" colspan="1">Propranolol (120) v. Nimodipine (30)</td><td align="left" rowspan="1" colspan="1">Migraine</td><td align="left" rowspan="1" colspan="1">IHS 2004</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">102 (2)</td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">83%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Grotemeyer, 1987, German</td><td align="left" rowspan="1" colspan="1">Propranolol (120) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad-hoc 1962</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">30 (20)</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">73%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Havanka-Kannianen, 1988, Finland</td><td align="left" rowspan="1" colspan="1">Propranolol (80) v. Propranolol (160)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad-hoc 1962</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">48 (13)</td><td align="left" rowspan="1" colspan="1">37.7</td><td align="left" rowspan="1" colspan="1">81%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Hedman, 1986, Denmark</td><td align="left" rowspan="1" colspan="1">Propranolol (80) v. Metoprolol (100)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">WFNRG 1970</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">12 (0)</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">67%</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Holdorff, 1977, Germany</td><td align="left" rowspan="1" colspan="1">Propranolol (120) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad-hoc 1962</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">53 (30)</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Holroyd, 2010, USA</td><td align="left" rowspan="1" colspan="1">Propranolol/Nadolol v. Propranolol/Nadolol + Behavior Therapy v. Behavior therapy v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">IHS 1988</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">64</td><td align="left" rowspan="1" colspan="1">232 (51)</td><td align="left" rowspan="1" colspan="1">38.2</td><td align="left" rowspan="1" colspan="1">79%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Jin, 2001, China</td><td align="left" rowspan="1" colspan="1">Propranolol (30) + Flunarizine (10) v. Diazepam (30) + Nimodipine (60)</td><td align="left" rowspan="1" colspan="1">Migraine</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">84 (0)</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">75%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Johnson, 1986, New Zealand</td><td align="left" rowspan="1" colspan="1">Propranolol (240) Mefenamic Acid (1500) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">29 (41)</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">69%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Kangasniemi 1983, Finland</td><td align="left" rowspan="1" colspan="1">Propranolol (160) v. Femoxetine (400)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">29 (11)</td><td align="left" rowspan="1" colspan="1">37</td><td align="left" rowspan="1" colspan="1">86%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Kangasniemi 1984, Finland</td><td align="left" rowspan="1" colspan="1">Propranolol (240) v. Metoprolol (200)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">WFNRG 1970</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">36 (6)</td><td align="left" rowspan="1" colspan="1">33.8</td><td align="left" rowspan="1" colspan="1">89%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Kaniecki, 1997, USA</td><td align="left" rowspan="1" colspan="1">Propranolol (240) v. Divalproex (1500)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">IHS 1988</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">37 (14)</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">81%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Kass, 1980, Norway</td><td align="left" rowspan="1" colspan="1">Propranolol (160) v. Clonidine (0.1)</td><td align="left" rowspan="1" colspan="1">Migraine-unspecified</td><td align="left" rowspan="1" colspan="1">WFNRG 1970</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">23 (9)</td><td align="left" rowspan="1" colspan="1">39.7</td><td align="left" rowspan="1" colspan="1">30%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Kaushik, 2005, India</td><td align="left" rowspan="1" colspan="1">Propranolol (80) v. Biofeedback</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">IHS 1988</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">192 (13)</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">69%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Ke, 2003, China</td><td align="left" rowspan="1" colspan="1">Propranolol (30) v. Propranolol (30) + Flunarizine (5) v. Flunarizine (5)</td><td align="left" rowspan="1" colspan="1">Migraine-chronic</td><td align="left" rowspan="1" colspan="1">IHS 1988</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">121 (0)</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">74%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Kjaersgard 1994, Denmark</td><td align="left" rowspan="1" colspan="1">Propranolol (120) v. Tolfenamic Acid (300)</td><td align="left" rowspan="1" colspan="1">Migraine-unspecified</td><td align="left" rowspan="1" colspan="1">IHS 1988</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">76 (26)</td><td align="left" rowspan="1" colspan="1">43.3</td><td align="left" rowspan="1" colspan="1">79%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Klapper, 1994,USA</td><td align="left" rowspan="1" colspan="1">Propranolol (140) v. Divalproex (1100)</td><td align="left" rowspan="1" colspan="1">Migraine-unspecified</td><td align="left" rowspan="1" colspan="1">IHS 1988</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">24 (50)</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Unclear</td></tr><tr><td align="left" rowspan="1" colspan="1">Kozubski, 1995, Poland</td><td align="left" rowspan="1" colspan="1">Propranolol (160) Valproaic Acid (1500)</td><td align="left" rowspan="1" colspan="1">Migraine-unspecified</td><td align="left" rowspan="1" colspan="1">IHS 1988</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">35 (NS)</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">100%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Kuritzky, 1987, Israel</td><td align="left" rowspan="1" colspan="1">Propranolol (160) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">38 (18)</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Li, 2002, China</td><td align="left" rowspan="1" colspan="1">Propranolol (30) v. Flunarizine (5)</td><td align="left" rowspan="1" colspan="1">Migraine-Episodic</td><td align="left" rowspan="1" colspan="1">IHS, 1988</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">126 (0)</td><td align="left" rowspan="1" colspan="1">38.7</td><td align="left" rowspan="1" colspan="1">60%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Li, 2004, China</td><td align="left" rowspan="1" colspan="1">Propranolol (60) v. Valproate (.45 mg/kg)</td><td align="left" rowspan="1" colspan="1">Migraine-Episodic</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">40 (0)</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Lucking, 1988, Germany</td><td align="left" rowspan="1" colspan="1">Propranolol (120) v. Flunarizine (10)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">521 (NS)</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">80%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Maissen, 1991, Germany</td><td align="left" rowspan="1" colspan="1">Propranolol (120) v. 5-Hydroxytryptophan (300)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">39 (18)</td><td align="left" rowspan="1" colspan="1">39.4</td><td align="left" rowspan="1" colspan="1">67%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Malvea, 1973, USA</td><td align="left" rowspan="1" colspan="1">Propranolol (NS) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">31 (6)</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">87%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Mathew, 1980, USA</td><td align="left" rowspan="1" colspan="1">Propranolol (160) v. Placebo v. Amitriptyline (75) v. Biofedback</td><td align="left" rowspan="1" colspan="1">Mixed- headaches</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">340 (20)</td><td align="left" rowspan="1" colspan="1">35.5</td><td align="left" rowspan="1" colspan="1">94%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Mikkelsen, 1986, Denmark</td><td align="left" rowspan="1" colspan="1">Propranolol (120) v. Tolfenamic Acid (300) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad-hoc 1962</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">31 (21)</td><td align="left" rowspan="1" colspan="1">39.4</td><td align="left" rowspan="1" colspan="1">84%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Nadelmann, 1986, USA</td><td align="left" rowspan="1" colspan="1">Propranolol (320) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-unspecified</td><td align="left" rowspan="1" colspan="1">Ad-hoc 1962</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">57 (39)</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">86%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Nair, 1975, India</td><td align="left" rowspan="1" colspan="1">Propranolol (80) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">20 (0)</td><td align="left" rowspan="1" colspan="1">27.3</td><td align="left" rowspan="1" colspan="1">50%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">Nambiar, 2011, India</td><td align="left" rowspan="1" colspan="1">Propranolol (80) v. Riboflavin (100)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">IHS 1988</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">100 (NS)</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">55%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Palferman, 1983, UK</td><td align="left" rowspan="1" colspan="1">Propranolol (120) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-unspecified</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">10 (38)</td><td align="left" rowspan="1" colspan="1">41.4</td><td align="left" rowspan="1" colspan="1">80%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Olerud, 1986, Sweden</td><td align="left" rowspan="1" colspan="1">Propranolol (80) v. Nadolol (80)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">28(NS)</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">79%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Pita, 1977, Spain</td><td align="left" rowspan="1" colspan="1">Propranolol (160) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad-hoc 1962</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">9 (0)</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">78%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Pradalier, 1989, Norway</td><td align="left" rowspan="1" colspan="1">Propranolol (160) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">IHS 1988</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">74 (26)</td><td align="left" rowspan="1" colspan="1">37.4</td><td align="left" rowspan="1" colspan="1">76%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Ryan, 1984, USA</td><td align="left" rowspan="1" colspan="1">Propranolol (160) v. Nadolol (80) v. Nadolol (160)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">48 (6)</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">73%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Sargent, 1985, USA</td><td align="left" rowspan="1" colspan="1">Propranolol (120) v. Naproxen (1100) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">149 (16)</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">79%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Shimell, 1990, South Africa</td><td align="left" rowspan="1" colspan="1">Propranolol (180) v. Flunarizine (10)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad hoc 1962</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">58 (2)</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">70%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Silberstein, 2012, USA</td><td align="left" rowspan="1" colspan="1">Propranolol (240) + Topiramate (100) v. Topiramate (100)</td><td align="left" rowspan="1" colspan="1">Migraine-chronic</td><td align="left" rowspan="1" colspan="1">IHS 2006</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">191 (39)</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">90%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Sjaastad, 1972, Norway</td><td align="left" rowspan="1" colspan="1">Pindolol (15) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">28 (14)</td><td align="left" rowspan="1" colspan="1">35.3</td><td align="left" rowspan="1" colspan="1">79%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Soyka, 1990, Germany</td><td align="left" rowspan="1" colspan="1">Propranolol (120) v. Flunarizine (10)</td><td align="left" rowspan="1" colspan="1">Migraine-unspecified</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">434</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">82%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Standnes, 1982, Norway</td><td align="left" rowspan="1" colspan="1">Propranolol (80) v. Timolol (10) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad-hoc 1962</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">25 (28)</td><td align="left" rowspan="1" colspan="1">41.4</td><td align="left" rowspan="1" colspan="1">80%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Stensrud, 1976, Norway</td><td align="left" rowspan="1" colspan="1">Propranolol (160) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad-hoc 1962</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">20 (5)</td><td align="left" rowspan="1" colspan="1">43.5</td><td align="left" rowspan="1" colspan="1">70%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Stensrud, 1980, Norway</td><td align="left" rowspan="1" colspan="1">Propranolol (80) v. Atenolol (50) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad-hoc 1962</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">35 (20)</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">69%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Stovner, 2014, Norway</td><td align="left" rowspan="1" colspan="1">Propranolol (160) v. Candesartan (16) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">72 (15)</td><td align="left" rowspan="1" colspan="1">37</td><td align="left" rowspan="1" colspan="1">82%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Sudilovsky, 1987, USA</td><td align="left" rowspan="1" colspan="1">Propranolol (160) v. Nadolol (80) v. Nadolol (160)</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad hoc 1962</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">140 (30)</td><td align="left" rowspan="1" colspan="1">39.3</td><td align="left" rowspan="1" colspan="1">76%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Tfelt-Hansen, 1984, Scandinavia</td><td align="left" rowspan="1" colspan="1">Propranolol (160) v. Timolol (20) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad-hoc 1962</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">96 (28)</td><td align="left" rowspan="1" colspan="1">39.5</td><td align="left" rowspan="1" colspan="1">74%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Weber, 1971, USA</td><td align="left" rowspan="1" colspan="1">Propranolol (20) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-unspecified</td><td align="left" rowspan="1" colspan="1">Ad-hoc 1962</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">25 (24)</td><td align="left" rowspan="1" colspan="1">40.6</td><td align="left" rowspan="1" colspan="1">52%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Wideroe, 1974, Norway</td><td align="left" rowspan="1" colspan="1">Propranolol (160) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad-hoc 1962</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">30 (13)</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">90%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Wen, 2016, China</td><td align="left" rowspan="1" colspan="1">Propranolol (30) v. Flunarizine (10)</td><td align="left" rowspan="1" colspan="1">Migraine Episodic</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">100 (0)</td><td align="left" rowspan="1" colspan="1">25.6</td><td align="left" rowspan="1" colspan="1">65%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Yuan, 2005, China</td><td align="left" rowspan="1" colspan="1">Propranolol (120) v. Topiramate (150)</td><td align="left" rowspan="1" colspan="1">Migraine-unspecified</td><td align="left" rowspan="1" colspan="1">IHS 1988</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">67 (0)</td><td align="left" rowspan="1" colspan="1">29.9</td><td align="left" rowspan="1" colspan="1">64%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">Zhu, 2005, China</td><td align="left" rowspan="1" colspan="1">Propranolol (30) v. Flunarizine (10)</td><td align="left" rowspan="1" colspan="1">Migraine-unspecified</td><td align="left" rowspan="1" colspan="1">IHS 1988</td><td align="left" rowspan="1" colspan="1">Parallel</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">90 (0)</td><td align="left" rowspan="1" colspan="1">28.1</td><td align="left" rowspan="1" colspan="1">73%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">Ziegler, 1993, USA</td><td align="left" rowspan="1" colspan="1">Propranolol (240) v. Amitriptyline (150) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">54 (44)</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">73%</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" colspan="11" rowspan="1"><bold>Timolol</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Briggs, 1979, UK</td><td align="left" rowspan="1" colspan="1">Timolol (20) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad-hoc 1962</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">14 (7)</td><td align="left" rowspan="1" colspan="1">NS</td><td align="left" rowspan="1" colspan="1">71%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Stellar, 1984, USA</td><td align="left" rowspan="1" colspan="1">Timolol (30) v. Placebo</td><td align="left" rowspan="1" colspan="1">Migraine-episodic</td><td align="left" rowspan="1" colspan="1">Ad-hoc 1962</td><td align="left" rowspan="1" colspan="1">Crossover</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">107 (12)</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">72%</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Yes</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>NS: Not Stated</p></fn></table-wrap-foot></table-wrap><p>Studies had a number of common quality problems (<xref ref-type="supplementary-material" rid="pone.0212785.s003">S3 Table</xref>) including high drop-out rates (16.1%, range 0&#x02013;51%), lack of intention to treat analysis (76%), inadequate sequence generation (83%), lack of evidence of concealed allocation (90%) and inadequate blinding (60%). Twenty-three studies assessed compliance (21%). Fifty-one (47%) studies reported all collected outcomes. Sixteen trials (15%) were sponsored by industry. All comparisons that had only a single study were graded as low-quality evidence.</p><sec id="sec009"><title>Episodic migraines</title><p>The primary outcome was headaches per month. Outcomes from placebo-controlled trials for all beta-blockers and time-points are provided in Tables <xref rid="pone.0212785.t002" ref-type="table">2</xref>&#x02013;<xref rid="pone.0212785.t003" ref-type="table">3</xref>. Outcomes at 8 weeks was the most commonly reported time point. Among patients with episodic migraines (<xref rid="pone.0212785.t002" ref-type="table">Table 2</xref>), the average number of headaches at baseline was 4.9 headaches/month (95% CI: 4.4&#x02013;5.4). The best studied beta-blocker was propranolol, which was more effective than placebo at 8 and 12 weeks (8 weeks: -1.5 ha/month, 95% CI: -2.3 to -0.65); 12 weeks: -1.2 ha/month, 95% CI: -1.8 to -0.60, <xref ref-type="fig" rid="pone.0212785.g002">Fig 2</xref>). Propranolol outcomes at 8 and 12 weeks were both graded as high-quality evidence. TSA analysis of propranolol vs. placebo for headache frequency demonstrated that it is unlikely that these results are due to a Type 1 error (<xref ref-type="fig" rid="pone.0212785.g003">Fig 3</xref>). Other beta-blockers that were more effective than placebo at 8 weeks (<xref ref-type="fig" rid="pone.0212785.g004">Fig 4</xref>) included bisoprolol (-0.70 ha/month, 95% CI: -1.4 to -0.05, low quality), metoprolol (-0.86 ha/month, 95% CI: -1.4 to -0.34, moderate quality) and timolol (-0.77 ha/month, 95% CI: -1.4 to -0.12, moderate quality). The remaining beta-blockers, in single trials did not significantly reduce headache frequency (<xref ref-type="fig" rid="pone.0212785.g003">Fig 3</xref>). There was a similar pattern at twelve weeks.</p><fig id="pone.0212785.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0212785.g002</object-id><label>Fig 2</label><caption><title>Headaches per month, Propranolol v. Placebo.</title></caption><graphic xlink:href="pone.0212785.g002"/></fig><fig id="pone.0212785.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0212785.g003</object-id><label>Fig 3</label><caption><title>Trial Sequential Analysis (Propranolol v. Placebo).</title></caption><graphic xlink:href="pone.0212785.g003"/></fig><fig id="pone.0212785.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0212785.g004</object-id><label>Fig 4</label><caption><title>Headaches per month, other Beta Blockers v Placebo.</title></caption><graphic xlink:href="pone.0212785.g004"/></fig><table-wrap id="pone.0212785.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0212785.t002</object-id><label>Table 2</label><caption><title>Placebo controlled primary outcome (headache frequency per month).</title></caption><alternatives><graphic id="pone.0212785.t002g" xlink:href="pone.0212785.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" colspan="4" rowspan="1">Episodic Migraines</th></tr><tr><th align="left" rowspan="1" colspan="1">Time point</th><th align="left" rowspan="1" colspan="1">Weighted Mean Difference (95% CI)</th><th align="left" rowspan="1" colspan="1">Heterogeneity</th><th align="left" rowspan="1" colspan="1">Quality of Evidence (GRADE)</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1"><bold>Acebutolol</bold> (HA frequency at baseline: 4.8 headaches/month (95% CI: -0.64 to 8.9))</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline Frequency</td><td align="center" rowspan="1" colspan="1">0.00 (-0.14 to 0.14)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="4" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-0.20 (-0.38 to -0.02)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.50 (-1.6 to 0.63)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.6 (-1.7 to 0.53)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="3" rowspan="1"><bold>Alprenolol</bold></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.80 (-1.9 to 0.31)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="3" rowspan="1"><bold>Atenolol</bold></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-1.7 (-3.0 to -0.32)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Bisoprolol</bold> (HA frequency at baseline: 5.5 headaches/month (95% CI: 2.7 to 8.3))</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="12" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">5 mg</td><td align="center" rowspan="1" colspan="1">0.40 (-0.19 to 0.99)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">10 mg</td><td align="center" rowspan="1" colspan="1">0.20 (-0.40 to 0.80)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">5 mg</td><td align="center" rowspan="1" colspan="1">-0.40 (-1.1 to 0.29)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">10 mg</td><td align="center" rowspan="1" colspan="1">-0.40 (-1.1 to 0.34)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">5 mg</td><td align="center" rowspan="1" colspan="1">-0.50 (-1.2 to 0.25)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">10 mg</td><td align="center" rowspan="1" colspan="1">-0.70 (-1.4 to -0.05)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">5 mg</td><td align="center" rowspan="1" colspan="1">-0.90 (-1.53 to -0.27)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">10 mg</td><td align="center" rowspan="1" colspan="1">-0.90 (-1.6 to -0.24)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Metoprolol</bold> (HA frequency at baseline: 3.9 headaches/month (3.1 to 4.7))</td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.04 (-0.49 to 0.41)</td><td align="center" rowspan="1" colspan="1">Q = 3.68, df = 3, I<sup>2</sup> = 18.5%</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-0.91 (-2.6 to 0.82)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.86(-1.4 to -0.34)</td><td align="center" rowspan="1" colspan="1">Q = 3.07, df = 2, I<sup>2</sup> = 34.8%</td><td align="left" rowspan="1" colspan="1">Moderate</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.90 (-2.2 to 0.41)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Nadolol</bold> (HA frequency at baseline: 6.7 headaches/month (3.4 to 9.9)</td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.22 (-1.8 to 2.3)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="4" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">1.1 (-0.98 to 3.2)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.86 (-2.9 to 1.3)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.96 (-3.1 to 1.2)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Oxprenolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.80 (-3.9 to 2.3)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Propranolol</bold> (HA frequency at baseline: 4.8 headaches/month (4.3 to 5.3))&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.04 (-0.28 to 0.20)</td><td align="center" rowspan="1" colspan="1">Q = 0.83, df = 10, I<sup>2</sup> = 0.0%</td><td align="left" rowspan="1" colspan="1">High</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-1.1 (-1.8 to -0.43)</td><td align="center" rowspan="1" colspan="1">Q = 0.0, df = 1, I2 = 0.0%</td><td align="left" rowspan="1" colspan="1">Moderate</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-1.5 (-2.3 to -0.65)</td><td align="center" rowspan="1" colspan="1">Q = 11.37, df = 7, I2 = 38.4%</td><td align="left" rowspan="1" colspan="1">High</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-1.2 (-1.8 to-0.60)</td><td align="center" rowspan="1" colspan="1">Q = 35.29, df = 8, I2 = 77.3%</td><td align="left" rowspan="1" colspan="1">High</td></tr><tr><td align="right" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">-1.2 (-2.4 to -0.01)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">20 weeks</td><td align="center" rowspan="1" colspan="1">-0.9 (-1.8 to -0.02)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">24 weeks</td><td align="center" rowspan="1" colspan="1">-0.9 (-1.5 to -0.32)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">40 weeks</td><td align="center" rowspan="1" colspan="1">-0.3 (-0.9 to 0.34)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">64 weeks</td><td align="center" rowspan="1" colspan="1">-0.3 (-0.98 to 0.38)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Timolol</bold> (HA frequency at baseline: 4.8 headaches/month (95% CI: -0.64 to 8.9))</td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">(-0.45 to 0.45)</td><td align="center" rowspan="1" colspan="1">Q = 0.0, df = 2, I2 = 0.0%</td><td align="left" rowspan="3" colspan="1">Moderate</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.77 (-1.4 to -0.12)</td><td align="center" rowspan="1" colspan="1">Q = 1.03, df = 1, I<sup>2</sup> = 3.2%</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-1.53 (-2.5 to -0.78)</td><td align="center" rowspan="1" colspan="1">Q = 0.16, df = 1, I<sup>2</sup> = 0.0%</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Migraine-Chronic</bold></td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Propranolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-2.1 (-5.5 to 1.3)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Chronic Tension-type HA</bold></td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Pindolol+ Amitriptyline</bold> (HA frequency at baseline: 20.0 headaches/month (95% CI: 18.5 to 29.5))</td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">1.4 (-2.2 to 5.0)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="3" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-7.8 (-13.9 to -1.5)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-11.2 (-16.7 to -5.5)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Propranolol</bold> (HA frequency at baseline: 20.0 headaches/month (95% CI: 18.5 to 29.5))</td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">(-8.1 to 8.1)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-4.5 (-8.2 to -0.82)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr></tbody></table></alternatives></table-wrap><table-wrap id="pone.0212785.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0212785.t003</object-id><label>Table 3</label><caption><title>Secondary outcomes of placebo controlled trials.</title></caption><alternatives><graphic id="pone.0212785.t003g" xlink:href="pone.0212785.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><tbody><tr><td align="left" colspan="4" rowspan="1"><bold>Episodic Migraines</bold></td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>50% Improvement in Headaches</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Beta-blocker</bold></td><td align="left" rowspan="1" colspan="1"><bold>RR (95% CI)/NNT</bold></td><td align="left" rowspan="1" colspan="1"><bold>Heterogeneity</bold></td><td align="left" rowspan="1" colspan="1"><bold>Quality of Evidence</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Atenolol</td><td align="left" rowspan="1" colspan="1">1.8 (1.0 to 3.2)/6.3 (3.2&#x02013;33.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1">Metoprolol</td><td align="left" rowspan="1" colspan="1">1.7 (1.0 to 2.9)/5 (3.5&#x02013;8.8)</td><td align="left" rowspan="1" colspan="1">Q = 8.85, df = 3, I<sup>2</sup> = 66.1%</td><td align="left" rowspan="1" colspan="1">Moderate</td></tr><tr><td align="left" rowspan="1" colspan="1">Nadolol</td><td align="left" rowspan="1" colspan="1">5.1 (0.32 to 81.3)/3.7 (1.9&#x02013;90.9)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1">Propranolol</td><td align="left" rowspan="1" colspan="1">1.4 (1.1 to 1.8)/5.3 (3.4&#x02013;11.4)</td><td align="left" rowspan="1" colspan="1">Q = 26.1, df = 10, I<sup>2</sup> = 59.5%</td><td align="left" rowspan="1" colspan="1">High</td></tr><tr><td align="left" rowspan="1" colspan="1">Timolol</td><td align="left" rowspan="1" colspan="1">1.8 (1.4 to 2.3)/4.5 (3.1&#x02013;7.7)</td><td align="left" rowspan="1" colspan="1">Q = 0.86, df = 2, I2 = 0.0%</td><td align="left" rowspan="1" colspan="1">Moderate</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Analgesic Medication Consumption</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Beta-blocker</bold><break/><bold>Time point</bold></td><td align="left" rowspan="1" colspan="1"><bold>Weighted Mean Difference (95% CI)</bold></td><td align="left" rowspan="1" colspan="1"><bold>Heterogeneity</bold></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Metoprolol</bold> (Baseline analgesic doses/month: 6.7, 95% CI: 3.4 to 10.0)</td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.17 (-1.4 to 1.1)</td><td align="left" rowspan="1" colspan="1">Q = 0.5, df = 3, I<sup>2</sup> = 0.0%</td><td align="left" rowspan="1" colspan="1">High</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-2.4 (-4.9 to 0.08)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-4.0 (-7.5 to -0.48)</td><td align="left" rowspan="1" colspan="1">Q = 3.49, df = 2, I<sup>2</sup> = 42.8%</td><td align="left" rowspan="1" colspan="1">Moderate</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Propranolol</bold> (Baseline analgesic doses/month 11.1, 95% CI: 4.8&#x02013;17.4)</td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.0 (-1.9 to 1.9)</td><td align="left" rowspan="1" colspan="1">Q = 0.26, df = 7, I<sup>2</sup> = 0.00</td><td align="left" rowspan="1" colspan="1">High</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-6.0 (-11.8 to -0.12)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-2.9 (-25.9 to 20.2)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-2.1 (-3.2 to -0.95)</td><td align="left" rowspan="1" colspan="1">Q = 33.82, df = 5, I<sup>2</sup> = 85.2%</td><td align="left" rowspan="1" colspan="1">High</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Headache Index</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Beta-blocker</bold><break/><bold>Time point</bold></td><td align="left" rowspan="1" colspan="1"><bold>Standardized Mean Difference (95% CI)</bold></td><td align="left" rowspan="1" colspan="1"><bold>Heterogeneity</bold></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Alprenolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">0.05 (-0.47 to 0.58)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Atenolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.62 (-1.2 to -0.004)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.65 (-1.3 to -0.01)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Metoprolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.12 (-0.22 to 0.47)</td><td align="left" rowspan="1" colspan="1">Q = 0.07, df = 1, I<sup>2</sup> = 0.0%</td><td align="left" rowspan="2" colspan="1">Moderate</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.42 (-0.77 to -0.07)</td><td align="left" rowspan="1" colspan="1">Q = 0.98, df = 1, I<sup>2</sup> = 0.0%</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Nadolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.12 (-0.24 to 0.48)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="4" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">0.16 (-0.20 to 0.52)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.14 (-0.50 to 0.23)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.27 (-0.64 to 0.10)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Oxprenolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-1.7 (-2.3 to -1.1)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.42 (-0.09 to 0.93)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Pindolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.14 (-0.52 to 0.80)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">0.27 (-0.40 to 0.93)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Propranolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">0 weeks</td><td align="center" rowspan="1" colspan="1">-0.03 (-0.23 to 0.16)</td><td align="left" rowspan="1" colspan="1">Q = 6.24, df = 6, I<sup>2</sup> = 19.9%</td><td align="left" rowspan="1" colspan="1">High</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-0.66 (-1.3 to -0.01)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.48 (-0.75 to -0.22)</td><td align="left" rowspan="1" colspan="1">Q = 2.54, df = 4, I<sup>2</sup> = 0.0%</td><td align="left" rowspan="1" colspan="1">High</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.41 (-0.65 to -0.17)</td><td align="left" rowspan="1" colspan="1">Q = 2.56, df = 3, I<sup>2</sup> = 0.0%</td><td align="left" rowspan="1" colspan="1">High</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Timolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.0 (-0.31 to 0.31)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.53 (-0.84 to -0.21)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Headache Severity</bold></td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Metoprolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.06 (-0.33 to 0.21)</td><td align="left" rowspan="1" colspan="1">Q = 1.65, df = 2, I<sup>2</sup> = 0.0%</td><td align="left" rowspan="1" colspan="1">High</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.53 (-0.71 to -0.14)</td><td align="left" rowspan="1" colspan="1">Q = 0.15, df = 1, I<sup>2</sup> = 0.0%</td><td align="left" rowspan="1" colspan="1">Moderate</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Propranolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">(-0.21 to 0.21)</td><td align="left" rowspan="1" colspan="1">Q = 0.00, df = 2, I<sup>2</sup> = 0.0%</td><td align="left" rowspan="3" colspan="1">High</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.51 (-0.76 to -0.26)</td><td align="left" rowspan="1" colspan="1">Q = 1.73, df = 4, I<sup>2</sup> = 0.0%</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.18 (-0.30 to 0.01)</td><td align="left" rowspan="1" colspan="1">Q = 3.70, df = 2, I<sup>2</sup> = 46.0%</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Timolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.00 (-0.31 to 0.31)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.35 (-0.66 to -0.04)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Headache Duration (hours)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Beta-blocker</bold><break/><bold>Time point</bold></td><td align="left" rowspan="1" colspan="1"><bold>Weighted Mean Difference (95% CI)</bold></td><td align="left" rowspan="1" colspan="1"><bold>Heterogeneity</bold></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Bisoprolol (baseline duration 20.6 hours, 95% CI: 0 to 46.7)</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-3.9 (-8.6 to 0.77)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-1.9 (-6.5 to 2.5)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Metoprolol (baseline duration: 11.6 hours, 95% CI: 2.6 to 20.5)</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.06 (-1.6 to 1.7)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="3" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-2.6 (-4.2 to -0.88)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-2.0 (-3.7 to -0.26)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Propranolol (baseline duration: 28.9 hours, 95% CI: 0 to 72.3)</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.22 (-2.4 to 2.8)</td><td align="left" rowspan="1" colspan="1">Q = 0.99, df = 2, I<sup>2</sup> = 0.0%</td><td align="left" rowspan="3" colspan="1">High</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-6.1 (-16.2 to -0.39)</td><td align="left" rowspan="1" colspan="1">Q = 5.67, df = 2, I<sup>2</sup> = 64.7%</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-1.6 (-3.0 to -0.11)</td><td align="left" rowspan="1" colspan="1">Q = 2.50, df = 4, I<sup>2</sup> = 0.0%</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Pindolol (baseline duration: 6.6 hours, 95% CI: 0 to 23.7)</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.93 (-9,7 to 7.8)</td><td align="left" rowspan="1" colspan="1">Q = 0.01, df = 1, I<sup>2</sup> = 0.0%</td><td align="left" rowspan="2" colspan="1">Moderate</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-0.18 (-8.8 to 8.4)</td><td align="left" rowspan="1" colspan="1">Q = 0.01, df = 1, I<sup>2</sup> = 0.0%</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Timolol (baseline duration 9.4 hours, 95% CI: 0 to 19.8)</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">(-1.3 to 1.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="3" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.70 (-2.2 to 0.80)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.54 (-2.7 to 1.6)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Tension-type Headache</bold></td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>50% improvement in Headache</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Beta-blocker</bold></td><td align="left" rowspan="1" colspan="1"><bold>RR (95% CI)</bold></td><td align="left" rowspan="1" colspan="1"><bold>Heterogeneity</bold></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Pindolol + Amitriptyline</td><td align="center" rowspan="1" colspan="1">3.8 (1.5 to 9.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Headache Index</bold></td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Propranolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-0.52 (-1.0 to -0.003)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Severity</bold></td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Pindolol + Amitriptyline</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.29 (-0.34 to 0.91)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.68 (-1.3 to -0.04)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr></tbody></table></alternatives></table-wrap><p>Among secondary outcomes, the majority of trials studied subjects with episodic migraine headaches (<xref rid="pone.0212785.t003" ref-type="table">Table 3</xref>). Propranolol was the most commonly studied beta-blocker. Propranolol was more likely to reduce headaches by 50% than placebo at 12 weeks (RR: 1.4, 95% CI: 1.1&#x02013;1.8, NNT: 4.5, 95% CI: 2.8&#x02013;12.9). Other effective beta-blockers included atenolol (RR: 1.8, 95% CI: 1.0&#x02013;3.2, NNT: 6.3, 95% CI: 3.2&#x02013;332.4), metoprolol (RR: 1.9, 95% CI: 1.3&#x02013;2.8, NNT: 4.7, 95% CI:3.0&#x02013;10.4) and timolol (RR: 1.8, 95% CI: 1.4&#x02013;2.3, NNT: 4.2, 95% CI: 2.7&#x02013;8.8,). At 8 weeks, metoprolol reduced analgesic medication use (-4.0 doses/month, 95% CI: -7.5 to -0.48) as did propranolol at 12 weeks (-2.1 doses/month, 95% CI: -3.2 to -0.95). The headache index was modestly reduced by a number of different beta-blockers including atenolol (SMD: -0.62, 95% CI: -1.2 to -0.004), metoprolol (SMD: -0.42, 95% CI: -0.77 to -0.07), propranolol (SMD: -0.48, 95% CI: -0.75 to -0.22) and timolol (SMD: -0.53, 95% CI: -0.84 to -0.21). At 8 weeks, headache severity was modestly reduced by both metoprolol (SMD: -0.53, 95% CI: -0.71 to -0.14) and propranolol (SMD: -0.51, 95% CI: -0.76 to -0.26). Headache duration was reduced by metoprolol (-2.0 hours, 95% CI: -3.7 to -0.26) and propranolol (-6.1 hours, 95% CI: -16.2 to -0.39).</p><sec id="sec010"><title>Network meta-analysis</title><p>For the primary outcome, headache frequency, the network meta-analysis found no difference at 8 weeks (p = 0.27) in effectiveness in comparisons between propranolol (n = 9) compared to bisoprolol (n = 2), metoprolol (n = 3) and nadolol (n = 3). Similarly, at 12 weeks, there was no difference (p = 0.84) n effectiveness in comparisons between propranolol (n = 9) compared to bisoprolol (n = 2), nadolol (n = 3) and timolol (n = 2). The 8- and 12-week analysis confirmed this lack of difference between all beta-blockers (<xref ref-type="fig" rid="pone.0212785.g005">Fig 5</xref>), including those with single trials (<xref ref-type="fig" rid="pone.0212785.g006">Fig 6</xref>)</p><fig id="pone.0212785.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0212785.g005</object-id><label>Fig 5</label><caption><title>Network meta-analysis map.</title></caption><graphic xlink:href="pone.0212785.g005"/></fig><fig id="pone.0212785.g006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0212785.g006</object-id><label>Fig 6</label><caption><title>Results of network meta-analysis comparisons.</title></caption><graphic xlink:href="pone.0212785.g006"/></fig></sec><sec id="sec011"><title>Comparative effectiveness trials</title><p>There were 83 randomized trials that included at least one comparison to a non-placebo treatment. Propranolol was the most commonly compared beta-blocker (n = 72, 87%). Propranolol was compared to pharmacologic interventions in 50 trials. Eleven comparisons that were from single trials (5-hydroxytryptophan, aspirin, atenolol, candesartan, clonidine, cyclandelate, mefenamic acid, naproxen, nifedipine, nimodipine, nortriptyline, pindolol, riboflavin). Comparisons with more than one study included: amitriptyline (n = 2), femoxetine (n = 2), flunarizine (n = 11), metoprolol (n = 4), nadolol (n = 3), nimodipine (n = 2), timolol (n = 2) tofenamic acid (n = 2), topiramate (n = 3) and valproate (n = 3). Several combinations were tested including propranolol + amitriptyline vs. amitriptyline (n = 1), and propranolol + flunarizine was compared to flunarizine. Propranolol combined with topiramate was compared with topiramate alone. Nonpharmacologic interventions were compared to propranolol in three trials (acupuncture, behavioral management, biofeedback). Metoprolol was assessed in 14 trials, 8 were comparisons with pharmacologic interventions (aspirin, bisoprolol, clomipramine, clonidine, flunarizine, nebivolol, pizotifen) and one with nonpharmacologic (acupuncture). Metoprolol was compared to a combination of metoprolol and fluoxetine in 2 trials and the combination of metoprolol and flunarizine was compared to flunarizine alone in 2 trials.</p><p>The primary outcome comparison (headache frequency) is provided in <xref rid="pone.0212785.t004" ref-type="table">Table 4</xref>, and secondary outcomes are in <xref rid="pone.0212785.t005" ref-type="table">Table 5</xref>. The majority of comparisons were single trials, making definitive conclusions difficult. Metoprolol, but not propranolol, was more effective than aspirin. Metoprolol was more effective than clomipramine, though comparable to acupuncture, bisoprolol, clonidine, flunarizine, nebivolol and pizotifen. Adding fluoxetine to metoprolol or flunarizine to either propranolol or metoprolol did not improve headache frequency. All comparisons were graded as low-quality. Propranolol was more effective than femoxetine, mefenamic acid, naproxen, nifedipine and very low-dose (40mg) nortriptyline, but comparable to 5-hydroxytryptophan, acupuncture, atenolol, behavioral management, biofeedback, candesartan, clonidine, cyclandelate, flunarizine, metoprolol, nadolol, naproxen, nimodipine, riboflavin, timolol, tolfenamic acid, topiramate and valproic acid. All comparisons were single trials and were rated as low-quality evidence with the exception of the comparisons to flunarizine and metoprolol at 8 weeks that were graded as moderate or high-quality. The network meta-analysis confirmed these findings, but suggested that metoprolol was also superior to naproxen (SMD: -1.2, 95% CI: -1.6 to -0.78).</p><table-wrap id="pone.0212785.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0212785.t004</object-id><label>Table 4</label><caption><title>Primary outcome (headache frequency) of comparative effectiveness trials.</title></caption><alternatives><graphic id="pone.0212785.t004g" xlink:href="pone.0212785.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Comparison, Time point</th><th align="left" rowspan="1" colspan="1">Weighted Mean Difference (95% CI)</th><th align="left" rowspan="1" colspan="1">Heterogeneity</th><th align="left" rowspan="1" colspan="1">Quality of Evidence</th></tr></thead><tbody><tr><td align="left" rowspan="5" colspan="1"><bold>Bisoprolol (5mg)</bold></td><td align="left" colspan="4" rowspan="1"><bold>Bisoprolol (10mg)</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">0.20 (-0.43 to 0.83)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="4" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 Weeks</td><td align="center" rowspan="1" colspan="1">0.0 (-0.74 to 0.74)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">0.20 (-0.47 to -0.87)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.0 (-0.67 to -0.67)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="28" colspan="1"><bold>Metoprolol</bold></td><td align="left" colspan="4" rowspan="1"><bold>Acupuncture</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">17 weeks</td><td align="center" rowspan="1" colspan="1">-0.7 (-2.7 to 1.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Aspirin</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-1.6 (-2.8 to -0.46)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Bisoprolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.0 (-0.31 to 0.31)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.09 (-0.62 to 0.44)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Clomipramine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-2.0 (-3.9 to -0.16)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Clonidine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.00 (-0.51 to 0.51)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-1.40 (-3.3 to 0.44)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Flunarizine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.60 (-1.4 to 0.19)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="6" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-0.3 (-1.1 to 0.53)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.9 (-1.7 to -0.10)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.5 (-1.3 to 0.33)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">-0.1 (-0.93 to 0.73)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">20 weeks</td><td align="center" rowspan="1" colspan="1">-0.36 (-1.5 to 0.75)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Metoprolol + Fluoxetine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.03 (-0.40 to 0.33)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">0.30 (0.19 to 0.40)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Nebivolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.10 (-0.62 to 0.82)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">-0.30 (-1.2 to 0.60)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Pizotifen</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.00 (-0.47 to 0.47)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">0.90 (-0.01 to 1.8)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="5" colspan="1"><bold>Metoprolol + Flunarizine</bold></td><td align="left" colspan="4" rowspan="1"><bold>Flunarizine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.9 (-1.6 to -0.22)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="4" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">24 weeks</td><td align="center" rowspan="1" colspan="1">-0.8 (-1.6 to -0.04)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">36 weeks</td><td align="center" rowspan="1" colspan="1">-0.6 (-2.4 to 1.2)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">48 weeks</td><td align="center" rowspan="1" colspan="1">-0.3 (-1.2 to 0.57)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="5" colspan="1"><bold>Nadolol (80mg)</bold></td><td align="left" colspan="4" rowspan="1"><bold>Nadolol (160mg)</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.57 (-2.1 to 3.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="4" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-0.25 (-2.9 to 2.4)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">0.11 (-2.6 to 2.8)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.34 (-3.1 to 2.4)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="3" colspan="1"><bold>Pindolol</bold></td><td align="left" colspan="4" rowspan="1"><bold>Pindolol (15mg)</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">4.0 (-0.6 to 8.1)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">4.0 (-0.05 to 8.1)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="82" colspan="1"><bold>Propranolol</bold></td><td align="left" colspan="4" rowspan="1"><bold>5-Hydroxy-tryptophan</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-2.3 (-5.9 to 1.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">-2.9 (-6.6 to 0.81)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Acupuncture</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.10 (-0.59 to 0.40)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.30 (-0.25 to 0.85)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Behavioral Management</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.40 (-1.1 to 0.34)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="3" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">40 weeks</td><td align="center" rowspan="1" colspan="1">-0.30 (-0.94 to 0.34)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">64 weeks</td><td align="center" rowspan="1" colspan="1">-0.20 (-0.89 to 0.49)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Propranolol + Behavioral Management</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.50 (-1.2 to 0.18)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="3" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">40 weeks</td><td align="center" rowspan="1" colspan="1">0.70 (-.16 to 1.2)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">64 weeks</td><td align="center" rowspan="1" colspan="1">0.80 (0.19 to 1.4)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Biofeedback</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">24 weeks</td><td align="center" rowspan="1" colspan="1">0.53 (0.08 to 0.97)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Candesartan</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.04 (-0.59 to 0.51)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Cyclandelate (HA days/mo)</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.16 (-0.66 to 0.35)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="3" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-0.32 (-0.83 to 0.18)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">0.13 (-0.37 to 0.63)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Femoxetine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.0 (-2.2 to 2.2)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="3" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.70 (-1.5 to 0.13)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-1.5 (-3.6 to 0.55)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Flunarizine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.005 (-0.11 to 0.10)</td><td align="left" rowspan="1" colspan="1">Q = 0.83, df = 5, I<sup>2</sup> = 0.0%</td><td align="left" rowspan="1" colspan="1">High</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">0.40 (-0.34 to 1.1)</td><td align="left" rowspan="1" colspan="1">Q = 3.1, df = 3, I<sup>2</sup> = 3.7%</td><td align="left" rowspan="1" colspan="1">High</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">0.42 (-0.55 to 1.4)</td><td align="left" rowspan="1" colspan="1">Q = 1.48, df = 1, I<sup>2</sup> = 32.6%</td><td align="left" rowspan="1" colspan="1">Moderate</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.68 (-0.06 to 1.4)</td><td align="left" rowspan="1" colspan="1">Q = 0.55, df = 2, I<sup>2</sup> = 0.0%</td><td align="left" rowspan="1" colspan="1">High</td></tr><tr><td align="right" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">-0.04 (-0.19 to 0.12)</td><td align="left" rowspan="1" colspan="1">Q = 5.44, df = 6, I<sup>2</sup> = 7.0%</td><td align="left" rowspan="1" colspan="1">High</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Mefenamic Acid</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-2.1 (-5.3 to 1.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Metoprolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">0.00 (-0.38 to 0.38)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="3" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="left" rowspan="1" colspan="1">-0.70 (-2.0 to 0.62)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="left" rowspan="1" colspan="1">0.00 (-0.54 to 0.56)</td><td align="left" rowspan="1" colspan="1">Q = 0.0, df = 1, I<sup>2</sup> = 0.0%</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Nadolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.27 (-2.6 to 3.2)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="5" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">1.6 (-0.28 to 3.4)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">1.7 (-0.23 to 3.6)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">1.8 (-0.16 to 3.7)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">24 weeks</td><td align="center" rowspan="1" colspan="1">-4.8 (-8.9 to -0.77)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Naproxen</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-1.4 (-1.9 to -0.95)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Nifedipine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">2.5 (1.0 to 3.9)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="3" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.40 (-2.6 to 1.8)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">24 weeks</td><td align="center" rowspan="1" colspan="1">0.70 (-1.5 to 2.9)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Nimodipine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.20 (-0.86 to 1.2)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="6" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">1.6 (-0.24 to 3.4)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-1.5 (-4.1 to 1.1)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-1.5 (-2.9 to -0.04)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">-0.30 (-1.7 to 1.1)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">24 weeks</td><td align="center" rowspan="1" colspan="1">-0.01 (-1.3 to 1.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Propranolol + Flunarizine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.14 (-1.8 to 1.5)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">0.18 (-1.4 to 1.8)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Riboflavin</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.00 (-0.39 to 0.39)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="5" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-0.60 (-0.92 to -0.28)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.10 (-0.42 to 0.22)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.0 (-0.27 to 0.27)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">24 weeks</td><td align="center" rowspan="1" colspan="1">-0.10 (-0.37 to 0.17)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Timolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.00 (-0.84 to 0.84)</td><td align="left" rowspan="1" colspan="1">Q = 0.00, df = 1 I<sup>2</sup> = 0.0%</td><td align="left" rowspan="2" colspan="1">Moderate</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.37 (-0.45 to 1.2)</td><td align="left" rowspan="1" colspan="1">Q = 0.01, df = 1, I<sup>2</sup> = 0.0%</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Tolfenamic Acid</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.01 (-0.68 to 0.70)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Topiramate</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.02 (-0.35 to 0.31)</td><td align="left" rowspan="1" colspan="1">Q = 1.47, df = 2 I<sup>2</sup> = 0.0%</td><td align="left" rowspan="2" colspan="1">Moderate</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-0.19 (-0.76 to 0.39)</td><td align="left" rowspan="1" colspan="1">Q = 0.18, df = 1 I<sup>2</sup> = 0.0%</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">0.30 (-0.30 to 0.91)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="5" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.10 (-0.98 to 1.2)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">0.30 (-0.94 to 1.5)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">20 weeks</td><td align="center" rowspan="1" colspan="1">0.40 (-0.60 to 1.4)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">24 weeks</td><td align="center" rowspan="1" colspan="1">-0.75 (-1.6 to 0.13)</td><td align="left" rowspan="1" colspan="1">Q = 4.38, df = 1 I<sup>2</sup> = 77.2%</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Valproic Acid</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.20 (-1.1 to 0.71)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.16 (-1.7 to 0.75)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="3" colspan="1"><bold>Propranolol + Flunarizine</bold></td><td align="left" colspan="4" rowspan="1"><bold>Topiramate</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.06 (-0.82 to 0.70)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.70 (0.29 to 1.1)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="2" colspan="1"><bold>Propranolol + Topiramate</bold></td><td align="left" colspan="4" rowspan="1"><bold>Topiramate</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">24 weeks</td><td align="center" rowspan="1" colspan="1">-0.01 (-2.4 to 2.1)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr></tbody></table></alternatives></table-wrap><table-wrap id="pone.0212785.t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0212785.t005</object-id><label>Table 5</label><caption><title>Secondary outcomes of comparative effectiveness trials.</title></caption><alternatives><graphic id="pone.0212785.t005g" xlink:href="pone.0212785.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Drug1</th><th align="left" rowspan="1" colspan="1">Comparison, Time Point</th><th align="left" rowspan="1" colspan="1">Weighted Mean Difference (95% CI)</th><th align="left" rowspan="1" colspan="1">Heterogeneity</th><th align="left" rowspan="1" colspan="1">Quality of Evidence</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1"><bold>Headache Days Weighted Mean Difference (95% CI)</bold></td></tr><tr><td align="left" rowspan="5" colspan="1"><bold>Metoprolol</bold></td><td align="left" colspan="4" rowspan="1"><bold>Clonidine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.0 (-3.7 to 3.7)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">8 Weeks</td><td align="center" rowspan="1" colspan="1">-1.8 (-5.7 to 2.14)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Metoprolol + Fluoxetine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">0.83 (0.63 to 1.0)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="5" colspan="1"><bold>Nadolol (80mg)</bold></td><td align="left" colspan="4" rowspan="1"><bold>Nadolol (160mg)</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">2.3 (-3.4 to 7.9)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="4" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-0.22 (-5.9 to 5.4)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.05 (-5.9 to 5.8)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">2.2 (-7.9 to 3.6)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="3" colspan="1"><bold>Pindolol (7.5mg)</bold></td><td align="left" colspan="4" rowspan="1"><bold>Pindolol (15mg)</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.05 (-0.94 to 1.0)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">0.28 (-0.72 to 1.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="47" colspan="1"><bold>Propranolol</bold></td><td align="left" colspan="4" rowspan="1"><bold>Acupuncture</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.0 (-1.0 to 1.0)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.70 (-0.43 to 1.8)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Atenolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">0.06 (-1.8 to 1.9)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Behavioral Management</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.50 (-0.88 to 1.9)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="3" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">40 weeks</td><td align="center" rowspan="1" colspan="1">-0.10 (-1.3 to 1.1)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">64 weeks</td><td align="center" rowspan="1" colspan="1">0.10 (-1.1 to 1.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Candesartan</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.45 (-1.2 to 2.1)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Clonidine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">0.10 (-2.1 to 2.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Cyclandelate</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.60 (-2.5 to 1.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="3" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-1.1 (-2.8 to 0.64)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">0.40 (-1.2 to 2.0)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Femoxetine</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-1.6 (-4.5 to 1.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Flunarizine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.80 (-2.2 to 0.59)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="5" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">1.4 (0.02 to 2.8)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">0.50 (-0.91 to 1.9)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.5 (-1.9 to 0.96)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">0.61 (-0.91 to 2.1)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Metoprolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.31 (-1.3 to 0.68)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-0.60 (-4.3 to 3.1)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.17 (-0.96 to 0.51)</td><td align="left" rowspan="1" colspan="1">Q = 0.73 df = 1, I<sup>2</sup> = 0.0%</td><td align="left" rowspan="1" colspan="1">Moderate</td></tr><tr><td align="right" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">0.06 (-1.9 to 2.02)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">24 weeks</td><td align="center" rowspan="1" colspan="1">-2.2 (-4.2 to -0.24)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Naproxen</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="left" rowspan="1" colspan="1">-2.8 (-3.6 to -1.9)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Nifedipine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.80 (-3.3 to 1.7)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="4" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-3.6 (-7.0 to -0.16)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">-2.2 (-4.0 to -0.32)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">28 weeks</td><td align="center" rowspan="1" colspan="1">-0.80 (-2.6 to 1.0)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Propranolol (80mg v 160mg)</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.0 (-1.7 to 1.7)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-2.7 (04.9 to -0.5)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Tolfenamic Acid</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.0 (-1.6 to 1.6)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.22 (-2.1 to 1.6)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Topiramate</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.12 (-0.3 to 0.55)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">24 weeks</td><td align="center" rowspan="1" colspan="1">-0.25 (01.13 to 0.63)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="5" rowspan="1"><bold>Headache Index, Standardized Mean Difference (95% CI)</bold></td></tr><tr><td align="left" rowspan="3" colspan="1"><bold>Metoprolol</bold></td><td align="left" colspan="4" rowspan="1"><bold>Clonidine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.0 (-0.49 to 0.49)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">8 Weeks</td><td align="center" rowspan="1" colspan="1">-0.24 (-0.76 to 0.29)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="3" colspan="1"><bold>Pindolol (7.5mg)</bold></td><td align="left" colspan="4" rowspan="1"><bold>Pindolol (15 mg)</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.05 (-0.94 to 1.04)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">0.27 (-0.72 to 1.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="53" colspan="1"><bold>Propranolol</bold></td><td align="left" colspan="4" rowspan="1"><bold>Amitriptyline</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.05 (-0.42 to 0.52)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">6 weeks</td><td align="center" rowspan="1" colspan="1">-0.42 (-0.89 to 0.06)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Amitriptyline + Biofeedback</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.08 (-0.37 to 0.53)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">6 weeks</td><td align="center" rowspan="1" colspan="1">-0.24 (-0.69 to 0.21)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Amitriptyline + Propranolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.01 (-0.44 to 0.46)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">6 weeks</td><td align="center" rowspan="1" colspan="1">0.06 (-0.39 to 0.51)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Amitriptyline + Propranolol + Biofeedback</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.04 (-0.52 to 0.44)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">6 weeks</td><td align="center" rowspan="1" colspan="1">0.25 (-0.23 to 0.74)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Biofeedback</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.17 (-0.31 to 0.64)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">6 weeks</td><td align="center" rowspan="1" colspan="1">-0.35 (-0.83 to 0.13)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Biofeedback + Propranolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.03 (-0.50 to 0.44)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">6 weeks</td><td align="center" rowspan="1" colspan="1">0.39 (-0.09 to 0.86)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Aspirin</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.00 (-0.65 to 0.65)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">6 weeks</td><td align="center" rowspan="1" colspan="1">0.25 (-0.56 to 1.05)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Atenolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">6 weeks</td><td align="center" rowspan="1" colspan="1">0.01 (-0.59 to 0.62)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Femoxetine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.00 (-0.57 to 0.57)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="3" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.24 (-0.70 to 0.21)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.35 (-0.92 to 0.22)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Flunarizine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.12 (-0.17 to 0.42)</td><td align="left" rowspan="1" colspan="1">Q = 1.59, df = 2, I<sup>2</sup> = 0.0%</td><td align="left" rowspan="5" colspan="1">Moderate</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-0.18 (-0.82 to 0.46)</td><td align="left" rowspan="1" colspan="1">Q = 2.45, df = 2, I<sup>2</sup> = 59.3%</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.13 (-0.75 to 0.48)</td><td align="left" rowspan="1" colspan="1">Q = 2.27, df = 1, I<sup>2</sup> = 55.9%</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.16 (-1.1 to 1.4)</td><td align="left" rowspan="1" colspan="1">Q = 8.7, df = 1, I<sup>2</sup> = 88.5%</td></tr><tr><td align="right" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">-0.08 (-0.48 to 0.32)</td><td align="left" rowspan="1" colspan="1">Q = 3.13, df = 2, I<sup>2</sup> = 49.3%</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Flunarizine + Propranolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.42 (-0.30 to 1.1)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="5" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">0.29 (-0.43 to 1.0)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">0.17 (-0.54 to 0.89)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.47 (-0.26 to 1.2)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">0.67 (-0.07 to 1.4)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Metoprolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.00 (-0.29 to 0.29)</td><td align="left" rowspan="1" colspan="1">Q = 0.00, df = 1, I<sup>2</sup> = 0.0%</td><td align="left" rowspan="2" colspan="1">Moderate</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">0.06 (-0.24 to 0.35)</td><td align="left" rowspan="1" colspan="1">Q = 0.23, df = 1, I<sup>2</sup> = 0.0%</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Nadolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.41 (-0.09 to 0.90)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="4" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">0.34 (-0.16 to 0.83)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">0.44 (-0.08 to 0.96)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.29 (-0.22 to 0.81)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Timolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.00 (-0.31 to 0.31)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.17 (-0.14 to 0.48)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Valproic Acid</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">-0.09 (-0.56 to 0.38)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">10 weeks</td><td align="left" rowspan="1" colspan="1">-0.03 (-0.50 to 0.44)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="3" colspan="1"><bold>Propranolol + Flunarizine</bold></td><td align="left" colspan="4" rowspan="1"><bold>Topiramate</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.07 (-0.36 to 0.57)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.99 (0.53 to 1.4)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="5" rowspan="1"><bold>Episodic Migraine, 50% reduction in Headaches</bold></td></tr><tr><td align="left" colspan="2" rowspan="1"><bold>Comparison</bold></td><td align="left" rowspan="1" colspan="1"><bold>RR (95% CI)</bold></td><td align="left" rowspan="1" colspan="1"><bold>Heterogeneity</bold></td><td align="left" rowspan="1" colspan="1"><bold>Quality</bold></td></tr><tr><td align="left" rowspan="5" colspan="1"><bold>Metoprolol</bold></td><td align="left" rowspan="1" colspan="1"><bold>ASA</bold></td><td align="left" rowspan="1" colspan="1">2.4 (0.88 to 6.7)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Clonidine</bold></td><td align="left" rowspan="1" colspan="1">1.3 (0.62 to 2.9)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Flunarizine</bold></td><td align="left" rowspan="1" colspan="1">1.1 (0.98 to 1.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Nebivolol</bold></td><td align="left" rowspan="1" colspan="1">1.1 (0.56 to 2.2)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Pizotifen</bold></td><td align="left" rowspan="1" colspan="1">0.69 (0.36 to 1.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Metoprolol + Flunarizine</bold></td><td align="left" rowspan="1" colspan="1"><bold>Flunarizine</bold></td><td align="left" rowspan="1" colspan="1">1.3 (1.0 to 1.6)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="17" colspan="1"><bold>Propranolol</bold></td><td align="left" rowspan="1" colspan="1"><bold>ASA</bold></td><td align="left" rowspan="1" colspan="1">1.3 (0.88 to 1.9)</td><td align="left" rowspan="1" colspan="1">Q = 2.44, df = 1, I<sup>2</sup> = 59.1%</td><td align="left" rowspan="1" colspan="1">Moderate</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Acupuncture</bold></td><td align="left" rowspan="1" colspan="1">0.88 (0.57 to 1.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Candesartan</bold></td><td align="left" rowspan="1" colspan="1">0.93 (0.61 to 1.4)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Clonidine</bold></td><td align="left" rowspan="1" colspan="1">1.6 (0.86 to 3.1)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Cyclandelate</bold></td><td align="left" rowspan="1" colspan="1">1.0 (0.71 to 1.5)</td><td align="left" rowspan="1" colspan="1">Q = 4.39, df = 2, I<sup>2</sup> = 54.4%</td><td align="left" rowspan="1" colspan="1">Moderate</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Femoxetine</bold></td><td align="left" rowspan="1" colspan="1">3.5 (0.43 to 29.4)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Flunarizine</bold></td><td align="left" rowspan="1" colspan="1">1.0 (0.89 to 1.2)</td><td align="left" rowspan="1" colspan="1">Q = 3.30, df = 5, I<sup>2</sup> = 0.0%</td><td align="left" rowspan="1" colspan="1">High</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Flunarizine + Propranolol</bold></td><td align="left" rowspan="1" colspan="1">0.86 (0.59 to 1.2)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Metoprolol</bold></td><td align="left" rowspan="1" colspan="1">0.86 (0.60 to 1.2)</td><td align="left" rowspan="1" colspan="1">Q = 0.11, df = 1, I<sup>2</sup> = 0.0%</td><td align="left" rowspan="1" colspan="1">Moderate</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Nadolol</bold></td><td align="left" rowspan="1" colspan="1">0.66 (0.27 to 1.6)</td><td align="left" rowspan="1" colspan="1">Q = 6.20, df = 2, I<sup>2</sup> = 67.8%</td><td align="left" rowspan="1" colspan="1">Moderate</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Nifedipine</bold></td><td align="left" rowspan="1" colspan="1">2.2 (1.3 to 3.8)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Nortriptyline</bold></td><td align="left" rowspan="1" colspan="1">1.5 (0.54 to 4.2)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Nortriptyline + Propranolol</bold></td><td align="left" rowspan="1" colspan="1">1.1 (0.48 to 2.7)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Propranolol (80 vs. 160mg)</bold></td><td align="left" rowspan="1" colspan="1">0.94 (0.72 to 1.2)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Timolol</bold></td><td align="left" rowspan="1" colspan="1">1.1 (0.84 to 1.4)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Topiramate</bold></td><td align="left" rowspan="1" colspan="1">1.2 (0.98 to 1.4)</td><td align="left" rowspan="1" colspan="1">Q = 0.05, df = 2 I<sup>2</sup> = 0.0%</td><td align="left" rowspan="1" colspan="1">Moderate</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Valproic Acid</bold></td><td align="left" rowspan="1" colspan="1">0.96 (0.77 to 1.2)</td><td align="left" rowspan="1" colspan="1">Q = 0.16, df = 2, I<sup>2</sup> = 0.0%</td><td align="left" rowspan="1" colspan="1">Moderate</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Propranolol + Amitriptyline</bold></td><td align="left" rowspan="1" colspan="1"><bold>Amitriptyline</bold></td><td align="left" rowspan="1" colspan="1">1.02 (0.92 to 1.1)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Propranolol + Flunarizine</bold></td><td align="left" rowspan="1" colspan="1"><bold>Nimodipine + Diazepam + Oryzanol</bold></td><td align="left" rowspan="1" colspan="1">1.5 (1.2 to 2.0)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Propranolol + Nadolol</bold></td><td align="left" rowspan="1" colspan="1"><bold>Behavioral Management</bold></td><td align="left" rowspan="1" colspan="1">0.98 (0.58 to 1.7)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Propranolol + Nadolol</bold></td><td align="left" rowspan="1" colspan="1"><bold>Behavioral Management + Propranolol</bold></td><td align="left" rowspan="1" colspan="1">0.44 (0.30 to 0.66)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="5" rowspan="1"><bold>Medicine Use (doses/month)</bold></td></tr><tr><td align="left" colspan="2" rowspan="1"><bold>Comparison</bold></td><td align="left" rowspan="1" colspan="1"><bold>Weighted Mean Difference (95% CI)</bold></td><td align="left" rowspan="1" colspan="1"><bold>Heterogeneity</bold></td><td align="left" rowspan="1" colspan="1"><bold>Quality of evidence</bold></td></tr><tr><td align="left" rowspan="6" colspan="1"><bold>Metoprolol</bold></td><td align="left" colspan="4" rowspan="1"><bold>Bisoprolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.0 (-0.31 to 0.31)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.01 (-0.30 to 0.32)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Clomipramine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-0.55 (-1.2 to 0.08)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Clonidine</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.0 (-0.50 to 0.50)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.52 (-1.0 to 0.02)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="24" colspan="1"><bold>Propranolol</bold></td><td align="left" colspan="4" rowspan="1"><bold>5-Hydroxytryptophan</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.48 (-0.16 to 1.1)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">0.22 (-0.41 to 0.85)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Candesartan</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="right" rowspan="1" colspan="1">-0.45 (-0.82 to -0.09)</td><td align="right" rowspan="1" colspan="1">&#x02014;</td><td align="right" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Cyclandelate</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.49 (-1.0 to 0.02)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="3" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-0.70 (-1.2 to -0.19)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.19 (-0.69 to 0.32)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Femoxetine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.00 (-0.57 to -0.57)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.83 (-1.4 to -0.24)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Flunarizine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.08 (-0.10 to 0.26)</td><td align="left" rowspan="1" colspan="1">Q = 1.98, df = 2, I<sup>2</sup> = 0.0%</td><td align="left" rowspan="1" colspan="1">Moderate</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-.44 (0.02 to 0.86)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.15 (-0.57 to 0.28)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.23 (-0.43 to -0.04)</td><td align="left" rowspan="1" colspan="1">Q = 0.06, df = 1, I<sup>2</sup> = 0.0%</td><td align="left" rowspan="1" colspan="1">Moderate</td></tr><tr><td align="right" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">-0.07 (-0.41 to 0.27)</td><td align="left" rowspan="1" colspan="1">Q = 0.01, df = 1, I<sup>2</sup> = 0.0%</td><td align="left" rowspan="1" colspan="1">Moderate</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Metoprolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.00 (-0.29 to 0.29)</td><td align="left" rowspan="1" colspan="1">Q = 0.00, df = 1, I<sup>2</sup> = 0.0%</td><td align="left" rowspan="2" colspan="1">Moderate</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.19 (-0.49 to 0.11)</td><td align="left" rowspan="1" colspan="1">Q = 1.00, df = 1, I<sup>2</sup> = 0.5%</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Nadolo</bold>l</td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.31 (-1.1 to 0.45)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">24 weeks</td><td align="center" rowspan="1" colspan="1">-0.73 (-1.5 to 0.05)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Health Related Quality of Life</bold></td></tr><tr><td align="left" colspan="2" rowspan="1"><bold>Comparison</bold></td><td align="left" rowspan="1" colspan="1"><bold>Standardized Mean Difference (95% CI)</bold></td><td align="left" rowspan="1" colspan="1"><bold>Heterogeneity</bold></td><td align="left" rowspan="1" colspan="1"><bold>Quality of evidence</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Metoprolol</bold></td><td align="left" colspan="4" rowspan="1"><bold>Nebivolol</bold> (MOS SF36)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.21 (-0.93 to 0.51)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1">16 Weeks</td><td align="center" rowspan="1" colspan="1">-0.46 (-1.2 to 0.27)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="16" colspan="1"><bold>Propranolol</bold></td><td align="left" colspan="4" rowspan="1"><bold>Acupuncture</bold> (MOS SF36)</td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.19 (-0.56 to 0.19)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.47 (-0.84 to -0.10)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Behavioral Management</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.14 (-0.24 to 0.52)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="3" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">40 weeks</td><td align="center" rowspan="1" colspan="1">0.48 (0.10 to 0.86)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">64 weeks</td><td align="center" rowspan="1" colspan="1">0.23 (-0.15 to 0.60)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Behavioral Management + Propranolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.07 (-0.28 to 0.43)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="3" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">40 weeks</td><td align="center" rowspan="1" colspan="1">0.68 (0.31 to 1.0)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">64 weeks</td><td align="center" rowspan="1" colspan="1">0.61 (-.24 to 0.97)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Candesartan</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="left" rowspan="1" colspan="1">-0.18 (-0.54 to 0.19)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Riboflavin</bold> (MIDAS)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.06 (-0.46 to 0.33)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">0.00 (-0.39 to 0.39)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="2" colspan="1"><bold>Propranolol + Topiramate</bold></td><td align="left" colspan="4" rowspan="1"><bold>Topiramate</bold> (MIDAS)</td></tr><tr><td align="right" rowspan="1" colspan="1">24 weeks</td><td align="left" rowspan="1" colspan="1">0.01 (-0.39 to 0.41)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="5" rowspan="1"><bold>Headache Severity</bold></td></tr><tr><td align="left" colspan="2" rowspan="1"><bold>Comparison</bold></td><td align="left" rowspan="1" colspan="1"><bold>Standardized Mean Difference (95% CI)</bold></td><td align="left" rowspan="1" colspan="1"><bold>Heterogeneity</bold></td><td align="left" rowspan="1" colspan="1"><bold>Quality of evidence</bold></td></tr><tr><td align="left" rowspan="19" colspan="1"><bold>Metoprolol</bold></td><td align="left" colspan="4" rowspan="1"><bold>Aspirin</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="left" rowspan="1" colspan="1">0.33 (-0.20 to 0.86)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Acupuncture</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">17 weeks</td><td align="center" rowspan="1" colspan="1">-0.46 (-0.91 to -0.002)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Bisoprolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.00 (-0.31 to 0.31)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.19 (-0.13 to 0.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Flunarizine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.46 (0.14 to 0.79)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="6" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">0.13 (-0.22 to 0.48)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">0.38 (0.02 to 0.73)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.13 (-0.22 to 0.48)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">0.75 (0.39 to 1.1)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">20 weeks</td><td align="center" rowspan="1" colspan="1">0.42 (0.07 to 0.77)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Nebivolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">0.19 (-0.53 to 0.91)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Pizotifen</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.00 (-0.47 to 0.47)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.91 (-1.4 to -0.40)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="5" colspan="1"><bold>Metoprolol + Flunarizine</bold></td><td align="left" colspan="4" rowspan="1"><bold>Flunarizine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.25 (-0.79 to 0.26)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="4" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">24 weeks</td><td align="center" rowspan="1" colspan="1">-0.55 (-1.1 to -0.02)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">36 weeks</td><td align="center" rowspan="1" colspan="1">-0.49 (-1.0 to 0.047)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">48 weeks</td><td align="center" rowspan="1" colspan="1">-0.54 (-0.72 to -0.19)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="49" colspan="1"><bold>Propranolol</bold></td><td align="left" colspan="4" rowspan="1"><bold>Acupuncture</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.26 (-0.13 to 0.65</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.63 (0.23 to 1.03)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>5-hydroxytryptophan</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">0.18 (-0.45 to 0.81)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">16 weeks</td><td align="left" rowspan="1" colspan="1">0.00 (-0.63 to 0.63)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Biofeedback</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.07 (-0.36 to 0.21)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">24 weeks</td><td align="center" rowspan="1" colspan="1">0.13 (-0.15 to 0.42)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Cyclandelate</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.07 (-0.58 to 0.43)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="3" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-0.17 (-0.68 to 0.33)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.01 (-0.51 to 0.48)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Flunarizine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.00 (-0.32 to 0.32)</td><td align="left" rowspan="1" colspan="1">Q = 0.0, df = 1, I<sup>2</sup> = 0.0%</td><td align="left" rowspan="1" colspan="1">Moderate</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-0.24 (-0.66 to 0.17)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.57 (-1.0 to -0.13)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.25 (-0.69 to 0.19)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">0.17 (-0.52 to 0.85)</td><td align="left" rowspan="1" colspan="1">Q = 79.7, df = 3, I<sup>2</sup> = 92.9%</td><td align="left" rowspan="1" colspan="1">High</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Metoprolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.0 (-0.37 to 0.37)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">0.0 (-0.38 to 0.38)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Nadolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">0.00 (-0.67 to 0.84)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">24 Weeks</td><td align="left" rowspan="1" colspan="1">0.86 (0.07 to 1.7)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Naproxen</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.14 (-0.29 to 0.56)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Nimodipine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">24 weeks</td><td align="left" rowspan="1" colspan="1">-0.50 (-0.89 to -0.11)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Propranolol (80 v 160mg doses)</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.00 (-0.40 to 0.40)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="3" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">0.00 (-0.51 to 0.51)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.00 (-0.43 to 0.43)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Riboflavin</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.32 (-0.08 to 0.71)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="5" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">0.33 (-0.07 to 0.72)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">0.21 (-0.18 to 0.60)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.42 (0.02 to 0.82)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">24 weeks</td><td align="center" rowspan="1" colspan="1">0.11 (-0.29 to 0.50)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Timolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.00 (-0.31 to 0.31)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.14 (-0.17 to 0.45)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Tolfenamic Acid</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.26 (-0.37 to 0.68)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.15 (-0.63 to 0.93)</td><td align="left" rowspan="1" colspan="1">Q = 4.53, df = 1, I<sup>2</sup> = 77.8%</td><td align="left" rowspan="1" colspan="1">Moderate</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Topiramate</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.44 (-0.95 to 0.07)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="3" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-0.19 (-0.69 to 0.32)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">0.23 (-0.28 to 0.74)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="5" rowspan="1"><bold>Headache Duration</bold></td></tr><tr><td align="left" colspan="2" rowspan="1"><bold>Comparison</bold></td><td align="left" rowspan="1" colspan="1"><bold>Weighted Mean Difference (95% CI)</bold></td><td align="left" rowspan="1" colspan="1"><bold>Heterogeneity</bold></td><td align="left" rowspan="1" colspan="1"><bold>Quality of evidence</bold></td></tr><tr><td align="left" rowspan="3" colspan="1"><bold>Bisoprolol (5mg)</bold></td><td align="left" colspan="4" rowspan="1"><bold>Bisoprolol (10 mg)</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">2.4 (-4.3 to 9.1)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-4.8 (-9.9 to 0.31)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="23" colspan="1"><bold>Metoprolol</bold></td><td align="left" colspan="4" rowspan="1"><bold>Acupuncture</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-2.4 (-6.5 to 1.7)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Bisoprolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.0 (-4.9 to 4.9)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.30 (-4.2 to 4.8)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Clomipramine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-2.8 (-4.4 to -1.2)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Flunarizine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-1.3 (-3.7 to 1.1)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="6" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-3.2 (-5.7 to -0.69)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-3.3 (-5.9 to -0.66)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-2.4 (-4.9 to 0.11)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">-0.40 (-3.2 to 2.4)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">20 weeks</td><td align="center" rowspan="1" colspan="1">-1.3 (-4.1 to 1.5)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Metoprolol + Fluoxetine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.10 (-0.15 to 0.35)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.53 (-0.75 to -0.31)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Nebivolol</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">11 (-18.6 to 40.6)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Nifedipine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">1.0 (-14.3 to 16.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="3" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">15.8 (0.49 to 31.1)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">28 weeks</td><td align="center" rowspan="1" colspan="1">12.2 (0.66 to 23.7)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="3" colspan="1"><bold>Pindolol (7.5 mg)</bold></td><td align="left" colspan="4" rowspan="1"><bold>Pindolol (15 mg)</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-0.70 (-7.9 to 6.6)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-0.80 (-8.2 to 6.5)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="59" colspan="1"><bold>Propranolol</bold></td><td align="left" colspan="4" rowspan="1"><bold>5-hydroxytryptophan</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">6.1 (-1.1 to 13.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">3.6 (-3.7 to 10.9)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Biofeedback</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.04 (-2.5 to 2.6)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">24 weeks</td><td align="center" rowspan="1" colspan="1">0.33 (-1.3 to 2.0)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Candesartan</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">6.3 (-1.9 to 14.5)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Cyclandelate</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">6.7 (-22.5 to 9.1)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="4" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-12.6 (-37.4 to 12.2)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">6.6 (-18.2 to 31.4)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-4.5 (-26.6 to 17.6)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Flunarizine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">2.7 (-1.2 to 6.6)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-0.55 (-4.8 to 3.7)</td><td align="left" rowspan="1" colspan="1">Q = 0.06, df = 1, I<sup>2</sup> = 0.0%</td><td align="left" rowspan="1" colspan="1">Moderate</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">0.29 (-3.3 to 3.9)</td><td align="left" rowspan="1" colspan="1">Q = 0.08, df = 1, I<sup>2</sup> = 0.0%</td><td align="left" rowspan="1" colspan="1">Moderate</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.21 (-3.3 to 2.9)</td><td align="left" rowspan="1" colspan="1">Q = 0.09, df = 1, I<sup>2</sup> = 0.0%</td><td align="left" rowspan="1" colspan="1">Moderate</td></tr><tr><td align="right" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">1.4 (0.23 to 2.6)</td><td align="left" rowspan="1" colspan="1">Q = 4.33, df = 4, I<sup>2</sup> = 7.6%</td><td align="left" rowspan="1" colspan="1">High</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Mefenamic Acid</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">7.0 (-27.3 to 41.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Metoprolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-24.0 (-40.3 to -7.7)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="4" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">4.2 (-12.1 to 20.5)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">0.0 (-12.3 to 12.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">28 weeks</td><td align="center" rowspan="1" colspan="1">33.0 (6.3 to 59.7)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Nadolo</bold>l</td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-8.1 (-11.4 to -4.8)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">24 weeks</td><td align="center" rowspan="1" colspan="1">-19.5 (-31.8 to -7.1)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Nifedipine</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-1.0 (-16.3 to 14.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="4" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-15.8 (-31.1 to -0.49)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">-12.2 (-23.7 to -0.66)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">28 weeks</td><td align="center" rowspan="1" colspan="1">20.0 (0.97 to 39.0)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Nimodipine</bold></td></tr><tr><td align="center" rowspan="1" colspan="1">24 weeks</td><td align="center" rowspan="1" colspan="1">-4.0 (-7.9 to -0.08)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Propranolol (80 mg vs 160mg)</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.0 (-1.2 to 1.2)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="3" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">-0.30 (-6.9 to 6.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">0.20 (-1.8 to 2.2)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Riboflavin</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.10 (-0.29 to 0.49)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="5" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">0.10 (-0.31 to 0.51)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">0.00 (-0.26 to 0.26)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.10 (-0.39 to 0.19)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">24 weeks</td><td align="center" rowspan="1" colspan="1">0.30 (-0.06 to 6.6)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Timolol</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">0.00 (-2.6 to 2.6)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">-0.03 (-2.3 to 2.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Tolfenamic Acid</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">6.4 (-21.9 to 34.7)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">1.7 (-4.6 to 8.0)</td><td align="left" rowspan="1" colspan="1">Q = 0.05, df = 1, I<sup>2</sup>-0.0%</td><td align="left" rowspan="1" colspan="1">Moderate</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Topiramate</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">-1.3 (-4.8 to 2.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="3" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">-1.2 (-4.6 to 2.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="right" rowspan="1" colspan="1">8 weeks</td><td align="center" rowspan="1" colspan="1">1.0 (-1.9 to 4.0)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="4" rowspan="1"><bold>Valproic Acid</bold></td></tr><tr><td align="right" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">-1.4 (-9.9 to 7.2)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="right" rowspan="1" colspan="1">10 weeks</td><td align="left" rowspan="1" colspan="1">-0.70 (-4.0 to 2.6)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr></tbody></table></alternatives></table-wrap></sec></sec><sec id="sec012"><title>Chronic migraine</title><p>There were four trials that evaluated beta-blockers for chronic migraine headaches, none were placebo controlled. (<xref rid="pone.0212785.t006" ref-type="table">Table 6</xref>). Propranolol was compared to flunarizine [<xref rid="pone.0212785.ref151" ref-type="bibr">151</xref>], nortriptyline [<xref rid="pone.0212785.ref076" ref-type="bibr">76</xref>], valproic acid [<xref rid="pone.0212785.ref105" ref-type="bibr">105</xref>] and to the combination of propranolol and flunarizine [<xref rid="pone.0212785.ref151" ref-type="bibr">151</xref>]. In addition, a combination of propranolol and topiramate was compared to topiramate alone [<xref rid="pone.0212785.ref129" ref-type="bibr">129</xref>]. Propranolol was no better than valproic acid or flunarizine and the combinations (propranolol + topiramate and propranolol + flunarizine) was no better than topiramate and flunarizine alone (<xref rid="pone.0212785.t006" ref-type="table">Table 6</xref>).</p><table-wrap id="pone.0212785.t006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0212785.t006</object-id><label>Table 6</label><caption><title>Non-episodic trials.</title></caption><alternatives><graphic id="pone.0212785.t006g" xlink:href="pone.0212785.t006"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" colspan="6" rowspan="1">Chronic Migraine</th></tr><tr><th align="left" rowspan="1" colspan="1">Comparison</th><th align="left" rowspan="1" colspan="1">Outcome</th><th align="left" rowspan="1" colspan="1">Time point</th><th align="left" rowspan="1" colspan="1">Effect</th><th align="left" rowspan="1" colspan="1">Heterogeneity</th><th align="left" rowspan="1" colspan="1">Quality of Evidence</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Propranolol v. Placebo</td><td align="left" rowspan="1" colspan="1">50% reduction in headache (RR)</td><td align="left" rowspan="1" colspan="1">42 weeks</td><td align="left" rowspan="1" colspan="1">2.0 (0.94 to 4.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="2" colspan="1">Propranolol v. Flunarizine</td><td align="left" rowspan="2" colspan="1">Headache Frequency (headaches/month)</td><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">3.0 (0.79 to 5.2)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1">8 weeks</td><td align="left" rowspan="1" colspan="1">1.0 (-1.5 to 3.5)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="3" colspan="1">Propranolol + Flunarizine vs. Flunarizine</td><td align="left" rowspan="2" colspan="1">Headache Frequency (headaches/month)</td><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">2.0 (-0.19 to 4.2)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1">8 weeks</td><td align="left" rowspan="1" colspan="1">3.0 (0.56 to 5.4)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">50% reduction in headache (RR)</td><td align="left" rowspan="1" colspan="1">8 weeks</td><td align="left" rowspan="1" colspan="1">1.3 (0.97 to 1.6)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="2" colspan="1">Propranolol v. Nortriptyline</td><td align="left" rowspan="2" colspan="1">Headache Frequency (Headaches/month)</td><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">-1.0 (-4.7 to 2.7)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1">8 weeks</td><td align="left" rowspan="1" colspan="1">-9.0 (-12.7 to -5.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="2" colspan="1">Propranolol v. Propranolol + Nortriptyline</td><td align="left" rowspan="2" colspan="1">Headache Frequency (Headaches/month)</td><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">-4.0 (-7.8 to -0.24)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1">8 weeks</td><td align="left" rowspan="1" colspan="1">-7.0 (-10.8 to -3.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="6" colspan="1">Propranolol + Topiramate v. Topiramate</td><td align="left" rowspan="2" colspan="1">Headache Frequency (headaches/month)</td><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">0.0 (-0.28 to 0.28)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1">12 weeks</td><td align="left" rowspan="1" colspan="1">-0.80 (-2.3 to 0.67)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="2" colspan="1">Health Related Quality of Life (MIDAS)</td><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">0.00 (-0.28 to 0.28)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1">12 weeks</td><td align="left" rowspan="1" colspan="1">0.09 (-0.26 to 0.44)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="2" colspan="1">50% reduction in headache (RR)</td><td align="left" rowspan="1" colspan="1">12 weeks</td><td align="left" rowspan="1" colspan="1">1.05 (0.63 to 1.7)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1">24 weeks</td><td align="left" rowspan="1" colspan="1">1.1 (0.79 to 1.8)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">Propranolol v. Valproic Acid</td><td align="left" rowspan="1" colspan="1">Headache Frequency (headaches/month)</td><td align="left" rowspan="1" colspan="1">8 weeks</td><td align="left" rowspan="1" colspan="1">4.8 (0.27 to 9.2)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" colspan="6" rowspan="1"><bold>Chronic Tension-Type Headache</bold></td></tr><tr><td align="left" rowspan="6" colspan="1">Pindolol + Amitriptyline v. Placebo</td><td align="left" rowspan="3" colspan="1">Headache Frequency (headaches/month)</td><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">1.4 (-2.3 to 5.0)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="3" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1">4 weeks</td><td align="left" rowspan="1" colspan="1">7.8 (-13.9 to -1.5)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">8 weeks</td><td align="left" rowspan="1" colspan="1">-11.6 (-16.8 to -5.5)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">50% reduction in headache (RR)</td><td align="left" rowspan="1" colspan="1">8 weeks</td><td align="left" rowspan="1" colspan="1">3.8 (1.5 to 9.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="2" colspan="1">Headache Severity (SMD)</td><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">0.29 (-0.34 to 0.91)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="2" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1">8 weeks</td><td align="left" rowspan="1" colspan="1">-0.68 (-1.3 to -0.04)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="6" colspan="1">Pindolol + Amitriptyline v. Amitriptyline</td><td align="left" rowspan="3" colspan="1">Headache Frequency (headaches/month)</td><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">1.6 (-2.2 to 5.3)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="3" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1">4 weeks</td><td align="left" rowspan="1" colspan="1">0.64 (-5.2 to 6.4)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">8 weeks</td><td align="left" rowspan="1" colspan="1">-1.2 (-6.4 to 4.1)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">50% reduction in headache (RR)</td><td align="left" rowspan="1" colspan="1">8 weeks</td><td align="left" rowspan="1" colspan="1">1.4 (0.87 to 2.2)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="2" colspan="1">Headache Severity (SMD)</td><td align="left" rowspan="1" colspan="1">Baseline</td><td align="left" rowspan="1" colspan="1">3.7 (2.7 to 4.7)</td><td align="left" rowspan="1" colspan="1">&#x02014;<break/>&#x02014;</td><td align="left" rowspan="2" style="background-color:#FFFFFF" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1">8 weeks</td><td align="left" rowspan="1" colspan="1">-0.05 (-0.65 to 0.56)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec013"><title>Tension-type headache</title><p>There was only one trial evaluating tension-type headache, comparing the combination of pindolol and amitriptyline to placebo and to amitriptyline alone [<xref rid="pone.0212785.ref057" ref-type="bibr">57</xref>]. The combination of pindolol and amitriptyline was more effective than placebo at reducing headache frequency at 4 and 8 weeks (<xref rid="pone.0212785.t006" ref-type="table">Table 6</xref>) and in reducing headaches by at least 50% (RR: 3.8, 95% CI: 1.5&#x02013;9.3), but equally effective with amitriptyline.</p></sec><sec id="sec014"><title>Adverse events</title><p>Participants on beta-blockers were more likely to experience side effects than those on placebo (RR: 1.2, 95% CI: 1.0&#x02013;1.4), though they were not more likely to withdraw (RR: 0.99, 95% CI: 0.83 to 1.2). Specific side effects more common with beta-blockers included dizziness (RR: 1.5, 95% CI: 1.0&#x02013;2.3) and fatigue (RR: 1.5, 95% CI: 1.2&#x02013;2.0). Depression, gastrointestinal problems, paresthesia&#x02019;s and weight gain were not significantly different than placebo.</p><p>Propranolol was the only beta-blocker with sufficient numbers of studies to perform sensitivity analysis. There was no evidence of publication bias for propranolol&#x02019;s reduction of headache frequency at 8 weeks (Egger&#x02019;s p = 0.77) or at 12 weeks (p = 0.62). There was no evidence of an effect of quality (p = 0.97), age (p = 0.71), percent women (p = 0.28), percentage of dropouts (p = 0.55), dose (p = 0.61), intention to treat analysis (p = 0.35), concealed allocation (p = 0.38) or appropriateness of blinding (p = 0.98).</p></sec></sec><sec sec-type="conclusions" id="sec015"><title>Discussion</title><p>This review included one hundred and eight randomized controlled trials. Nearly all evaluated the efficacy of beta-blockers for episodic migraine headaches. Compared to placebo, propranolol was effective in reducing episodic migraine frequency. The effect began as early as four weeks. Migraine headache sufferers experienced an average reduction of 1.3 headaches/month; this translates to a reduction from 4.8 to 3.5 headaches a month. Subjects given propranolol were more likely to report at least 50% reduction in headaches and to reduce their consumption of analgesic medications. In addition to reducing the number of headaches, the residual headaches were less severe and shorter in duration compared to those receiving placebo. Outcomes from the propranolol comparisons to placebo were rated as high-quality evidence. In three trials, metoprolol also reduced headache frequency, though the reduction was less than 1 headache a month. Conclusions regarding the efficacy of other beta-blockers is less certain, as most were studied in just one trial each. Atenolol, bisoprolol and timolol had weak evidence of benefit. Acebutolol, alprenolol and nadolol appeared to be ineffective in migraine prophylaxis. This is unlikely to be due to properties of the beta-blockers. Propranolol is nonselective as is alprenolol and nadolol. Metoprolol, also effective is a &#x000df;-1 selective drug as is atenolol, bisoprolol and acebutolol. Given that acebutolol, alprenolol and nadolol were only studied in one trial each, it is possible that this may be either random variation in outcomes or a problem with the trials (such as dose or duration). The network analysis suggests that the benefit of beta-blocker may be a class effect.</p><p>The literature comparing beta-blockers to other modalities consisted mostly of single-trials with the exception of the comparison of propranolol to metoprolol (moderate quality, no difference) and to flunarizine (high quality, no difference). Flunarizine, not available in the United States, is well-established as effective in treating migraine headache. Universally, beta-blockers were associated with bradycardia and with lower average pulse rates than placebo trials. This is not surprising given their impact on chronotropy. Other side effects more common among participants taking beta-blockers included dizziness and fatigue, though subjects on beta-blockers were not more likely to withdraw from the studies.</p><p>While these conclusions are similar to previous reviews, this analysis is a unique contribution in many ways, first it included many more trials than previously reported, including Chinese trials that had previously not been included. Secondly, all beta-blockers were carefully parsed by type of headache (tension v. migraine, episodic v. chronic). Third, this study examined outcomes at the specific times reported, it is common for meta-analyses to pool trials at the last time point, regardless of whether there were significant differences in that time-point. Fourth, trial sequential analysis that demonstrated the adequacy of the current database for propranolol, suggesting that there is low likelihood of type 1 error in the conclusions. Fifth, the network meta-analysis didn&#x02019;t show clear benefit of one beta-blocker over another, suggesting a class effect, though other beta-blockers have weaker evidence for benefit.</p><p>An important question, unanswered in this review, is how effective beta-blockers are compared to other commonly used prophylactic regimens. Propranolol, metoprolol and flunarizine appear to have similar efficacy. The other comparisons were all single-trial comparisons, making definitive conclusions impossible. In a previous review, tricyclic antidepressants resulted in a reduction in headache frequency for patients experiencing chronic migraines of 1.3 SMD, compared to placebo, a large effect [<xref rid="pone.0212785.ref017" ref-type="bibr">17</xref>]. In this study, there was only had one trial on chronic migraines, and the calculated SMD was 0.58, about half of the effect previously reported for TCAs. In a network meta-analysis of chronic migraines, tricyclic antidepressants were more effective than propranolol [<xref rid="pone.0212785.ref017" ref-type="bibr">17</xref>] but propranolol was similar in efficacy to antiepileptics and flunarizine, similar to findings in this study, though it is important to note that the majority of trials for beta-blockers are for episodic rather than chronic migraines. Definitive answer to this comparative effectiveness question requires additional studies that directly compare the different prophylactic modalities.</p><p>This review has several important limitations. First, while the quality of evidence for the comparison between propranolol and placebo was high, in general, the remaining comparisons were of low quality, consisting mostly of underpowered single randomized trials. While all the included trials were randomized, there were significant methodologic problems; combining poorly designed studies can lead to questionable results. It is important to note that most of the comparisons were graded as being of low-quality evidence because of the paucity of studies and concern about study problems. Secondly, studies were inconsistent in reporting outcomes, so even when there were more than one trial available, specific outcomes may only be provided by a single study. Moreover, there were significant problems with selective reporting of outcomes and many studies did not collect information on headache frequency, the measure preferred by the International Headache Society. Third, the number of studies available precluded sensitivity analyses, such as assessing for publication bias or exploring sources of heterogeneity. Fourth, beta-blockers have been studied almost exclusively in the management of episodic migraine headaches. Their benefit for chronic episodic or tension-type headaches is uncertain. Fifth, because of the paucity of trials for most beta-blockers the network analysis was underpowered to show differences between beta-blockers, Sixth, the average age of participants was 38, and mostly female. While this reflects the demographics of headache, it limits applicability to older adults.</p></sec><sec sec-type="conclusions" id="sec016"><title>Conclusions</title><p>Propranolol is effective in reducing the burden of patients with episodic migraine headaches, reducing headaches from 5 to 3 headaches a month. This means that migraine sufferers given propranolol will have substantial residual headache burden. Propranolol reduces headaches by more than 50% as well as reducing the number of analgesic medication doses required. It also reduces the severity or duration of the headaches experienced. Propranolol and metoprolol exert similar effects and propranolol is as effective as flunarizine. The data for other beta-blockers and other comparisons are less clear.</p></sec><sec sec-type="supplementary-material" id="sec017"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0212785.s001"><label>S1 Table</label><caption><title>Prisma checklist.</title><p>(DOC)</p></caption><media xlink:href="pone.0212785.s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0212785.s002"><label>S2 Table</label><caption><title>Search strategy.</title><p>(DOCX)</p></caption><media xlink:href="pone.0212785.s002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0212785.s003"><label>S3 Table</label><caption><title>Quality ratings of included trials.</title><p>(DOCX)</p></caption><media xlink:href="pone.0212785.s003.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The views reflected in this manuscript are those of the authors and should not be construed, in any way, to be those of the Department of Veterans Affairs.</p></ack><ref-list><title>References</title><ref id="pone.0212785.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Rasmussen</surname><given-names>BK</given-names></name>. <article-title>Epidemiology of headache</article-title>. <source>Cephalalgia</source>
<year>2001</year>; <volume>21</volume>(<issue>7</issue>):<fpage>774</fpage>&#x02013;<lpage>777</lpage>. <pub-id pub-id-type="doi">10.1177/033310240102100708</pub-id>
<?supplied-pmid 11595011?><pub-id pub-id-type="pmid">11595011</pub-id></mixed-citation></ref><ref id="pone.0212785.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>SJ</given-names></name>. <article-title>Epidemiology of migraine and other types of headache in Asia</article-title>. <source>Current Neurology &#x00026; Neuroscience Reports</source>
<year>2003</year>; <volume>3</volume>(<issue>2</issue>):<fpage>104</fpage>&#x02013;<lpage>108</lpage>.<pub-id pub-id-type="pmid">12583837</pub-id></mixed-citation></ref><ref id="pone.0212785.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Radtke</surname><given-names>A</given-names></name>, <name><surname>Neuhauser</surname><given-names>H</given-names></name>. <article-title>Prevalence and burden of headache and migraine in Germany</article-title>. <source>Headache</source>
<year>2009</year>; <volume>49</volume>(<issue>1</issue>):<fpage>79</fpage>&#x02013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1111/j.1526-4610.2008.01263.x</pub-id>
<?supplied-pmid 19125877?><pub-id pub-id-type="pmid">19125877</pub-id></mixed-citation></ref><ref id="pone.0212785.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Karli</surname><given-names>N</given-names></name>, <name><surname>Zarifoglu</surname><given-names>M</given-names></name>, <name><surname>Ertafs</surname><given-names>M</given-names></name>, <name><surname>Saip</surname><given-names>S</given-names></name>, <name><surname>Ozturk</surname><given-names>V</given-names></name>, <name><surname>Bicakci</surname><given-names>S</given-names></name>
<etal>et al</etal>
<article-title>Economic impact of primary headaches in Turkey: a university hospital based study: part II</article-title>. <source>J Headache Pain</source>
<year>2006</year>; <volume>7</volume>(<issue>2</issue>):<fpage>75</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1007/s10194-006-0273-7</pub-id>
<?supplied-pmid 16538424?><pub-id pub-id-type="pmid">16538424</pub-id></mixed-citation></ref><ref id="pone.0212785.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Falavigna</surname><given-names>A</given-names></name>, <name><surname>Teles</surname><given-names>AR</given-names></name>, <name><surname>Velho</surname><given-names>MC</given-names></name>, <name><surname>Vedana</surname><given-names>VM</given-names></name>, <name><surname>Silva</surname><given-names>RC</given-names></name>, <name><surname>Mazzocchin</surname><given-names>T</given-names></name>
<etal>et al</etal>
<article-title>Prevalence and impact of headache in undergraduate students in Southern Brazil</article-title>. <source>Arq Neuropsiquiatr</source>
<year>2010</year>; <volume>68</volume>(<issue>6</issue>):<fpage>873</fpage>&#x02013;<lpage>877</lpage>. <?supplied-pmid 21243244?><pub-id pub-id-type="pmid">21243244</pub-id></mixed-citation></ref><ref id="pone.0212785.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Lipton</surname><given-names>RB</given-names></name>, <name><surname>Bigal</surname><given-names>ME</given-names></name>, <name><surname>Kolodner</surname><given-names>K</given-names></name>, <name><surname>Stewart</surname><given-names>WF</given-names></name>, <name><surname>Liberman</surname><given-names>JN</given-names></name>, <name><surname>Steiner</surname><given-names>TJ</given-names></name>. <article-title>The family impact of migraine: population-based studies in the USA and UK</article-title>. <source>Cephalalgia</source>
<year>2003</year>; <volume>23</volume>(<issue>6</issue>):<fpage>429</fpage>&#x02013;<lpage>440</lpage>. <pub-id pub-id-type="doi">10.1046/j.1468-2982.2003.00543.x</pub-id>
<?supplied-pmid 12807522?><pub-id pub-id-type="pmid">12807522</pub-id></mixed-citation></ref><ref id="pone.0212785.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Lipton</surname><given-names>RB</given-names></name>, <name><surname>Liberman</surname><given-names>JN</given-names></name>, <name><surname>Kolodner</surname><given-names>KB</given-names></name>, <name><surname>Bigal</surname><given-names>ME</given-names></name>, <name><surname>Dowson</surname><given-names>A</given-names></name>, <name><surname>Stewart</surname><given-names>WF</given-names></name>. <article-title>Migraine headache disability and health-related quality-of-life: a population-based case-control study from England</article-title>. <source>Cephalalgia</source>
<year>2003</year>; <volume>23</volume>(<issue>6</issue>):<fpage>441</fpage>&#x02013;<lpage>450</lpage>. <pub-id pub-id-type="doi">10.1046/j.1468-2982.2003.00546.x</pub-id>
<?supplied-pmid 12807523?><pub-id pub-id-type="pmid">12807523</pub-id></mixed-citation></ref><ref id="pone.0212785.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Adams</surname><given-names>AM</given-names></name>, <name><surname>Serrano</surname><given-names>D</given-names></name>, <name><surname>Buse</surname><given-names>DC</given-names></name>, <name><surname>Reed</surname><given-names>ML</given-names></name>, <name><surname>Marske</surname><given-names>V</given-names></name>, <name><surname>Fanning</surname><given-names>KM</given-names></name>
<etal>et al</etal>
<article-title>The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results</article-title>. <source>Cephalalgia</source>
<year>2015</year>; <volume>35</volume>(<issue>7</issue>):<fpage>563</fpage>&#x02013;<lpage>578</lpage>. <pub-id pub-id-type="doi">10.1177/0333102414552532</pub-id>
<?supplied-pmid 25304766?><pub-id pub-id-type="pmid">25304766</pub-id></mixed-citation></ref><ref id="pone.0212785.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Buse</surname><given-names>DC</given-names></name>, <name><surname>Manack</surname><given-names>AN</given-names></name>, <name><surname>Fanning</surname><given-names>KM</given-names></name>, <name><surname>Serrano</surname><given-names>D</given-names></name>, <name><surname>Reed</surname><given-names>ML</given-names></name>, <name><surname>Turkel</surname><given-names>CC</given-names></name>
<etal>et al</etal>
<article-title>Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study</article-title>. <source>Headache</source>
<year>2012</year>; <volume>52</volume>(<issue>10</issue>):<fpage>1456</fpage>&#x02013;<lpage>1470</lpage>. <pub-id pub-id-type="doi">10.1111/j.1526-4610.2012.02223.x</pub-id>
<?supplied-pmid 22830411?><pub-id pub-id-type="pmid">22830411</pub-id></mixed-citation></ref><ref id="pone.0212785.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Blumenfeld</surname><given-names>AM</given-names></name>, <name><surname>Varon</surname><given-names>SF</given-names></name>, <name><surname>Wilcox</surname><given-names>TK</given-names></name>, <name><surname>Buse</surname><given-names>DC</given-names></name>, <name><surname>Kawata</surname><given-names>AK</given-names></name>, <name><surname>Manack</surname><given-names>A</given-names></name>
<etal>et al</etal>
<article-title>Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS)</article-title>. <source>Cephalalgia</source>
<year>2011</year>; <volume>31</volume>(<issue>3</issue>):<fpage>301</fpage>&#x02013;<lpage>315</lpage>. <pub-id pub-id-type="doi">10.1177/0333102410381145</pub-id>
<?supplied-pmid 20813784?><pub-id pub-id-type="pmid">20813784</pub-id></mixed-citation></ref><ref id="pone.0212785.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Leonardi</surname><given-names>M</given-names></name>, <name><surname>Raggi</surname><given-names>A</given-names></name>, <name><surname>Bussone</surname><given-names>G</given-names></name>, <name><surname>D'Amico</surname><given-names>D</given-names></name>. <article-title>Health-related quality of life, disability and severity of disease in patients with migraine attending to a specialty headache center</article-title>. <source>Headache</source>
<year>2010</year>; <volume>50</volume>(<issue>10</issue>):<fpage>1576</fpage>&#x02013;<lpage>1586</lpage>. <pub-id pub-id-type="doi">10.1111/j.1526-4610.2010.01770.x</pub-id>
<?supplied-pmid 21029083?><pub-id pub-id-type="pmid">21029083</pub-id></mixed-citation></ref><ref id="pone.0212785.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Raggi</surname><given-names>A</given-names></name>, <name><surname>Leonardi</surname><given-names>M</given-names></name>, <name><surname>Bussone</surname><given-names>G</given-names></name>, <name><surname>D'Amico</surname><given-names>D</given-names></name>. <article-title>Value and utility of disease-specific and generic instruments for assessing disability in patients with migraine, and their relationships with health-related quality of life</article-title>. <source>Neurol Sci</source>
<year>2010</year>.</mixed-citation></ref><ref id="pone.0212785.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Tepper</surname><given-names>SJ</given-names></name>. <article-title>A pivotal moment in 50 years of headache history: the first American Migraine Study</article-title>. <source>Headache</source>
<year>2008</year>; <volume>48</volume>(<issue>5</issue>):<fpage>730</fpage>&#x02013;<lpage>731</lpage>. <pub-id pub-id-type="doi">10.1111/j.1526-4610.2008.01117_1.x</pub-id>
<?supplied-pmid 18471125?><pub-id pub-id-type="pmid">18471125</pub-id></mixed-citation></ref><ref id="pone.0212785.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Freitag</surname><given-names>FG</given-names></name>. <article-title>The cycle of migraine: patients' quality of life during and between migraine attacks</article-title>. <source>Clin Ther</source>
<year>2007</year>; <volume>29</volume>(<issue>5</issue>):<fpage>939</fpage>&#x02013;<lpage>949</lpage>. <pub-id pub-id-type="doi">10.1016/j.clinthera.2007.05.008</pub-id>
<?supplied-pmid 17697913?><pub-id pub-id-type="pmid">17697913</pub-id></mixed-citation></ref><ref id="pone.0212785.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Hu</surname><given-names>XH</given-names></name>, <name><surname>Markson</surname><given-names>LE</given-names></name>, <name><surname>Lipton</surname><given-names>RB</given-names></name>, <name><surname>Stewart</surname><given-names>WF</given-names></name>, <name><surname>Berger</surname><given-names>ML</given-names></name>. <article-title>Burden of migraine in the United States: disability and economic costs</article-title>. <source>Archives of Internal Medicine</source>
<year>1999</year>; <volume>159</volume>(<issue>8</issue>):<fpage>813</fpage>&#x02013;<lpage>818</lpage>. <?supplied-pmid 10219926?><pub-id pub-id-type="pmid">10219926</pub-id></mixed-citation></ref><ref id="pone.0212785.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Goldberg</surname><given-names>LD</given-names></name>. <article-title>The cost of migraine and its treatment</article-title>. <source>Am J Manag Care</source>
<year>2005</year>; <volume>11</volume>(<issue>2</issue> Suppl):<fpage>S62</fpage>&#x02013;<lpage>S67</lpage>.<pub-id pub-id-type="pmid">16095269</pub-id></mixed-citation></ref><ref id="pone.0212785.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Jackson</surname><given-names>JL</given-names></name>, <name><surname>Cogbill</surname><given-names>E</given-names></name>, <name><surname>Santana-Davila</surname><given-names>R</given-names></name>, <name><surname>Eldredge</surname><given-names>C</given-names></name>, <name><surname>Collier</surname><given-names>W</given-names></name>, <name><surname>Gradall</surname><given-names>A</given-names></name>
<etal>et al</etal>
<article-title>A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache</article-title>. <source>Plos One</source>
<year>2015</year>; <volume>10</volume>(<issue>7</issue>):<fpage>e0130733</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0130733</pub-id>
<?supplied-pmid 26172390?><pub-id pub-id-type="pmid">26172390</pub-id></mixed-citation></ref><ref id="pone.0212785.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Ferrante</surname><given-names>T</given-names></name>, <name><surname>Manzoni</surname><given-names>GC</given-names></name>, <name><surname>Russo</surname><given-names>M</given-names></name>, <name><surname>Camarda</surname><given-names>C</given-names></name>, <name><surname>Taga</surname><given-names>A</given-names></name>, <name><surname>Veronesi</surname><given-names>L</given-names></name>
<etal>et al</etal>
<article-title>Prevalence of tension-type headache in adult general population: the PACE study and review of the literature</article-title>. <source>Neurological Sciences</source>
<year>2013</year>; <volume>34</volume>
<issue>Suppl 1</issue>:<fpage>S137</fpage>&#x02013;<lpage>S138</lpage>.<pub-id pub-id-type="pmid">23695063</pub-id></mixed-citation></ref><ref id="pone.0212785.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Lyngberg</surname><given-names>AC</given-names></name>, <name><surname>Rasmussen</surname><given-names>BK</given-names></name>, <name><surname>Jorgensen</surname><given-names>T</given-names></name>, <name><surname>Jensen</surname><given-names>R</given-names></name>. <article-title>Has the prevalence of migraine and tension-type headache changed over a 12-year period</article-title>? <source>European Journal of Epidemiology</source>
<year>2005</year>; <volume>20</volume>(<issue>3</issue>):<fpage>243</fpage>&#x02013;<lpage>249</lpage>. <?supplied-pmid 15921042?><pub-id pub-id-type="pmid">15921042</pub-id></mixed-citation></ref><ref id="pone.0212785.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Rasmussen</surname><given-names>BK</given-names></name>, <name><surname>Jensen</surname><given-names>R</given-names></name>, <name><surname>Schroll</surname><given-names>M</given-names></name>, <name><surname>Olesen</surname><given-names>J</given-names></name>. <article-title>Epidemiology of headache in a general population&#x02014;A prevalence study</article-title>. <source>Journal of Clinical Epidemiology</source>
<year>1991</year>; <volume>44</volume>(<issue>11</issue>):<fpage>1147</fpage>&#x02013;<lpage>1157</lpage>. <?supplied-pmid 1941010?><pub-id pub-id-type="pmid">1941010</pub-id></mixed-citation></ref><ref id="pone.0212785.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Schwartz</surname><given-names>BS</given-names></name>, <name><surname>Stewart</surname><given-names>WF</given-names></name>, <name><surname>Simon</surname><given-names>D</given-names></name>, <name><surname>Lipton</surname><given-names>RB</given-names></name>. <article-title>Epidemiology of tension-type headache</article-title>. <source>JAMA</source>
<year>1998</year>; <volume>279</volume>(<issue>5</issue>):<fpage>381</fpage>&#x02013;<lpage>383</lpage>. <?supplied-pmid 9459472?><pub-id pub-id-type="pmid">9459472</pub-id></mixed-citation></ref><ref id="pone.0212785.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Stovner</surname><given-names>LJ</given-names></name>, <name><surname>Hagen</surname><given-names>K</given-names></name>, <name><surname>Jensen</surname><given-names>J</given-names></name>, <name><surname>Katsarava</surname><given-names>Z</given-names></name>, <name><surname>Lipton</surname><given-names>RB</given-names></name>, <name><surname>Scher</surname><given-names>AI</given-names></name>
<etal>et al</etal>
<article-title>The global burden of headache: a documentation of headache prevalence and disability worldwide</article-title>. <source>Cephalalgia</source>
<year>2007</year>; <volume>27</volume>(<issue>3</issue>):<fpage>193</fpage>&#x02013;<lpage>210</lpage>. <pub-id pub-id-type="doi">10.1111/j.1468-2982.2007.01288.x</pub-id>
<?supplied-pmid 17381554?><pub-id pub-id-type="pmid">17381554</pub-id></mixed-citation></ref><ref id="pone.0212785.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Abu Bakar</surname><given-names>N</given-names></name>, <name><surname>Tanprawate</surname><given-names>S</given-names></name>, <name><surname>Lambru</surname><given-names>G</given-names></name>, <name><surname>Torkamani</surname><given-names>M</given-names></name>, <name><surname>Jahanshahi</surname><given-names>M</given-names></name>, <name><surname>Matharu</surname><given-names>M</given-names></name>. <article-title>Quality of life in primary headache disorders: A review</article-title>. <source>Cephalalgia</source>
<year>2016</year>; <volume>36</volume>(<issue>1</issue>):<fpage>67</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1177/0333102415580099</pub-id>
<?supplied-pmid 25888584?><pub-id pub-id-type="pmid">25888584</pub-id></mixed-citation></ref><ref id="pone.0212785.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Latinovic</surname><given-names>R</given-names></name>, <name><surname>Gulliford</surname><given-names>M</given-names></name>, <name><surname>Ridsdale</surname><given-names>L</given-names></name>. <article-title>Headache and migraine in primary care: consultation, prescription, and referral rates in a large population</article-title>. <source>J Neurol Neurosurg Psychiatry</source>
<year>2006</year>; <volume>77</volume>(<issue>3</issue>):<fpage>385</fpage>&#x02013;<lpage>387</lpage>. <pub-id pub-id-type="doi">10.1136/jnnp.2005.073221</pub-id>
<?supplied-pmid 16484650?><pub-id pub-id-type="pmid">16484650</pub-id></mixed-citation></ref><ref id="pone.0212785.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Linde</surname><given-names>M</given-names></name>, <name><surname>Gustavsson</surname><given-names>A</given-names></name>, <name><surname>Stovner</surname><given-names>LJ</given-names></name>, <name><surname>Steiner</surname><given-names>TJ</given-names></name>, <name><surname>Barr</surname><given-names>AJ</given-names></name>., <name><surname>Katsarava</surname><given-names>Z</given-names></name>
<etal>et al</etal>
<article-title>The cost of headache disorders in Europe: the Eurolight project</article-title>. <source>European Journal of Neurology</source>
<year>2012</year>; <volume>19</volume>(<issue>5</issue>):<fpage>703</fpage>&#x02013;<lpage>711</lpage>. <pub-id pub-id-type="doi">10.1111/j.1468-1331.2011.03612.x</pub-id>
<?supplied-pmid 22136117?><pub-id pub-id-type="pmid">22136117</pub-id></mixed-citation></ref><ref id="pone.0212785.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Chronicle</surname><given-names>E</given-names></name>, <name><surname>Mulleners</surname><given-names>W</given-names></name>. <article-title>Anticonvulsant drugs for migraine prophylaxis</article-title>. <source>Cochrane Library</source>
<year>2004</year>;(<issue>3</issue>).</mixed-citation></ref><ref id="pone.0212785.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Linde</surname><given-names>K</given-names></name>, <name><surname>Rossnagel</surname><given-names>K</given-names></name>. <article-title>Propranolol for migraine prophylaxis</article-title>. <source>Cochrane Database Syst Rev</source>
<year>2004</year>;(<issue>2</issue>):<fpage>CD003225</fpage>
<pub-id pub-id-type="doi">10.1002/14651858.CD003225.pub2</pub-id>
<?supplied-pmid 15106196?><pub-id pub-id-type="pmid">15106196</pub-id></mixed-citation></ref><ref id="pone.0212785.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Jackson</surname><given-names>JL</given-names></name>, <name><surname>Kuriyama</surname><given-names>A</given-names></name>, <name><surname>Hayashino</surname><given-names>Y</given-names></name>. <article-title>Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis</article-title>. <source>JAMA</source>
<year>2012</year>; <volume>307</volume>(<issue>16</issue>):<fpage>1736</fpage>&#x02013;<lpage>1745</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2012.505</pub-id>
<?supplied-pmid 22535858?><pub-id pub-id-type="pmid">22535858</pub-id></mixed-citation></ref><ref id="pone.0212785.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Pringsheim</surname><given-names>T</given-names></name>, <name><surname>Davenport</surname><given-names>WJ</given-names></name>, <name><surname>Becker</surname><given-names>WJ</given-names></name>. <article-title>Prophylaxis of migraine headache</article-title>. <source>CMAJ</source>
<year>2010</year>; <volume>182</volume>(<issue>7</issue>):<fpage>E269</fpage>&#x02013;<lpage>E276</lpage>. <pub-id pub-id-type="doi">10.1503/cmaj.081657</pub-id>
<?supplied-pmid 20159899?><pub-id pub-id-type="pmid">20159899</pub-id></mixed-citation></ref><ref id="pone.0212785.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Lance</surname><given-names>JW</given-names></name>, <name><surname>Anthony</surname><given-names>M</given-names></name>. <article-title>Clinical trial of a new serotonin antagonist, BC105, in the prevention of migraine</article-title>. <source>Med J Aust</source>
<year>1968</year>; <volume>1</volume>(<issue>2</issue>):<fpage>54</fpage>&#x02013;<lpage>55</lpage>. <?supplied-pmid 4867512?><pub-id pub-id-type="pmid">4867512</pub-id></mixed-citation></ref><ref id="pone.0212785.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Moja</surname><given-names>PL</given-names></name>, <name><surname>Cusi</surname><given-names>C</given-names></name>, <name><surname>Sterzi</surname><given-names>RR</given-names></name>, <name><surname>Canepari</surname><given-names>C</given-names></name>. <article-title>Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches</article-title>. <source>Cochrane Database Syst Rev</source>
<year>2005</year>;(<issue>3</issue>):<fpage>CD002919</fpage>
<pub-id pub-id-type="doi">10.1002/14651858.CD002919.pub2</pub-id>
<?supplied-pmid 16034880?><pub-id pub-id-type="pmid">16034880</pub-id></mixed-citation></ref><ref id="pone.0212785.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Jackson</surname><given-names>JL</given-names></name>, <name><surname>Shimeall</surname><given-names>W</given-names></name>, <name><surname>Sessums</surname><given-names>L</given-names></name>, <name><surname>Dezee</surname><given-names>KJ</given-names></name>, <name><surname>Becher</surname><given-names>D</given-names></name>, <name><surname>Diemer</surname><given-names>M</given-names></name>
<etal>et al</etal>
<article-title>Tricyclic antidepressants and headaches: systematic review and meta-analysis</article-title>. <source>BMJ</source>
<year>2010</year>; <volume>341</volume>:<fpage>c5222</fpage>
<pub-id pub-id-type="doi">10.1136/bmj.c5222</pub-id>
<?supplied-pmid 20961988?><pub-id pub-id-type="pmid">20961988</pub-id></mixed-citation></ref><ref id="pone.0212785.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Rapaport</surname><given-names>AM</given-names></name>. <article-title>Recurrent migraine: cost-effective care</article-title>. <source>Neurology</source>
<year>1994</year>; <volume>44</volume>(<issue>5</issue> Suppl 3):<fpage>S25</fpage>&#x02013;<lpage>S28</lpage>.<pub-id pub-id-type="pmid">8202231</pub-id></mixed-citation></ref><ref id="pone.0212785.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Silberstein</surname><given-names>SD</given-names></name>, <name><surname>Holland</surname><given-names>S</given-names></name>, <name><surname>Freitag</surname><given-names>F</given-names></name>, <name><surname>Dodick</surname><given-names>DW</given-names></name>, <name><surname>Argoff</surname><given-names>C</given-names></name>, <name><surname>Ashman</surname><given-names>E</given-names></name>. <article-title>Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society</article-title>. <source>Neurology</source>
<year>2012</year>; <volume>78</volume>(<issue>17</issue>):<fpage>1337</fpage>&#x02013;<lpage>1345</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0b013e3182535d20</pub-id>
<?supplied-pmid 22529202?><pub-id pub-id-type="pmid">22529202</pub-id></mixed-citation></ref><ref id="pone.0212785.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Ferrari</surname><given-names>A</given-names></name>, <name><surname>Pasciullo</surname><given-names>G</given-names></name>, <name><surname>Savino</surname><given-names>G</given-names></name>, <name><surname>Cicero</surname><given-names>AF</given-names></name>, <name><surname>Ottani</surname><given-names>A</given-names></name>, <name><surname>Bertolini</surname><given-names>A</given-names></name>
<etal>et al</etal>
<article-title>Headache treatment before and after the consultation of a specialized centre: a pharmacoepidemiology study</article-title>. <source>Cephalalgia</source>
<year>2004</year>; <volume>24</volume>(<issue>5</issue>):<fpage>356</fpage>&#x02013;<lpage>362</lpage>. <pub-id pub-id-type="doi">10.1111/j.1468-2982.2004.00678.x</pub-id>
<?supplied-pmid 15096224?><pub-id pub-id-type="pmid">15096224</pub-id></mixed-citation></ref><ref id="pone.0212785.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Takaki</surname><given-names>H</given-names></name>, <name><surname>Onzuka</surname><given-names>D</given-names></name>, <name><surname>Hagihara</surname><given-names>A</given-names></name>. <article-title>Migraine-preventive prescription patters by specialty in ambulatory care settings in the United States</article-title>. <source>Prev Med</source>
<year>2017</year>; <volume>9</volume>:<fpage>62</fpage>&#x02013;<lpage>67</lpage>.</mixed-citation></ref><ref id="pone.0212785.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Hepp</surname><given-names>Z</given-names></name>, <name><surname>Dodick</surname><given-names>D</given-names></name>. <article-title>Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis</article-title>. <source>Cephalagia</source>
<year>2017</year>; <volume>37</volume>(<issue>5</issue>):<fpage>470</fpage>&#x02013;<lpage>485</lpage>.</mixed-citation></ref><ref id="pone.0212785.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Mafi</surname><given-names>JN</given-names></name>, <name><surname>Edwards</surname><given-names>ST</given-names></name>, <name><surname>Pedersen</surname><given-names>NP</given-names></name>, <name><surname>Davis</surname><given-names>RB</given-names></name>, <name><surname>McCarthy</surname><given-names>EP</given-names></name>, <name><surname>Landon</surname><given-names>BE</given-names></name>. <article-title>Trends in the ambulatory management of headache: analysis of NAMCS and NHAMCS data 1999&#x02013;2010</article-title>. <source>J Gen Intern Med</source>
<year>2015</year>; <volume>30</volume>(<issue>5</issue>):<fpage>548</fpage>&#x02013;<lpage>555</lpage>. <pub-id pub-id-type="doi">10.1007/s11606-014-3107-3</pub-id>
<?supplied-pmid 25567755?><pub-id pub-id-type="pmid">25567755</pub-id></mixed-citation></ref><ref id="pone.0212785.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Holroyd</surname><given-names>KA</given-names></name>, <name><surname>Penzien</surname><given-names>DB</given-names></name>, <name><surname>Cordingley</surname><given-names>GE</given-names></name>. <article-title>Propranolol in the management of recurrent migraine: a meta-analytic review</article-title>. <source>Headache</source>
<year>1991</year>; <volume>31</volume>(<issue>5</issue>):<fpage>333</fpage>&#x02013;<lpage>340</lpage>. <?supplied-pmid 1830566?><pub-id pub-id-type="pmid">1830566</pub-id></mixed-citation></ref><ref id="pone.0212785.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Linde</surname><given-names>K</given-names></name>, <name><surname>Rossnagel</surname><given-names>K</given-names></name>. <article-title>Propranolol for migraine prophylaxis</article-title>. <source>Cochrane Database Syst Rev</source>
<year>2004</year>;(<issue>2</issue>):<fpage>CD003225</fpage>
<pub-id pub-id-type="doi">10.1002/14651858.CD003225.pub2</pub-id>
<?supplied-pmid 15106196?><pub-id pub-id-type="pmid">15106196</pub-id></mixed-citation></ref><ref id="pone.0212785.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Shamliyan</surname><given-names>TA</given-names></name>, <name><surname>Choi</surname><given-names>JY</given-names></name>, <name><surname>Ramakrishnan</surname><given-names>R</given-names></name>, <name><surname>Miller</surname><given-names>JB</given-names></name>, <name><surname>Wang</surname><given-names>SY</given-names></name>, <name><surname>Taylor</surname><given-names>FR</given-names></name>
<etal>et al</etal>
<article-title>Preventive pharmacologic treatments for episodic migraine in adults</article-title>. <source>J Gen Intern Med</source>
<year>2013</year>; <volume>28</volume>(<issue>9</issue>):<fpage>1225</fpage>&#x02013;<lpage>1237</lpage>. <pub-id pub-id-type="doi">10.1007/s11606-013-2433-1</pub-id>
<?supplied-pmid 23592242?><pub-id pub-id-type="pmid">23592242</pub-id></mixed-citation></ref><ref id="pone.0212785.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Moher</surname><given-names>D</given-names></name>, <name><surname>Liverati</surname><given-names>A</given-names></name>, <name><surname>Tetzlaff</surname><given-names>J</given-names></name>, <name><surname>Altman</surname><given-names>DG</given-names></name>. <article-title>Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement</article-title>. <source>PLOS Medicine</source>
<year>2009</year>; <volume>6</volume>(<issue>7</issue>):<fpage>e1000097</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pmed.1000097</pub-id>
<?supplied-pmid 19621072?><pub-id pub-id-type="pmid">19621072</pub-id></mixed-citation></ref><ref id="pone.0212785.ref043"><label>43</label><mixed-citation publication-type="journal"><collab>Headache Classification Committee of the International Headache Society (IHS)</collab>
<article-title>The International Classification of Headache Disorders, 3rd edition</article-title>. <source>Cephalalgia</source>
<year>2018</year>; <volume>38</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>211</lpage>. <pub-id pub-id-type="doi">10.1177/0333102417738202</pub-id>
<?supplied-pmid 29368949?><pub-id pub-id-type="pmid">29368949</pub-id></mixed-citation></ref><ref id="pone.0212785.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Bendtsen</surname><given-names>L</given-names></name>, <name><surname>Bigal</surname><given-names>ME</given-names></name>, <name><surname>Cerbo</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Guidelines for controlled trials of drugs in tension-type headache: Second edition</article-title>. <source>Cephalalgia</source>
<year>2010</year>; <volume>30</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1111/j.1468-2982.2009.01948.x</pub-id>
<?supplied-pmid 19614696?><pub-id pub-id-type="pmid">19614696</pub-id></mixed-citation></ref><ref id="pone.0212785.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Higgins</surname><given-names>JPT</given-names></name>, <name><surname>Green</surname><given-names>S</given-names></name>. <article-title>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.cochrane-handbook.org">www.cochrane-handbook.org</ext-link>. <year>2011</year>
<source>Ref Type: Generic</source></mixed-citation></ref><ref id="pone.0212785.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Jadad</surname><given-names>AR</given-names></name>, <name><surname>Moore</surname><given-names>RA</given-names></name>, <name><surname>Carroll</surname><given-names>D</given-names></name>, <name><surname>Jenkinson</surname><given-names>C</given-names></name>, <name><surname>Reynolds</surname><given-names>DJ</given-names></name>, <name><surname>Gavaghan</surname><given-names>DJ</given-names></name>
<etal>et al</etal>
<article-title>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</article-title>
<source>Control Clin Trials</source>
<year>1996</year>; <volume>17</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>12</lpage>. <?supplied-pmid 8721797?><pub-id pub-id-type="pmid">8721797</pub-id></mixed-citation></ref><ref id="pone.0212785.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Kazis</surname><given-names>LE</given-names></name>, <name><surname>Anderson</surname><given-names>JJ</given-names></name>, <name><surname>Meenan</surname><given-names>RF</given-names></name>. <article-title>Effect sizes for interpreting changes in health status</article-title>. <source>Medical Care</source>
<year>1989</year>; <volume>27</volume>
<issue>Suppl 3</issue>:<fpage>S178</fpage>&#x02013;<lpage>S189</lpage>.<pub-id pub-id-type="pmid">2646488</pub-id></mixed-citation></ref><ref id="pone.0212785.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Follmann</surname><given-names>D</given-names></name>, <name><surname>Elliott</surname><given-names>P</given-names></name>, <name><surname>Suh</surname><given-names>I</given-names></name>, <name><surname>Cutler</surname><given-names>J</given-names></name>. <article-title>Variance imputation for overviews of clinical trials with continuous response</article-title>. <source>Journal of Clinical Epidemiology</source>
<year>1992</year>; <volume>45</volume>(<issue>7</issue>):<fpage>769</fpage>&#x02013;<lpage>773</lpage>. <?supplied-pmid 1619456?><pub-id pub-id-type="pmid">1619456</pub-id></mixed-citation></ref><ref id="pone.0212785.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Galbraith</surname><given-names>RF</given-names></name>. <article-title>A note on graphical presentation of estimated odds ratios from several clinical trials</article-title>. <source>Statistics in Medicine</source>
<year>1988</year>; <volume>7</volume>(<issue>8</issue>):<fpage>889</fpage>&#x02013;<lpage>894</lpage>. <?supplied-pmid 3413368?><pub-id pub-id-type="pmid">3413368</pub-id></mixed-citation></ref><ref id="pone.0212785.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Higgins</surname><given-names>JP</given-names></name>, <name><surname>Thompson</surname><given-names>SG</given-names></name>, <name><surname>Deeks</surname><given-names>JJ</given-names></name>, <name><surname>Altman</surname><given-names>DG</given-names></name>. <article-title>Measuring inconsistency in meta-analyses</article-title>. <source>BMJ</source>
<year>2003</year>; <volume>327</volume>(<issue>7414</issue>):<fpage>557</fpage>&#x02013;<lpage>560</lpage>. <pub-id pub-id-type="doi">10.1136/bmj.327.7414.557</pub-id>
<?supplied-pmid 12958120?><pub-id pub-id-type="pmid">12958120</pub-id></mixed-citation></ref><ref id="pone.0212785.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>DerSimonian</surname><given-names>R</given-names></name>, <name><surname>Laird</surname><given-names>N</given-names></name>. <article-title>Meta-analysis in clinical trials</article-title>. <source>Controlled Clinical Trials</source>
<year>1986</year>; <volume>7</volume>(<issue>3</issue>):<fpage>177</fpage>&#x02013;<lpage>188</lpage>. <?supplied-pmid 3802833?><pub-id pub-id-type="pmid">3802833</pub-id></mixed-citation></ref><ref id="pone.0212785.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Peters</surname><given-names>JL</given-names></name>, <name><surname>Sutton</surname><given-names>AJ</given-names></name>, <name><surname>Jones</surname><given-names>DR</given-names></name>, <name><surname>Abrams</surname><given-names>KR</given-names></name>, <name><surname>Rushton</surname><given-names>L</given-names></name>. <article-title>Comparison of two methods to detect publication bias in meta-analysis</article-title>. <source>JAMA</source>
<year>2006</year>; <volume>295</volume>(<issue>6</issue>):<fpage>676</fpage>&#x02013;<lpage>680</lpage>. <pub-id pub-id-type="doi">10.1001/jama.295.6.676</pub-id>
<?supplied-pmid 16467236?><pub-id pub-id-type="pmid">16467236</pub-id></mixed-citation></ref><ref id="pone.0212785.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Egger</surname><given-names>M</given-names></name>, <name><surname>Davey Smith</surname><given-names>G</given-names></name>, <name><surname>Schneider</surname><given-names>M</given-names></name>, <name><surname>Minder</surname><given-names>C</given-names></name>. <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>BMJ</source>
<year>1997</year>; <volume>315</volume>(<issue>7109</issue>):<fpage>629</fpage>&#x02013;<lpage>634</lpage>. <?supplied-pmid 9310563?><pub-id pub-id-type="pmid">9310563</pub-id></mixed-citation></ref><ref id="pone.0212785.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Wetterslev</surname><given-names>J</given-names></name>, <name><surname>Thorlund</surname><given-names>K</given-names></name>, <name><surname>Brok</surname><given-names>J</given-names></name>, <name><surname>Gluud</surname><given-names>C</given-names></name>. <article-title>Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis</article-title>. <source>J Clin Epidemiol</source>
<year>2008</year>; <volume>61</volume>(<issue>1</issue>):<fpage>64</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1016/j.jclinepi.2007.03.013</pub-id>
<?supplied-pmid 18083463?><pub-id pub-id-type="pmid">18083463</pub-id></mixed-citation></ref><ref id="pone.0212785.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Knapp</surname><given-names>G</given-names></name>, <name><surname>Hartung</surname><given-names>J</given-names></name>. <article-title>Improved tests for a random effects meta-regression with a single covariate</article-title>. <source>Stat Med</source>
<year>2003</year>; <volume>22</volume>(<issue>17</issue>):<fpage>2693</fpage>&#x02013;<lpage>2710</lpage>. <pub-id pub-id-type="doi">10.1002/sim.1482</pub-id>
<?supplied-pmid 12939780?><pub-id pub-id-type="pmid">12939780</pub-id></mixed-citation></ref><ref id="pone.0212785.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>White</surname><given-names>I</given-names></name>. <article-title>Multivariate random-effects meta-analysis</article-title>. <source>Stata Journal</source>
<year>2009</year>; <volume>9</volume>:<fpage>40</fpage>&#x02013;<lpage>56</lpage>.</mixed-citation></ref><ref id="pone.0212785.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Agius</surname><given-names>AM</given-names></name>, <name><surname>Jones</surname><given-names>NS</given-names></name>, <name><surname>Muscat</surname><given-names>R</given-names></name>. <source>A Randomized Controlled Trial comparing the efficacy of low-dose amitriptyline, amitriptyline with pindolol and surrogate placebo in the treatment of chronic tension-type facial pain</source>. <year>2013</year>; <volume>51</volume>(<issue>2</issue>):<fpage>143</fpage>&#x02013;<lpage>153</lpage>.</mixed-citation></ref><ref id="pone.0212785.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Ahuja</surname><given-names>GK</given-names></name>, <name><surname>Verma</surname><given-names>AK</given-names></name>. <article-title>Propranolol in prophylaxis of migraine</article-title>. <source>Indian J Med Res</source>
<year>1985</year>; <volume>82</volume>:<fpage>263</fpage>&#x02013;<lpage>265</lpage>. <?supplied-pmid 3908306?><pub-id pub-id-type="pmid">3908306</pub-id></mixed-citation></ref><ref id="pone.0212785.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>al-Qassab</surname><given-names>HK</given-names></name>, <name><surname>Findley</surname><given-names>LJ</given-names></name>. <article-title>Comparison of propranolol LA 80 mg and propranolol LA 160 mg in migraine prophylaxis: a placebo controlled study</article-title>. <source>Cephalalgia</source>
<year>1993</year>; <volume>13</volume>(<issue>2</issue>):<fpage>128</fpage>&#x02013;<lpage>131</lpage>. <pub-id pub-id-type="doi">10.1046/j.1468-2982.1993.1302128.x</pub-id>
<?supplied-pmid 8495455?><pub-id pub-id-type="pmid">8495455</pub-id></mixed-citation></ref><ref id="pone.0212785.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Albers</surname><given-names>GW</given-names></name>, <name><surname>Simon</surname><given-names>LT</given-names></name>, <name><surname>Hamik</surname><given-names>A</given-names></name>, <name><surname>Peroutka</surname><given-names>SJ</given-names></name>. <article-title>Nifedipine versus propranolol for the initial prophylaxis of migraine</article-title>. <source>Headache</source>
<year>1989</year>; <volume>29</volume>(<issue>4</issue>):<fpage>215</fpage>&#x02013;<lpage>218</lpage>. <?supplied-pmid 2654067?><pub-id pub-id-type="pmid">2654067</pub-id></mixed-citation></ref><ref id="pone.0212785.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Andersson</surname><given-names>PG</given-names></name>, <name><surname>Petersen</surname><given-names>EN</given-names></name>. <article-title>Propranolol and femoxetine, a HT-uptake inhibitor, in migraine prophylaxis. A double-blind crossover study</article-title>. <source>Acta Neurol Scand</source>
<year>1981</year>; <volume>64</volume>(<issue>4</issue>):<fpage>280</fpage>&#x02013;<lpage>288</lpage>. <?supplied-pmid 7032183?><pub-id pub-id-type="pmid">7032183</pub-id></mixed-citation></ref><ref id="pone.0212785.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Andersson</surname><given-names>PG</given-names></name>, <name><surname>Dahl</surname><given-names>S</given-names></name>, <name><surname>Hansen</surname><given-names>JH</given-names></name>, <name><surname>Hansen</surname><given-names>PE</given-names></name>, <name><surname>Hedman</surname><given-names>C</given-names></name>, <name><surname>Kristensen</surname><given-names>TN</given-names></name>
<etal>et al</etal>
<article-title>Prophylactic treatment of classical and non-classical migraine with metoprolol&#x02014;a comparison with placebo</article-title>. <source>Cephalalgia</source>
<year>1983</year>; <volume>3</volume>(<issue>4</issue>):<fpage>207</fpage>&#x02013;<lpage>212</lpage>. <pub-id pub-id-type="doi">10.1046/j.1468-2982.1983.0304207.x</pub-id>
<?supplied-pmid 6640652?><pub-id pub-id-type="pmid">6640652</pub-id></mixed-citation></ref><ref id="pone.0212785.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>Ashtari</surname><given-names>F</given-names></name>, <name><surname>Shaygannejad</surname><given-names>V</given-names></name>, <name><surname>Akbari</surname><given-names>M</given-names></name>. <source>A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis</source>. <year>2008</year>; <volume>118</volume>(<issue>5</issue>):<fpage>301</fpage>&#x02013;<lpage>305</lpage>.</mixed-citation></ref><ref id="pone.0212785.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Baldrati</surname><given-names>A</given-names></name>, <name><surname>Cortelli</surname><given-names>P</given-names></name>, <name><surname>Procaccianti</surname><given-names>G</given-names></name>, <name><surname>Gamberini</surname><given-names>G</given-names></name>, <name><surname>D'Alessandro</surname><given-names>R</given-names></name>, <name><surname>Baruzzi</surname><given-names>A</given-names></name>
<etal>et al</etal>
<article-title>Propranolol and acetylsalicylic acid in migraine prophylaxis. Double-blind crossover study</article-title>. <source>Acta Neurol Scand</source>
<year>1983</year>; <volume>67</volume>(<issue>3</issue>):<fpage>181</fpage>&#x02013;<lpage>186</lpage>. <?supplied-pmid 6868956?><pub-id pub-id-type="pmid">6868956</pub-id></mixed-citation></ref><ref id="pone.0212785.ref065"><label>65</label><mixed-citation publication-type="journal"><name><surname>Behan</surname><given-names>PO</given-names></name>, <name><surname>Reid</surname><given-names>M</given-names></name>. <article-title>Propranolol in the treatment of migraine</article-title>. <source>Practitioner</source>
<year>1980</year>; <volume>224</volume>(<issue>1340</issue>):<fpage>201</fpage>&#x02013;<lpage>203</lpage>. <?supplied-pmid 6988825?><pub-id pub-id-type="pmid">6988825</pub-id></mixed-citation></ref><ref id="pone.0212785.ref066"><label>66</label><mixed-citation publication-type="journal"><name><surname>Bonuso</surname><given-names>S</given-names></name>, <name><surname>Di</surname><given-names>SE</given-names></name>, <name><surname>Marano</surname><given-names>E</given-names></name>, <name><surname>de</surname><given-names>AS</given-names></name>, <name><surname>Amato</surname><given-names>D</given-names></name>, <name><surname>Scellini</surname><given-names>T</given-names></name>
<etal>et al</etal>
<article-title>Long-term outcome of migraine therapy: predictive value of the frontotemporal nitroglycerin test</article-title>. <source>Neurology</source>
<year>1998</year>; <volume>51</volume>(<issue>5</issue>):<fpage>1475</fpage>&#x02013;<lpage>1478</lpage>. <?supplied-pmid 9818888?><pub-id pub-id-type="pmid">9818888</pub-id></mixed-citation></ref><ref id="pone.0212785.ref067"><label>67</label><mixed-citation publication-type="journal"><name><surname>Bordini</surname><given-names>CA</given-names></name>, <name><surname>Arruda</surname><given-names>MA</given-names></name>, <name><surname>Ciciarelli</surname><given-names>MC</given-names></name>, <name><surname>Speciali</surname><given-names>JG</given-names></name>. <article-title>Propranolol vs flunarizine vs flunarizine plus propranolol in migraine without aura prophylaxis. A double-blind trial</article-title>. <source>Arq Neuropsiquiatr</source>
<year>1997</year>; <volume>55</volume>(<issue>3B</issue>):<fpage>536</fpage>&#x02013;<lpage>541</lpage>. <?supplied-pmid 9629401?><pub-id pub-id-type="pmid">9629401</pub-id></mixed-citation></ref><ref id="pone.0212785.ref068"><label>68</label><mixed-citation publication-type="journal"><name><surname>Borgesen</surname><given-names>SE</given-names></name>, <name><surname>Nielsen</surname><given-names>JL</given-names></name>, <name><surname>Moller</surname><given-names>CE</given-names></name>. <article-title>Prophylactic treatment of migraine with propranolol. A clinical trial</article-title>. <source>Acta Neurol Scand</source>
<year>1974</year>; <volume>50</volume>(<issue>5</issue>):<fpage>651</fpage>&#x02013;<lpage>656</lpage>. <?supplied-pmid 4611129?><pub-id pub-id-type="pmid">4611129</pub-id></mixed-citation></ref><ref id="pone.0212785.ref069"><label>69</label><mixed-citation publication-type="journal"><name><surname>Briggs</surname><given-names>RS</given-names></name>, <name><surname>Millac</surname><given-names>PA</given-names></name>. <article-title>Timolol in migraine prophylaxis</article-title>. <source>Headache</source>
<year>1979</year>; <volume>19</volume>:<fpage>379</fpage>&#x02013;<lpage>381</lpage>. <?supplied-pmid 511540?><pub-id pub-id-type="pmid">511540</pub-id></mixed-citation></ref><ref id="pone.0212785.ref070"><label>70</label><mixed-citation publication-type="journal"><name><surname>Carroll</surname><given-names>JD</given-names></name>, <name><surname>Reidy</surname><given-names>M</given-names></name>, <name><surname>Savundra</surname><given-names>PA</given-names></name>, <name><surname>Cleave</surname><given-names>N</given-names></name>, <name><surname>McAinsh</surname><given-names>J</given-names></name>. <article-title>Long-acting propranolol in the prophylaxis of migraine: a comparative study of two doses</article-title>. <source>Cephalalgia</source>
<year>1990</year>; <volume>10</volume>(<issue>2</issue>):<fpage>101</fpage>&#x02013;<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1046/j.1468-2982.1990.1002101.x</pub-id>
<?supplied-pmid 2193712?><pub-id pub-id-type="pmid">2193712</pub-id></mixed-citation></ref><ref id="pone.0212785.ref071"><label>71</label><mixed-citation publication-type="journal"><name><surname>Dahlof</surname><given-names>C</given-names></name>. <article-title>No clearcut longterm prophylactic effect of one month of treatment with propranolol in migraineurs</article-title>. <source>Cephalalgia</source>
<year>1987</year>; <volume>7</volume>:<fpage>459</fpage>&#x02013;<lpage>460</lpage>.</mixed-citation></ref><ref id="pone.0212785.ref072"><label>72</label><mixed-citation publication-type="journal"><name><surname>Diener</surname><given-names>HC</given-names></name>, <name><surname>Foh</surname><given-names>M</given-names></name>, <name><surname>Iaccarino</surname><given-names>C</given-names></name>, <name><surname>Wessely</surname><given-names>P</given-names></name>, <name><surname>Isler</surname><given-names>H</given-names></name>, <name><surname>Strenge</surname><given-names>H</given-names></name>
<etal>et al</etal>
<article-title>Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol</article-title>. <collab>The Study group</collab>. <source>Cephalalgia</source>
<year>1996</year>; <volume>16</volume>(<issue>6</issue>):<fpage>441</fpage>&#x02013;<lpage>447</lpage>. <pub-id pub-id-type="doi">10.1046/j.1468-2982.1996.1606441.x</pub-id>
<?supplied-pmid 8902255?><pub-id pub-id-type="pmid">8902255</pub-id></mixed-citation></ref><ref id="pone.0212785.ref073"><label>73</label><mixed-citation publication-type="journal"><name><surname>Diener</surname><given-names>HC</given-names></name>, <name><surname>Hartung</surname><given-names>E</given-names></name>, <name><surname>Chrubasik</surname><given-names>J</given-names></name>, <name><surname>Evers</surname><given-names>S</given-names></name>, <name><surname>Schoenen</surname><given-names>J</given-names></name>, <name><surname>Eikermann</surname><given-names>A</given-names></name>
<etal>et al</etal>
<article-title>A comparative study of oral acetylsalicyclic acid and metoprolol for the prophylactic treatment of migraine. A randomized, controlled, double-blind, parallel group phase III study</article-title>. <source>Cephalalgia</source>
<year>2001</year>; <volume>21</volume>(<issue>2</issue>):<fpage>120</fpage>&#x02013;<lpage>128</lpage>. <pub-id pub-id-type="doi">10.1046/j.1468-2982.2001.00168.x</pub-id>
<?supplied-pmid 11422094?><pub-id pub-id-type="pmid">11422094</pub-id></mixed-citation></ref><ref id="pone.0212785.ref074"><label>74</label><mixed-citation publication-type="journal"><name><surname>Diener</surname><given-names>HC</given-names></name>, <name><surname>Matias-Guiu</surname><given-names>J</given-names></name>, <name><surname>Hartung</surname><given-names>E</given-names></name>, <name><surname>Pfaffenrath</surname><given-names>V</given-names></name>, <name><surname>Ludin</surname><given-names>HP</given-names></name>, <name><surname>Nappi</surname><given-names>G</given-names></name>
<etal>et al</etal>
<article-title>Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily</article-title>. <source>Cephalalgia</source>
<year>2002</year>; <volume>22</volume>(<issue>3</issue>):<fpage>209</fpage>&#x02013;<lpage>221</lpage>. <pub-id pub-id-type="doi">10.1046/j.1468-2982.2002.t01-1-00309.x</pub-id>
<?supplied-pmid 12047461?><pub-id pub-id-type="pmid">12047461</pub-id></mixed-citation></ref><ref id="pone.0212785.ref075"><label>75</label><mixed-citation publication-type="journal"><name><surname>Diener</surname><given-names>HC</given-names></name>, <name><surname>Tfelt-Hansen</surname><given-names>P</given-names></name>, <name><surname>Dahlof</surname><given-names>C</given-names></name>, <name><surname>Lainez</surname><given-names>MJ</given-names></name>, <name><surname>Sandrini</surname><given-names>G</given-names></name>, <name><surname>Wang</surname><given-names>SJ</given-names></name>
<etal>et al</etal>
<article-title>Topiramate in migraine prophylaxis&#x02014;results from a placebo-controlled trial with propranolol as an active control</article-title>. <source>J Neurol</source>
<year>2004</year>; <volume>251</volume>(<issue>8</issue>):<fpage>943</fpage>&#x02013;<lpage>950</lpage>. <pub-id pub-id-type="doi">10.1007/s00415-004-0464-6</pub-id>
<?supplied-pmid 15316798?><pub-id pub-id-type="pmid">15316798</pub-id></mixed-citation></ref><ref id="pone.0212785.ref076"><label>76</label><mixed-citation publication-type="journal"><name><surname>Domingues</surname><given-names>RB</given-names></name>, <name><surname>Piraj&#x000c3;&#x000a1; Da Silva</surname><given-names>AL</given-names></name>, <name><surname>Domingues</surname><given-names>SA</given-names></name>, <name><surname>Aquino</surname><given-names>CCH</given-names></name>, <name><surname>Kuster</surname><given-names>GW</given-names></name>. <source>A double-blind randomized controlled trial of low doses of propranolol, nortriptyline, and the combination of propranolol and nortriptyline for the preventive treatment of migraine</source>. <year>2009</year>; <volume>67</volume>(<issue>4</issue>):<fpage>973</fpage>&#x02013;<lpage>977</lpage>.</mixed-citation></ref><ref id="pone.0212785.ref077"><label>77</label><mixed-citation publication-type="journal"><name><surname>Ekbom</surname><given-names>K</given-names></name>, <name><surname>Lundberg</surname><given-names>PO</given-names></name>. <article-title>Clinical trial of LB-46 (d, 1-4-(2-hydroxy-3-isopropylaminopropoxy)indol. An adrenergic beta-receptor blocking agent in migraine prophylaxis</article-title>. <source>Headache</source>
<year>1972</year>; <volume>12</volume>(<issue>1</issue>):<fpage>15</fpage>&#x02013;<lpage>17</lpage>. <?supplied-pmid 4402287?><pub-id pub-id-type="pmid">4402287</pub-id></mixed-citation></ref><ref id="pone.0212785.ref078"><label>78</label><mixed-citation publication-type="journal"><name><surname>Ekbom</surname><given-names>K</given-names></name>. <article-title>Alprenolol for migraine prophylaxis</article-title>. <source>Headache</source>
<year>1975</year>; <volume>15</volume>(<issue>2</issue>):<fpage>129</fpage>&#x02013;<lpage>132</lpage>. <?supplied-pmid 1097368?><pub-id pub-id-type="pmid">1097368</pub-id></mixed-citation></ref><ref id="pone.0212785.ref079"><label>79</label><mixed-citation publication-type="journal"><name><surname>Ekbom</surname><given-names>K</given-names></name>, <name><surname>Zetterman</surname><given-names>M</given-names></name>. <article-title>Oxprenolol in the treatment of migraine</article-title>. <source>Acta Neurol Scand</source>
<year>1977</year>; <volume>56</volume>(<issue>2</issue>):<fpage>181</fpage>&#x02013;<lpage>184</lpage>. <?supplied-pmid 331835?><pub-id pub-id-type="pmid">331835</pub-id></mixed-citation></ref><ref id="pone.0212785.ref080"><label>80</label><mixed-citation publication-type="journal"><name><surname>Formisano</surname><given-names>R</given-names></name>, <name><surname>Falaschi</surname><given-names>P</given-names></name>, <name><surname>Cerbo</surname><given-names>R</given-names></name>, <name><surname>Proietti</surname><given-names>A</given-names></name>, <name><surname>Catarci</surname><given-names>T</given-names></name>, <name><surname>D'Urso</surname><given-names>R</given-names></name>
<etal>et al</etal>
<article-title>Nimodipine in migraine: clinical efficacy and endocrinological effects</article-title>. <source>Eur J Clin Pharmacol</source>
<year>1991</year>; <volume>41</volume>(<issue>1</issue>):<fpage>69</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1007/BF00280110</pub-id>
<?supplied-pmid 1782981?><pub-id pub-id-type="pmid">1782981</pub-id></mixed-citation></ref><ref id="pone.0212785.ref081"><label>81</label><mixed-citation publication-type="journal"><name><surname>Forssman</surname><given-names>B</given-names></name>, <name><surname>Henriksson</surname><given-names>KG</given-names></name>, <name><surname>Johannsson</surname><given-names>V</given-names></name>. <article-title>Propranolol for migraine prophylaxis</article-title>. <source>Headache</source>
<year>1976</year>; <volume>16</volume>:<fpage>238</fpage>&#x02013;<lpage>245</lpage>. <?supplied-pmid 977330?><pub-id pub-id-type="pmid">977330</pub-id></mixed-citation></ref><ref id="pone.0212785.ref082"><label>82</label><mixed-citation publication-type="journal"><name><surname>Forssman</surname><given-names>B</given-names></name>, <name><surname>Lindblad</surname><given-names>CJ</given-names></name>, <name><surname>Zbornikova</surname><given-names>V</given-names></name>. <article-title>Atenolol for migraine prophylaxis</article-title>. <source>Headache</source>
<year>1983</year>; <volume>23</volume>(<issue>4</issue>):<fpage>188</fpage>&#x02013;<lpage>190</lpage>. <?supplied-pmid 6350226?><pub-id pub-id-type="pmid">6350226</pub-id></mixed-citation></ref><ref id="pone.0212785.ref083"><label>83</label><mixed-citation publication-type="journal"><name><surname>Freitag</surname><given-names>FG</given-names></name>, <name><surname>Diamond</surname><given-names>S</given-names></name>. <article-title>Nadolol and placebo comparison study in the prophylactic treatment of migraine</article-title>. <source>J Am Osteopath Assoc</source>
<year>1984</year>; <volume>84</volume>(<issue>4</issue>):<fpage>343</fpage>&#x02013;<lpage>347</lpage>. <?supplied-pmid 6150909?><pub-id pub-id-type="pmid">6150909</pub-id></mixed-citation></ref><ref id="pone.0212785.ref084"><label>84</label><mixed-citation publication-type="journal"><name><surname>Gawel</surname><given-names>MJ</given-names></name>, <name><surname>Kreeft</surname><given-names>J</given-names></name>, <name><surname>Nelson</surname><given-names>RF</given-names></name>, <name><surname>Simard</surname><given-names>D</given-names></name>, <name><surname>Arnott</surname><given-names>WS</given-names></name>. <article-title>Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine</article-title>. <source>Can J Neurol Sci</source>
<year>1992</year>; <volume>19</volume>(<issue>3</issue>):<fpage>340</fpage>&#x02013;<lpage>345</lpage>. <?supplied-pmid 1393843?><pub-id pub-id-type="pmid">1393843</pub-id></mixed-citation></ref><ref id="pone.0212785.ref085"><label>85</label><mixed-citation publication-type="journal"><name><surname>Gerber</surname><given-names>WD</given-names></name>, <name><surname>Diener</surname><given-names>HC</given-names></name>, <name><surname>Scholz</surname><given-names>E</given-names></name>, <name><surname>Niederberger</surname><given-names>U</given-names></name>. <article-title>Responders and non-responders to metoprolol, propranolol and nifedipine treatment in migraine prophylaxis: a dose-range study based on time-series analysis</article-title>. <source>Cephalalgia</source>
<year>1991</year>; <volume>11</volume>(<issue>1</issue>):<fpage>37</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1046/j.1468-2982.1991.1101037.x</pub-id>
<?supplied-pmid 2036669?><pub-id pub-id-type="pmid">2036669</pub-id></mixed-citation></ref><ref id="pone.0212785.ref086"><label>86</label><mixed-citation publication-type="journal"><name><surname>Gerber</surname><given-names>WD</given-names></name>, <name><surname>Schellenberg</surname><given-names>R</given-names></name>, <name><surname>Thom</surname><given-names>M</given-names></name>, <name><surname>Haufe</surname><given-names>C</given-names></name>, <name><surname>Bolsche</surname><given-names>F</given-names></name>, <name><surname>Wedekind</surname><given-names>W</given-names></name>
<etal>et al</etal>
<article-title>Cyclandelate versus propranolol in the prophylaxis of migraine&#x02014;a double-blind placebo-controlled study</article-title>. <source>Funct Neurol</source>
<year>1995</year>; <volume>10</volume>(<issue>1</issue>):<fpage>27</fpage>&#x02013;<lpage>35</lpage>. <?supplied-pmid 7649498?><pub-id pub-id-type="pmid">7649498</pub-id></mixed-citation></ref><ref id="pone.0212785.ref087"><label>87</label><mixed-citation publication-type="journal"><name><surname>Ghobadi</surname><given-names>SH</given-names></name>, <name><surname>Jivad</surname><given-names>N</given-names></name>. <article-title>The prophylactic activity of propranol and nimodipineon migraine headache</article-title>. <year>2013</year>; <volume>8</volume>(<issue>2</issue>):<fpage>144</fpage>&#x02013;<lpage>146</lpage>.</mixed-citation></ref><ref id="pone.0212785.ref088"><label>88</label><mixed-citation publication-type="journal"><name><surname>Grotemeyer</surname><given-names>KH</given-names></name>, <name><surname>Husstedt</surname><given-names>IW</given-names></name>, <name><surname>Schlake</surname><given-names>HP</given-names></name>. [<article-title>Betablocker vs placebo in vasomotor headache. A double-blind crossover study</article-title>]. <source>Dtsch Med Wochenschr</source>
<year>1987</year>; <volume>112</volume>(<issue>45</issue>):<fpage>1740</fpage>&#x02013;<lpage>1743</lpage>. <pub-id pub-id-type="doi">10.1055/s-2008-1068322</pub-id>
<?supplied-pmid 2890509?><pub-id pub-id-type="pmid">2890509</pub-id></mixed-citation></ref><ref id="pone.0212785.ref089"><label>89</label><mixed-citation publication-type="journal"><name><surname>Grotemeyer</surname><given-names>KH</given-names></name>, <name><surname>Schlake</surname><given-names>HP</given-names></name>, <name><surname>Husstedt</surname><given-names>IW</given-names></name>. [<article-title>Prevention of migraine with metoprolol and flunarizine. A double-blind crossover study</article-title>]. <source>Nervenarzt</source>
<year>1988</year>; <volume>59</volume>(<issue>9</issue>):<fpage>549</fpage>&#x02013;<lpage>552</lpage>. <?supplied-pmid 3054595?><pub-id pub-id-type="pmid">3054595</pub-id></mixed-citation></ref><ref id="pone.0212785.ref090"><label>90</label><mixed-citation publication-type="journal"><name><surname>Grotemeyer</surname><given-names>KH</given-names></name>, <name><surname>Scharafinski</surname><given-names>HW</given-names></name>, <name><surname>Schlake</surname><given-names>HP</given-names></name>, <name><surname>Husstedt</surname><given-names>IW</given-names></name>. <article-title>Acetylsalicylic acid vs. metoprolol in migraine prophylaxis&#x02014;a double-blind cross-over study</article-title>. <source>Headache</source>
<year>1990</year>; <volume>30</volume>(<issue>10</issue>):<fpage>639</fpage>&#x02013;<lpage>641</lpage>. <?supplied-pmid 2272812?><pub-id pub-id-type="pmid">2272812</pub-id></mixed-citation></ref><ref id="pone.0212785.ref091"><label>91</label><mixed-citation publication-type="journal"><name><surname>Havanka-Kanniainen</surname><given-names>H</given-names></name>, <name><surname>Hokkanen</surname><given-names>E</given-names></name>, <name><surname>Myllyla</surname><given-names>VV</given-names></name>. <article-title>Long acting propranolol in the prophylaxis of migraine. Comparison of the daily doses of 80 mg and 160 mg</article-title>. <source>Headache</source>
<year>1988</year>; <volume>28</volume>(<issue>9</issue>):<fpage>607</fpage>&#x02013;<lpage>611</lpage>. <?supplied-pmid 3248938?><pub-id pub-id-type="pmid">3248938</pub-id></mixed-citation></ref><ref id="pone.0212785.ref092"><label>92</label><mixed-citation publication-type="journal"><name><surname>Hedman</surname><given-names>C</given-names></name>, <name><surname>Winther</surname><given-names>K</given-names></name>, <name><surname>Knudsen</surname><given-names>JB</given-names></name>. <article-title>The difference between non-selective and beta 1-selective beta-blockers in their effect on platelet function in migraine patients</article-title>. <source>Acta Neurol Scand</source>
<year>1986</year>; <volume>74</volume>(<issue>6</issue>):<fpage>475</fpage>&#x02013;<lpage>478</lpage>. <?supplied-pmid 3030039?><pub-id pub-id-type="pmid">3030039</pub-id></mixed-citation></ref><ref id="pone.0212785.ref093"><label>93</label><mixed-citation publication-type="journal"><name><surname>Hesse</surname><given-names>J</given-names></name>, <name><surname>Mogelvang</surname><given-names>B</given-names></name>, <name><surname>Simonsen</surname><given-names>H</given-names></name>. <article-title>Acupuncture versus metoprolol in migraine prophylaxis: a randomized trial of trigger point inactivation</article-title>. <source>J Intern Med</source>
<year>1994</year>; <volume>235</volume>(<issue>5</issue>):<fpage>451</fpage>&#x02013;<lpage>456</lpage>. <?supplied-pmid 8182401?><pub-id pub-id-type="pmid">8182401</pub-id></mixed-citation></ref><ref id="pone.0212785.ref094"><label>94</label><mixed-citation publication-type="journal"><name><surname>Holdorff</surname><given-names>B</given-names></name>, <name><surname>Sinn</surname><given-names>M</given-names></name>, <name><surname>Roth</surname><given-names>G</given-names></name>. <article-title>Propranolol for prophylaxis of migraine</article-title>. <source>Medizinische Klinik</source>
<year>1977</year>; <volume>72</volume>(<issue>25</issue>):<fpage>1115</fpage>&#x02013;<lpage>1118</lpage>. <?supplied-pmid 329085?><pub-id pub-id-type="pmid">329085</pub-id></mixed-citation></ref><ref id="pone.0212785.ref095"><label>95</label><mixed-citation publication-type="journal"><name><surname>Holroyd</surname><given-names>KA</given-names></name>, <name><surname>Cottrell</surname><given-names>CK</given-names></name>, <name><surname>O'Donnell</surname><given-names>FJ</given-names></name>, <name><surname>Cordingley</surname><given-names>GE</given-names></name>, <name><surname>Drew</surname><given-names>JB</given-names></name>, <name><surname>Carlson</surname><given-names>BW</given-names></name>
<etal>et al</etal>
<article-title>Effect of preventive (&#x000ce;<sup>2</sup> blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: Randomised controlled trial</article-title>. <year>2010</year>; <volume>341</volume>(<issue>7776</issue>):<fpage>769</fpage>
<pub-id pub-id-type="doi">10.1136/bmj.c4871</pub-id>
<?supplied-pmid 20880898?><pub-id pub-id-type="pmid">20880898</pub-id></mixed-citation></ref><ref id="pone.0212785.ref096"><label>96</label><mixed-citation publication-type="journal"><name><surname>Johannsson</surname><given-names>V</given-names></name>, <name><surname>Nilsson</surname><given-names>LR</given-names></name>, <name><surname>Widelius</surname><given-names>T</given-names></name>, <name><surname>Javerfalk</surname><given-names>T</given-names></name>, <name><surname>Hellman</surname><given-names>P</given-names></name>, <name><surname>Akesson</surname><given-names>JA</given-names></name>
<etal>et al</etal>
<article-title>Atenolol in migraine prophylaxis a double-blind cross-over multicentre study</article-title>. <source>Headache</source>
<year>1987</year>; <volume>27</volume>(<issue>7</issue>):<fpage>372</fpage>&#x02013;<lpage>374</lpage>. <?supplied-pmid 3308768?><pub-id pub-id-type="pmid">3308768</pub-id></mixed-citation></ref><ref id="pone.0212785.ref097"><label>97</label><mixed-citation publication-type="journal"><name><surname>Johnson</surname><given-names>RH</given-names></name>, <name><surname>Hornabrook</surname><given-names>RW</given-names></name>, <name><surname>Lambie</surname><given-names>DG</given-names></name>. <article-title>Comparison of mefenamic acid and propranolol with placebo in migraine prophylaxis</article-title>. <source>Acta Neurol Scand</source>
<year>1986</year>; <volume>73</volume>(<issue>5</issue>):<fpage>490</fpage>&#x02013;<lpage>492</lpage>. <?supplied-pmid 3524092?><pub-id pub-id-type="pmid">3524092</pub-id></mixed-citation></ref><ref id="pone.0212785.ref098"><label>98</label><mixed-citation publication-type="journal"><name><surname>Kangasniemi</surname><given-names>P</given-names></name>, <name><surname>Hedman</surname><given-names>C</given-names></name>. <article-title>Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study</article-title>. <source>Cephalalgia</source>
<year>1984</year>; <volume>4</volume>(<issue>2</issue>):<fpage>91</fpage>&#x02013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1046/j.1468-2982.1984.0402091.x</pub-id>
<?supplied-pmid 6428749?><pub-id pub-id-type="pmid">6428749</pub-id></mixed-citation></ref><ref id="pone.0212785.ref099"><label>99</label><mixed-citation publication-type="journal"><name><surname>Kangasniemi</surname><given-names>P</given-names></name>, <name><surname>Andersen</surname><given-names>AR</given-names></name>, <name><surname>Andersson</surname><given-names>PG</given-names></name>, <name><surname>Gilhus</surname><given-names>NE</given-names></name>, <name><surname>Hedman</surname><given-names>C</given-names></name>, <name><surname>Hultgren</surname><given-names>M</given-names></name>
<etal>et al</etal>
<article-title>Classic migraine: effective prophylaxis with metoprolol</article-title>. <source>Cephalalgia</source>
<year>1987</year>; <volume>7</volume>(<issue>4</issue>):<fpage>231</fpage>&#x02013;<lpage>238</lpage>. <pub-id pub-id-type="doi">10.1046/j.1468-2982.1987.0704231.x</pub-id>
<?supplied-pmid 3322569?><pub-id pub-id-type="pmid">3322569</pub-id></mixed-citation></ref><ref id="pone.0212785.ref100"><label>100</label><mixed-citation publication-type="journal"><name><surname>Kangasniemi</surname><given-names>PJ</given-names></name>, <name><surname>Nyrke</surname><given-names>T</given-names></name>, <name><surname>Lang</surname><given-names>AH</given-names></name>, <name><surname>Petersen</surname><given-names>E</given-names></name>. <article-title>Femoxetine&#x02014;a new 5-HT uptake inhibitor&#x02014;and propranolol in the prophylactic treatment of migraine</article-title>. <source>Acta neurologica Scandinavica</source>
<year>1983</year>; <volume>68</volume>:<fpage>262</fpage>&#x02013;<lpage>267</lpage>. <?supplied-pmid 6606930?><pub-id pub-id-type="pmid">6606930</pub-id></mixed-citation></ref><ref id="pone.0212785.ref101"><label>101</label><mixed-citation publication-type="journal"><name><surname>Kaniecki</surname><given-names>RG</given-names></name>. <article-title>A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura</article-title>. <source>Arch Neurol</source>
<year>1997</year>; <volume>54</volume>(<issue>9</issue>):<fpage>1141</fpage>&#x02013;<lpage>1145</lpage>. <?supplied-pmid 9311358?><pub-id pub-id-type="pmid">9311358</pub-id></mixed-citation></ref><ref id="pone.0212785.ref102"><label>102</label><mixed-citation publication-type="journal"><name><surname>Kass</surname><given-names>B</given-names></name>, <name><surname>Nestvold</surname><given-names>K</given-names></name>. <article-title>Propranolol (Inderal) and clonidine (Catapressan) in the prophylactic treatment of migraine. A comparative trial.</article-title>
<source>Acta Neurol Scand</source>
<year>1980</year>; <volume>61</volume>(<issue>6</issue>):<fpage>351</fpage>&#x02013;<lpage>356</lpage>. <?supplied-pmid 6998250?><pub-id pub-id-type="pmid">6998250</pub-id></mixed-citation></ref><ref id="pone.0212785.ref103"><label>103</label><mixed-citation publication-type="journal"><name><surname>Kaushik</surname><given-names>R</given-names></name>, <name><surname>Kaushik</surname><given-names>RM</given-names></name>, <name><surname>Mahajan</surname><given-names>SK</given-names></name>, <name><surname>Rajesh</surname><given-names>V</given-names></name>. <article-title>Biofeedback assisted diaphragmatic breathing and systematic relaxation versus propranolol in long term prophylaxis of migraine</article-title>. <source>Complement Ther Med</source>
<year>2005</year>; <volume>13</volume>(<issue>3</issue>):<fpage>165</fpage>&#x02013;<lpage>174</lpage>. <pub-id pub-id-type="doi">10.1016/j.ctim.2005.04.004</pub-id>
<?supplied-pmid 16150370?><pub-id pub-id-type="pmid">16150370</pub-id></mixed-citation></ref><ref id="pone.0212785.ref104"><label>104</label><mixed-citation publication-type="journal"><name><surname>Kjaersgard Rasmussen</surname><given-names>MJ</given-names></name>, <name><surname>Holt</surname><given-names>LB</given-names></name>, <name><surname>Borg</surname><given-names>L</given-names></name>, <name><surname>Soelberg</surname><given-names>SP</given-names></name>, <name><surname>Hansen</surname><given-names>PE</given-names></name>. <article-title>Tolfenamic acid versus propranolol in the prophylactic treatment of migraine</article-title>. <source>Acta Neurol Scand</source>
<year>1994</year>; <volume>89</volume>(<issue>6</issue>):<fpage>446</fpage>&#x02013;<lpage>450</lpage>. <?supplied-pmid 7976233?><pub-id pub-id-type="pmid">7976233</pub-id></mixed-citation></ref><ref id="pone.0212785.ref105"><label>105</label><mixed-citation publication-type="journal"><name><surname>Klapper</surname><given-names>JA</given-names></name>. <article-title>An open label cross-over comparison of divalproex sodium and propranolol HCl in the prevention of migraine headaches</article-title>. <source>HEADACHE Q</source>
<year>1994</year>; <volume>5</volume>:<fpage>50</fpage>&#x02013;<lpage>53</lpage>.</mixed-citation></ref><ref id="pone.0212785.ref106"><label>106</label><mixed-citation publication-type="journal"><name><surname>Kozubski</surname><given-names>W</given-names></name>, <name><surname>Prusinski</surname><given-names>A</given-names></name>. [<article-title>Sodium valproate versus propranolol in the prophylactic treatment of migraine</article-title>]. <source>Neurol Neurochir Pol</source>
<year>1995</year>; <volume>29</volume>(<issue>6</issue>):<fpage>937</fpage>&#x02013;<lpage>947</lpage>. <?supplied-pmid 8714731?><pub-id pub-id-type="pmid">8714731</pub-id></mixed-citation></ref><ref id="pone.0212785.ref107"><label>107</label><mixed-citation publication-type="journal"><name><surname>Kuritzky</surname><given-names>A</given-names></name>, <name><surname>Hering</surname><given-names>R</given-names></name>. <article-title>Prophylactic treatment of migraine with long acting propranolol&#x02014;a comparison with placebo</article-title>. <source>Cephalalgia</source>
<year>1987</year>; <volume>7</volume>:<fpage>457</fpage>&#x02013;<lpage>458</lpage>.</mixed-citation></ref><ref id="pone.0212785.ref108"><label>108</label><mixed-citation publication-type="journal"><name><surname>Langohr</surname><given-names>HD</given-names></name>, <name><surname>Gerber</surname><given-names>WD</given-names></name>, <name><surname>Koletzki</surname><given-names>E</given-names></name>, <name><surname>Mayer</surname><given-names>K</given-names></name>, <name><surname>Schroth</surname><given-names>G</given-names></name>. <article-title>Clomipramine and metoprolol in migraine prophylaxis&#x02014;a double-blind crossover study</article-title>. <source>Headache</source>
<year>1985</year>; <volume>25</volume>(<issue>2</issue>):<fpage>107</fpage>&#x02013;<lpage>113</lpage>. <?supplied-pmid 3886599?><pub-id pub-id-type="pmid">3886599</pub-id></mixed-citation></ref><ref id="pone.0212785.ref109"><label>109</label><mixed-citation publication-type="journal"><name><surname>Louis</surname><given-names>P</given-names></name>, <name><surname>Schoenen</surname><given-names>J</given-names></name>, <name><surname>Hedman</surname><given-names>C</given-names></name>. <article-title>Metoprolol v. clonidine in the prophylactic treatment of migraine</article-title>. <source>Cephalalgia</source>
<year>1985</year>; <volume>5</volume>(<issue>3</issue>):<fpage>159</fpage>&#x02013;<lpage>165</lpage>. <pub-id pub-id-type="doi">10.1046/j.1468-2982.1985.0503159.x</pub-id>
<?supplied-pmid 3899370?><pub-id pub-id-type="pmid">3899370</pub-id></mixed-citation></ref><ref id="pone.0212785.ref110"><label>110</label><mixed-citation publication-type="journal"><name><surname>Lucking</surname><given-names>CH</given-names></name>, <name><surname>Oestreich</surname><given-names>W</given-names></name>, <name><surname>Schmidt</surname><given-names>R</given-names></name>, <name><surname>Soyka</surname><given-names>D</given-names></name>. <article-title>Flunarizine vs. propranolol in the prophylaxis of migraine: two double-blind comparative studies in more than 400 patients</article-title>. <source>Cephalalgia</source>
<year>1988</year>; <volume>8</volume>
<issue>Suppl 8</issue>:<fpage>21</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="pmid">3180198</pub-id></mixed-citation></ref><ref id="pone.0212785.ref111"><label>111</label><mixed-citation publication-type="journal"><name><surname>Ludin</surname><given-names>HP</given-names></name>. <article-title>Flunarizine and propranolol in the treatment of migraine</article-title>. <source>Headache</source>
<year>1989</year>; <volume>29</volume>(<issue>4</issue>):<fpage>219</fpage>&#x02013;<lpage>224</lpage>. <?supplied-pmid 2654068?><pub-id pub-id-type="pmid">2654068</pub-id></mixed-citation></ref><ref id="pone.0212785.ref112"><label>112</label><mixed-citation publication-type="journal"><name><surname>Maissen</surname><given-names>CP</given-names></name>, <name><surname>Ludin</surname><given-names>HP</given-names></name>. [<article-title>Comparison of the effect of 5-hydroxytryptophan and propranolol in the interval treatment of migraine</article-title>]. <source>Schweiz Med Wochenschr</source>
<year>1991</year>; <volume>121</volume>(<issue>43</issue>):<fpage>1585</fpage>&#x02013;<lpage>1590</lpage>. <?supplied-pmid 1947955?><pub-id pub-id-type="pmid">1947955</pub-id></mixed-citation></ref><ref id="pone.0212785.ref113"><label>113</label><mixed-citation publication-type="journal"><name><surname>Malvea</surname><given-names>BP</given-names></name>, <name><surname>Gwon</surname><given-names>N</given-names></name>, <name><surname>Graham</surname><given-names>JR</given-names></name>. <article-title>Propranolol prophylaxis of migraine</article-title>. <source>Headache</source>
<year>1973</year>; <volume>12</volume>(<issue>4</issue>):<fpage>163</fpage>&#x02013;<lpage>167</lpage>. <?supplied-pmid 4566216?><pub-id pub-id-type="pmid">4566216</pub-id></mixed-citation></ref><ref id="pone.0212785.ref114"><label>114</label><mixed-citation publication-type="journal"><name><surname>Mathew</surname><given-names>NT</given-names></name>. <article-title>Prophylaxis of migraine and mixed headache. A randomized controlled study</article-title>. <source>Headache</source>
<year>1981</year>; <volume>21</volume>(<issue>3</issue>):<fpage>105</fpage>&#x02013;<lpage>109</lpage>. <?supplied-pmid 7021472?><pub-id pub-id-type="pmid">7021472</pub-id></mixed-citation></ref><ref id="pone.0212785.ref115"><label>115</label><mixed-citation publication-type="journal"><name><surname>Mikkelsen</surname><given-names>B</given-names></name>, <name><surname>Pedersen</surname><given-names>KK</given-names></name>, <name><surname>Christiansen</surname><given-names>LV</given-names></name>. <article-title>Prophylactic treatment of migraine with tolfenamic acid, propranolol and placebo</article-title>. <source>Acta Neurol Scand</source>
<year>1986</year>; <volume>73</volume>(<issue>4</issue>):<fpage>423</fpage>&#x02013;<lpage>427</lpage>. <?supplied-pmid 3727918?><pub-id pub-id-type="pmid">3727918</pub-id></mixed-citation></ref><ref id="pone.0212785.ref116"><label>116</label><mixed-citation publication-type="journal"><name><surname>Nadelmann</surname><given-names>JW</given-names></name>, <name><surname>Phil</surname><given-names>M</given-names></name>, <name><surname>Stevens</surname><given-names>J</given-names></name>, <name><surname>Saper</surname><given-names>JR</given-names></name>. <article-title>Propranolol in the prophylaxis of migraine</article-title>. <source>Headache</source>
<year>1986</year>; <volume>26</volume>(<issue>4</issue>):<fpage>175</fpage>&#x02013;<lpage>182</lpage>. <?supplied-pmid 3519529?><pub-id pub-id-type="pmid">3519529</pub-id></mixed-citation></ref><ref id="pone.0212785.ref117"><label>117</label><mixed-citation publication-type="journal"><name><surname>Nambiar</surname><given-names>NJ</given-names></name>, <name><surname>Aiyappa</surname><given-names>C</given-names></name>, <name><surname>Srinivasa</surname><given-names>R</given-names></name>. <article-title>Oral riboflavin versus oral propranolol in migraine prophylaxis: An open label randomized controlled trial</article-title>. <year>2011</year>; <volume>16</volume>(<issue>3</issue>):<fpage>223</fpage>&#x02013;<lpage>229</lpage>.</mixed-citation></ref><ref id="pone.0212785.ref118"><label>118</label><mixed-citation publication-type="journal"><name><surname>Nanda</surname><given-names>RN</given-names></name>, <name><surname>Johnson</surname><given-names>RH</given-names></name>, <name><surname>Gray</surname><given-names>J</given-names></name>, <name><surname>Keogh</surname><given-names>HJ</given-names></name>, <name><surname>Melville</surname><given-names>ID</given-names></name>. <article-title>A double blind trial of acebutolol for migraine prophylaxis</article-title>. <source>Headache</source>
<year>1978</year>; <volume>18</volume>(<issue>1</issue>):<fpage>20</fpage>&#x02013;<lpage>22</lpage>. <?supplied-pmid 348644?><pub-id pub-id-type="pmid">348644</pub-id></mixed-citation></ref><ref id="pone.0212785.ref119"><label>119</label><mixed-citation publication-type="journal"><name><surname>Olerud</surname><given-names>B</given-names></name>, <name><surname>Gustavsson</surname><given-names>CL</given-names></name>, <name><surname>Furberg</surname><given-names>B</given-names></name>. <article-title>Nadolol and propranolol in migraine management</article-title>. <source>Headache</source>
<year>1986</year>; <volume>26</volume>(<issue>10</issue>):<fpage>490</fpage>&#x02013;<lpage>493</lpage>. <?supplied-pmid 3546194?><pub-id pub-id-type="pmid">3546194</pub-id></mixed-citation></ref><ref id="pone.0212785.ref120"><label>120</label><mixed-citation publication-type="journal"><name><surname>Olsson</surname><given-names>JE</given-names></name>, <name><surname>Behring</surname><given-names>HC</given-names></name>, <name><surname>Forssman</surname><given-names>B</given-names></name>, <name><surname>Hedman</surname><given-names>C</given-names></name>, <name><surname>Hedman</surname><given-names>G</given-names></name>, <name><surname>Johansson</surname><given-names>F</given-names></name>
<etal>et al</etal>
<article-title>Metoprolol and propranolol in migraine prophylaxis: a double-blind multicentre study</article-title>. <source>Acta Neurol Scand</source>
<year>1984</year>; <volume>70</volume>(<issue>3</issue>):<fpage>160</fpage>&#x02013;<lpage>168</lpage>. <?supplied-pmid 6391066?><pub-id pub-id-type="pmid">6391066</pub-id></mixed-citation></ref><ref id="pone.0212785.ref121"><label>121</label><mixed-citation publication-type="journal"><name><surname>Palferman</surname><given-names>TG</given-names></name>, <name><surname>Gibberd</surname><given-names>FB</given-names></name>, <name><surname>Simmonds</surname><given-names>JP</given-names></name>. <article-title>Prophylactic propranolol in the treatment of headache</article-title>. <source>Br J Clin Pract</source>
<year>1983</year>; <volume>37</volume>(<issue>1</issue>):<fpage>28</fpage>&#x02013;<lpage>29</lpage>. <?supplied-pmid 6340710?><pub-id pub-id-type="pmid">6340710</pub-id></mixed-citation></ref><ref id="pone.0212785.ref122"><label>122</label><mixed-citation publication-type="journal"><name><surname>Pita</surname><given-names>E</given-names></name>, <name><surname>Higueras</surname><given-names>A</given-names></name>, <name><surname>Bolanos</surname><given-names>J</given-names></name>, <name><surname>Perez</surname><given-names>N</given-names></name>, <name><surname>Mundo</surname><given-names>A</given-names></name>. <article-title>Propranolol and migraine. A clinical trial</article-title>. <source>Arch Farmacol Toxicol</source>
<year>1977</year>; <volume>3</volume>(<issue>3</issue>):<fpage>273</fpage>&#x02013;<lpage>278</lpage>. <?supplied-pmid 350168?><pub-id pub-id-type="pmid">350168</pub-id></mixed-citation></ref><ref id="pone.0212785.ref123"><label>123</label><mixed-citation publication-type="journal"><name><surname>Pradalier</surname><given-names>A</given-names></name>, <name><surname>Serratrice</surname><given-names>G</given-names></name>, <name><surname>Collard</surname><given-names>M</given-names></name>, <name><surname>Hirsch</surname><given-names>E</given-names></name>, <name><surname>Feve</surname><given-names>J</given-names></name>, <name><surname>Masson</surname><given-names>M</given-names></name>
<etal>et al</etal>
<article-title>Long-acting propranolol in migraine prophylaxis: results of a double-blind, placebo-controlled study</article-title>. <source>Cephalalgia</source>
<year>1989</year>; <volume>9</volume>(<issue>4</issue>):<fpage>247</fpage>&#x02013;<lpage>253</lpage>. <pub-id pub-id-type="doi">10.1046/j.1468-2982.1989.0904247.x</pub-id>
<?supplied-pmid 2692838?><pub-id pub-id-type="pmid">2692838</pub-id></mixed-citation></ref><ref id="pone.0212785.ref124"><label>124</label><mixed-citation publication-type="journal"><name><surname>Ryan</surname><given-names>RE</given-names><suffix>Sr.</suffix></name>, <name><surname>Ryan</surname><given-names>RE</given-names><suffix>Jr.</suffix></name>, <name><surname>Sudilovsky</surname><given-names>A</given-names></name>. <article-title>Nadolol and placebo comparison study in the prophylactic treatment of migraine</article-title>. <source>Panminerva Med</source>
<year>1982</year>; <volume>24</volume>(<issue>2</issue>):<fpage>89</fpage>&#x02013;<lpage>94</lpage>. <?supplied-pmid 6128710?><pub-id pub-id-type="pmid">6128710</pub-id></mixed-citation></ref><ref id="pone.0212785.ref125"><label>125</label><mixed-citation publication-type="journal"><name><surname>Ryan</surname><given-names>RE</given-names><suffix>Sr.</suffix></name>
<article-title>Comparative study of nadolol and propranolol in prophylactic treatment of migraine</article-title>. <source>Am Heart J</source>
<year>1984</year>; <volume>108</volume>(<issue>4</issue> Pt 2):<fpage>1156</fpage>&#x02013;<lpage>1159</lpage>.<pub-id pub-id-type="pmid">6148878</pub-id></mixed-citation></ref><ref id="pone.0212785.ref126"><label>126</label><mixed-citation publication-type="journal"><name><surname>Sargent</surname><given-names>J</given-names></name>, <name><surname>Solbach</surname><given-names>P</given-names></name>, <name><surname>Damasio</surname><given-names>H</given-names></name>, <name><surname>Baumel</surname><given-names>B</given-names></name>, <name><surname>Corbett</surname><given-names>J</given-names></name>, <name><surname>Eisner</surname><given-names>L</given-names></name>
<etal>et al</etal>
<article-title>A comparison of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache</article-title>. <source>Headache</source>
<year>1985</year>; <volume>25</volume>(<issue>6</issue>):<fpage>320</fpage>&#x02013;<lpage>324</lpage>. <?supplied-pmid 3902723?><pub-id pub-id-type="pmid">3902723</pub-id></mixed-citation></ref><ref id="pone.0212785.ref127"><label>127</label><mixed-citation publication-type="journal"><name><surname>Schellenberg</surname><given-names>R</given-names></name>, <name><surname>Lichtenthal</surname><given-names>A</given-names></name>, <name><surname>Wohling</surname><given-names>H</given-names></name>, <name><surname>Graf</surname><given-names>C</given-names></name>, <name><surname>Brixius</surname><given-names>K</given-names></name>. <article-title>Nebivolol and metoprolol for treating migraine: an advance on beta-blocker treatment?</article-title>
<source>Headache</source>
<year>2008</year>; <volume>48</volume>(<issue>1</issue>):<fpage>118</fpage>&#x02013;<lpage>125</lpage>. <pub-id pub-id-type="doi">10.1111/j.1526-4610.2007.00785.x</pub-id>
<?supplied-pmid 18184294?><pub-id pub-id-type="pmid">18184294</pub-id></mixed-citation></ref><ref id="pone.0212785.ref128"><label>128</label><mixed-citation publication-type="journal"><name><surname>Shimell</surname><given-names>CJ</given-names></name>, <name><surname>Fritz</surname><given-names>VU</given-names></name>, <name><surname>Levien</surname><given-names>SL</given-names></name>. <article-title>A comparative trial of flunarizine and propranolol in the prevention of migraine</article-title>. <source>S Afr Med J</source>
<year>1990</year>; <volume>77</volume>(<issue>2</issue>):<fpage>75</fpage>&#x02013;<lpage>77</lpage>. <?supplied-pmid 2404346?><pub-id pub-id-type="pmid">2404346</pub-id></mixed-citation></ref><ref id="pone.0212785.ref129"><label>129</label><mixed-citation publication-type="journal"><name><surname>Silberstein</surname><given-names>SD</given-names></name>, <name><surname>Dodick</surname><given-names>DW</given-names></name>, <name><surname>Lindblad</surname><given-names>AS</given-names></name>, <name><surname>Holroyd</surname><given-names>K</given-names></name>, <name><surname>Harrington</surname><given-names>M</given-names></name>, <name><surname>Mathew</surname><given-names>NT</given-names></name><etal>et al</etal>
<article-title>Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine</article-title>. <source>Neurology</source>
<year>2012</year>; <volume>78</volume>(<issue>13</issue>):<fpage>976</fpage>&#x02013;<lpage>984</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0b013e31824d5846</pub-id>
<?supplied-pmid 22377815?><pub-id pub-id-type="pmid">22377815</pub-id></mixed-citation></ref><ref id="pone.0212785.ref130"><label>130</label><mixed-citation publication-type="journal"><name><surname>Siniatchkin</surname><given-names>M</given-names></name>, <name><surname>Andrasik</surname><given-names>F</given-names></name>, <name><surname>Kropp</surname><given-names>P</given-names></name>, <name><surname>Niederberger</surname><given-names>U</given-names></name>, <name><surname>Strenge</surname><given-names>H</given-names></name>, <name><surname>Averkina</surname><given-names>N</given-names></name>
<etal>et al</etal>
<article-title>Central mechanisms of controlled-release metoprolol in migraine: a double-blind, placebo-controlled study</article-title>. <source>Cephalalgia</source>
<year>2007</year>; <volume>27</volume>(<issue>9</issue>):<fpage>1024</fpage>&#x02013;<lpage>1032</lpage>. <pub-id pub-id-type="doi">10.1111/j.1468-2982.2007.01377.x</pub-id>
<?supplied-pmid 17680819?><pub-id pub-id-type="pmid">17680819</pub-id></mixed-citation></ref><ref id="pone.0212785.ref131"><label>131</label><mixed-citation publication-type="journal"><name><surname>Sorensen</surname><given-names>PS</given-names></name>, <name><surname>Larsen</surname><given-names>BH</given-names></name>, <name><surname>Rasmussen</surname><given-names>MJ</given-names></name>, <name><surname>Kinge</surname><given-names>E</given-names></name>, <name><surname>Iversen</surname><given-names>H</given-names></name>, <name><surname>Alslev</surname><given-names>T</given-names></name>
<etal>et al</etal>
<article-title>Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability</article-title>. <source>Headache</source>
<year>1991</year>; <volume>31</volume>(<issue>10</issue>):<fpage>650</fpage>&#x02013;<lpage>657</lpage>. <?supplied-pmid 1769820?><pub-id pub-id-type="pmid">1769820</pub-id></mixed-citation></ref><ref id="pone.0212785.ref132"><label>132</label><mixed-citation publication-type="journal"><name><surname>Soyka</surname><given-names>D</given-names></name>, <name><surname>Oestreich</surname><given-names>W</given-names></name>. <article-title>Flunarizine versus propranolol in interval treatment of migraine</article-title>. <source>Nervenheilkunde</source>
<year>1990</year>; <volume>9</volume>:<fpage>45</fpage>&#x02013;<lpage>51</lpage>.</mixed-citation></ref><ref id="pone.0212785.ref133"><label>133</label><mixed-citation publication-type="journal"><name><surname>Standnes</surname><given-names>B</given-names></name>. <article-title>The prophylactic effect of timolol versus propranolol and placebo in common migraine: beta-blockers in migraine</article-title>. <source>Cephalalgia</source>
<year>1982</year>; <volume>2</volume>(<issue>3</issue>):<fpage>165</fpage>&#x02013;<lpage>170</lpage>. <pub-id pub-id-type="doi">10.1046/j.1468-2982.1982.0203165.x</pub-id>
<?supplied-pmid 6758949?><pub-id pub-id-type="pmid">6758949</pub-id></mixed-citation></ref><ref id="pone.0212785.ref134"><label>134</label><mixed-citation publication-type="journal"><name><surname>Steiner</surname><given-names>TJ</given-names></name>, <name><surname>Joseph</surname><given-names>R</given-names></name>, <name><surname>Hedman</surname><given-names>C</given-names></name>, <name><surname>Rose</surname><given-names>FC</given-names></name>. <article-title>Metoprolol in the prophylaxis of migraine: parallel-groups comparison with placebo and dose-ranging follow-up</article-title>. <source>Headache</source>
<year>1988</year>; <volume>28</volume>(<issue>1</issue>):<fpage>15</fpage>&#x02013;<lpage>23</lpage>. <?supplied-pmid 3277926?><pub-id pub-id-type="pmid">3277926</pub-id></mixed-citation></ref><ref id="pone.0212785.ref135"><label>135</label><mixed-citation publication-type="journal"><name><surname>Stellar</surname><given-names>S</given-names></name>, <name><surname>Ahrens</surname><given-names>SP</given-names></name>, <name><surname>Meibohm</surname><given-names>AR</given-names></name>, <name><surname>Reines</surname><given-names>SA</given-names></name>. <article-title>Migraine prevention with timolol. A double-blind crossover study</article-title>. <source>JAMA</source>
<year>1984</year>; <volume>252</volume>(<issue>18</issue>):<fpage>2576</fpage>&#x02013;<lpage>2580</lpage>. <?supplied-pmid 6387197?><pub-id pub-id-type="pmid">6387197</pub-id></mixed-citation></ref><ref id="pone.0212785.ref136"><label>136</label><mixed-citation publication-type="journal"><name><surname>Stensrud</surname><given-names>P</given-names></name>, <name><surname>Sjaastad</surname><given-names>O</given-names></name>. <article-title>Short-term clinical trial of phopranolol in racemic form (Inderal), D-propranolol and placebo in migraine</article-title>. <source>Acta Neurol Scand</source>
<year>1976</year>; <volume>53</volume>(<issue>3</issue>):<fpage>229</fpage>&#x02013;<lpage>232</lpage>. <?supplied-pmid 773081?><pub-id pub-id-type="pmid">773081</pub-id></mixed-citation></ref><ref id="pone.0212785.ref137"><label>137</label><mixed-citation publication-type="journal"><name><surname>Stensrud</surname><given-names>P</given-names></name>, <name><surname>Sjaastad</surname><given-names>O</given-names></name>. <article-title>Comparative trial of Tenormin (atenolol) and Inderal (propranolol) in migraine</article-title>. <source>Headache</source>
<year>1980</year>; <volume>20</volume>(<issue>4</issue>):<fpage>204</fpage>&#x02013;<lpage>207</lpage>. <?supplied-pmid 6993420?><pub-id pub-id-type="pmid">6993420</pub-id></mixed-citation></ref><ref id="pone.0212785.ref138"><label>138</label><mixed-citation publication-type="journal"><name><surname>Stovner</surname><given-names>LJ</given-names></name>, <name><surname>Linde</surname><given-names>M</given-names></name>, <name><surname>Gravdahl</surname><given-names>GB</given-names></name>, <name><surname>Tronvik</surname><given-names>E</given-names></name>, <name><surname>Aamodt</surname><given-names>AH</given-names></name>, <name><surname>Sand</surname><given-names>T</given-names></name>
<etal>et al</etal>
<article-title>A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study</article-title>. <source>Cephalalgia</source>
<year>2013</year>; <volume>34</volume>(<issue>7</issue>):<fpage>523</fpage>&#x02013;<lpage>532</lpage>. <pub-id pub-id-type="doi">10.1177/0333102413515348</pub-id>
<?supplied-pmid 24335848?><pub-id pub-id-type="pmid">24335848</pub-id></mixed-citation></ref><ref id="pone.0212785.ref139"><label>139</label><mixed-citation publication-type="journal"><name><surname>Streng</surname><given-names>A</given-names></name>, <name><surname>Linde</surname><given-names>K</given-names></name>, <name><surname>Hoppe</surname><given-names>A</given-names></name>, <name><surname>Pfaffenrath</surname><given-names>V</given-names></name>, <name><surname>Hammes</surname><given-names>M</given-names></name>, <name><surname>Wagenpfeil</surname><given-names>S</given-names></name>
<etal>et al</etal>
<article-title>Effectiveness and tolerability of acupuncture compared with metoprolol in migraine prophylaxis</article-title>. <source>Headache</source>
<year>2006</year>; <volume>46</volume>(<issue>10</issue>):<fpage>1492</fpage>&#x02013;<lpage>1502</lpage>. <pub-id pub-id-type="doi">10.1111/j.1526-4610.2006.00598.x</pub-id>
<?supplied-pmid 17115982?><pub-id pub-id-type="pmid">17115982</pub-id></mixed-citation></ref><ref id="pone.0212785.ref140"><label>140</label><mixed-citation publication-type="journal"><name><surname>Sudilovsky</surname><given-names>A</given-names></name>, <name><surname>Elkind</surname><given-names>AH</given-names></name>, <name><surname>Ryan</surname><given-names>RE</given-names><suffix>Sr.</suffix></name>, <name><surname>Saper</surname><given-names>JR</given-names></name>, <name><surname>Stern</surname><given-names>MA</given-names></name>, <name><surname>Meyer</surname><given-names>JH</given-names></name>. <article-title>Comparative efficacy of nadolol and propranolol in the management of migraine</article-title>. <source>Headache</source>
<year>1987</year>; <volume>27</volume>(<issue>8</issue>):<fpage>421</fpage>&#x02013;<lpage>426</lpage>. <?supplied-pmid 3312113?><pub-id pub-id-type="pmid">3312113</pub-id></mixed-citation></ref><ref id="pone.0212785.ref141"><label>141</label><mixed-citation publication-type="journal"><name><surname>Tfelt-Hansen</surname><given-names>P</given-names></name>, <name><surname>Standnes</surname><given-names>B</given-names></name>, <name><surname>Kangasneimi</surname><given-names>P</given-names></name>, <name><surname>Hakkarainen</surname><given-names>H</given-names></name>, <name><surname>Olesen</surname><given-names>J</given-names></name>. <article-title>Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial.</article-title>
<source>Acta Neurol Scand</source>
<year>1984</year>; <volume>69</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>8</lpage>. <?supplied-pmid 6367336?><pub-id pub-id-type="pmid">6367336</pub-id></mixed-citation></ref><ref id="pone.0212785.ref142"><label>142</label><mixed-citation publication-type="journal"><name><surname>van de Ven</surname><given-names>LL</given-names></name>, <name><surname>Franke</surname><given-names>CL</given-names></name>, <name><surname>Koehler</surname><given-names>PJ</given-names></name>. <article-title>Prophylactic treatment of migraine with bisoprolol: a placebo-controlled study</article-title>. <source>Cephalalgia</source>
<year>1997</year>; <volume>17</volume>(<issue>5</issue>):<fpage>596</fpage>&#x02013;<lpage>599</lpage>. <pub-id pub-id-type="doi">10.1046/j.1468-2982.1997.1705596.x</pub-id>
<?supplied-pmid 9251876?><pub-id pub-id-type="pmid">9251876</pub-id></mixed-citation></ref><ref id="pone.0212785.ref143"><label>143</label><mixed-citation publication-type="journal"><name><surname>Vilming</surname><given-names>S</given-names></name>, <name><surname>Standnes</surname><given-names>B</given-names></name>, <name><surname>Hedman</surname><given-names>C</given-names></name>. <article-title>Metoprolol and pizotifen in the prophylactic treatment of classical and common migraine. A double-blind investigation</article-title>. <source>Cephalalgia</source>
<year>1985</year>; <volume>5</volume>(<issue>1</issue>):<fpage>17</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1046/j.1468-2982.1985.0501017.x</pub-id>
<?supplied-pmid 3986895?><pub-id pub-id-type="pmid">3986895</pub-id></mixed-citation></ref><ref id="pone.0212785.ref144"><label>144</label><mixed-citation publication-type="journal"><name><surname>Weber</surname><given-names>RB</given-names></name>, <name><surname>Reinmuth</surname><given-names>OM</given-names></name>. <article-title>The treatment of migraine with propranolol</article-title>. <source>Neurology</source>
<year>1971</year>; <volume>21</volume>:<fpage>404</fpage>&#x02013;<lpage>405</lpage>.</mixed-citation></ref><ref id="pone.0212785.ref145"><label>145</label><mixed-citation publication-type="journal"><name><surname>Wideroe</surname><given-names>TE</given-names></name>, <name><surname>Vigander</surname><given-names>T</given-names></name>. <article-title>Propranolol in the treatment of migraine</article-title>. <source>Br Med J</source>
<year>1974</year>; <volume>2</volume>(<issue>5921</issue>):<fpage>699</fpage>&#x02013;<lpage>701</lpage>. <?supplied-pmid 4604977?><pub-id pub-id-type="pmid">4604977</pub-id></mixed-citation></ref><ref id="pone.0212785.ref146"><label>146</label><mixed-citation publication-type="journal"><name><surname>Worz</surname><given-names>R</given-names></name>, <name><surname>Reinhardt-Benmalek</surname><given-names>B</given-names></name>, <name><surname>Foh</surname><given-names>M</given-names></name>, <name><surname>Grotemeyer</surname><given-names>KH</given-names></name>, <name><surname>Scharafinski</surname><given-names>HW</given-names></name>. [<article-title>Prevention of migraine using bisoprolol. Results of a double-blind study versus metoprolol</article-title>]. <source>Fortschr Med</source>
<year>1992</year>; <volume>110</volume>(<issue>14</issue>):<fpage>268</fpage>&#x02013;<lpage>272</lpage>. <?supplied-pmid 1351025?><pub-id pub-id-type="pmid">1351025</pub-id></mixed-citation></ref><ref id="pone.0212785.ref147"><label>147</label><mixed-citation publication-type="journal"><name><surname>Nair</surname><given-names>KG</given-names></name>. <article-title>A pilot study of the value of propranolol in migraine</article-title>. <source>J Postgrad Med</source>
<year>1975</year>; <volume>21</volume>(<issue>3</issue>):<fpage>111</fpage>&#x02013;<lpage>113</lpage>. <?supplied-pmid 1107526?><pub-id pub-id-type="pmid">1107526</pub-id></mixed-citation></ref><ref id="pone.0212785.ref148"><label>148</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>J</given-names></name>. <article-title>Clinical study of topiramate in preventing migraine attacks</article-title>. <source>Sichuan Medical Journal</source>
<year>2009</year>; <volume>30</volume>(<issue>1</issue>):<fpage>119</fpage>.</mixed-citation></ref><ref id="pone.0212785.ref149"><label>149</label><mixed-citation publication-type="journal"><name><surname>Ziegler</surname><given-names>DK</given-names></name>, <name><surname>Hurwitz</surname><given-names>A</given-names></name>, <name><surname>Preskorn</surname><given-names>S</given-names></name>, <name><surname>Hassanein</surname><given-names>R</given-names></name>, <name><surname>Seim</surname><given-names>J</given-names></name>. <article-title>Propranolol and amitriptyline in prophylaxis of migraine. Pharmacokinetic and therapeutic effects</article-title>. <source>Arch Neurol</source>
<year>1993</year>; <volume>50</volume>(<issue>8</issue>):<fpage>825</fpage>&#x02013;<lpage>830</lpage>. <?supplied-pmid 8352668?><pub-id pub-id-type="pmid">8352668</pub-id></mixed-citation></ref><ref id="pone.0212785.ref150"><label>150</label><mixed-citation publication-type="journal"><name><surname>Gong</surname><given-names>X</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>. <article-title>Therapeutic effect of metoprolol tartrate combined with flunarizine on migraine in the treatment of migraine</article-title>. <source>Journ of Integrative Medicine, Cardiovascular and Cerebrovascular Diseases</source>
<year>2016</year>; <volume>25</volume>(<issue>14</issue>):<fpage>24</fpage>&#x02013;<lpage>2957</lpage>.</mixed-citation></ref><ref id="pone.0212785.ref151"><label>151</label><mixed-citation publication-type="journal"><name><surname>Ke</surname><given-names>D</given-names></name>. <article-title>Sibiling combined with propranolol to treat migraine</article-title>. <source>Modern Practical Medicine</source>
<year>2003</year>; <volume>15</volume>(<issue>12</issue>):<fpage>760</fpage>.</mixed-citation></ref><ref id="pone.0212785.ref152"><label>152</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>P</given-names></name>. <article-title>Double-blind therapeutic effect of &#x000e2;-blockers on menopausal migraine</article-title>. <source>Chinese Journal of Practical Nervous Diseases</source>
<year>2006</year>; <volume>9</volume>(<issue>5</issue>):<fpage>120</fpage>&#x02013;<lpage>121</lpage>.</mixed-citation></ref><ref id="pone.0212785.ref153"><label>153</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>S</given-names></name>. <article-title>Therapeutic effect of sodium valproate on prevention of migraine recurrence</article-title>. <source>Sichuan Medical Journal</source>
<year>2004</year>; <volume>25</volume>(<issue>4</issue>):<fpage>416</fpage>.</mixed-citation></ref><ref id="pone.0212785.ref154"><label>154</label><mixed-citation publication-type="journal"><name><surname>Ma</surname><given-names>W</given-names></name>. <article-title>Therapeutic effect of metoprolol tartrate combined with flunarizine on migraine in the treatment of migraine</article-title>. <source>Modern Practical Medicine</source>
<year>2011</year>; <volume>23</volume>(<issue>11</issue>):<fpage>1275</fpage>&#x02013;<lpage>1276</lpage>.</mixed-citation></ref><ref id="pone.0212785.ref155"><label>155</label><mixed-citation publication-type="journal"><name><surname>Wen</surname><given-names>JB</given-names></name>. <article-title>Clinical effect analysis of sibelium prophylactic treatment of migraine</article-title>. <source>Contemporary Medicine</source>
<year>2016</year>; <volume>22</volume>(<issue>6</issue>):<fpage>141</fpage>.</mixed-citation></ref><ref id="pone.0212785.ref156"><label>156</label><mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>G</given-names></name>. <article-title>Observation on the efficacy of propranolol in preventing menopausal migraine</article-title>. <source>Chinese Journal of Misdiagnosis</source>
<year>2006</year>; <volume>6</volume>(<issue>24</issue>):<fpage>4760</fpage>&#x02013;<lpage>4761</lpage>.</mixed-citation></ref><ref id="pone.0212785.ref157"><label>157</label><mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>Y</given-names></name>. <article-title>The effect of metoprolol combined with fluoxetine on preventing migraine and its effect on serotonin</article-title>. <source>Chinese Journal of Modern Drug Application</source>
<year>2016</year>; <volume>10</volume>(<issue>6</issue>):<fpage>109</fpage>&#x02013;<lpage>110</lpage>.</mixed-citation></ref><ref id="pone.0212785.ref158"><label>158</label><mixed-citation publication-type="journal"><name><surname>Yuan</surname><given-names>Q</given-names></name>, <name><surname>Lu</surname><given-names>X</given-names></name>. <article-title>Preliminary randomized controlled trial of topiramate and propranolol to prevent migraine attacks</article-title>. <source>Huaxi Pharmaceutical Journal</source>
<year>2005</year>; <volume>20</volume>(<issue>2</issue>):<fpage>182</fpage>&#x02013;<lpage>183</lpage>.</mixed-citation></ref><ref id="pone.0212785.ref159"><label>159</label><mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>J</given-names></name>, <name><surname>Zhu</surname><given-names>Y</given-names></name>, <name><surname>Zheng</surname><given-names>W</given-names></name>, <name><surname>Chen</surname><given-names>Y</given-names></name>, <name><surname>Lin</surname><given-names>L</given-names></name>, <name><surname>Tian</surname><given-names>X</given-names></name>. <article-title>The efficacy of metoprolol combined with fluoxetine in preventing migraine</article-title>. <source>Journal of Clinical and Experimental Medicine</source>
<year>2015</year>; <volume>14</volume>(<issue>10</issue>):<fpage>836</fpage>&#x02013;<lpage>839</lpage>.</mixed-citation></ref><ref id="pone.0212785.ref160"><label>160</label><mixed-citation publication-type="journal"><name><surname>Zhu</surname><given-names>J</given-names></name>, <name><surname>Wei</surname><given-names>Q</given-names></name>, <name><surname>Yan</surname><given-names>T</given-names></name>. <article-title>Therapeutic effect of sibelium on migraine</article-title>. <source>Journal of Medical Forum</source>
<year>2005</year>; <volume>26</volume>(<issue>1</issue>):<fpage>51</fpage>&#x02013;<lpage>52</lpage>.</mixed-citation></ref><ref id="pone.0212785.ref161"><label>161</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>Z</given-names></name>, <name><surname>Li</surname><given-names>X</given-names></name>, <name><surname>Xiong</surname><given-names>X</given-names></name>. <article-title>A clinical study of Sibelium combining Topiramate in prophylactic treatment of migraine</article-title>. <source>Chinese Journal of Primary Medicine and Pharmacy</source>
<year>2002</year>; <volume>19</volume>(<issue>5</issue>):<fpage>419</fpage>&#x02013;<lpage>420</lpage>.</mixed-citation></ref><ref id="pone.0212785.ref162"><label>162</label><mixed-citation publication-type="journal"><name><surname>Sjaastad</surname><given-names>O</given-names></name>, <name><surname>Stensrud</surname><given-names>P</given-names></name>. <article-title>Clinical trial of a beta-receptor blocking agent (LB 46) in migraine prophylaxis</article-title>. <source>Acta Neurol Scand</source>
<year>1972</year>; <volume>48</volume>(<issue>1</issue>):<fpage>124</fpage>&#x02013;<lpage>128</lpage>. <?supplied-pmid 4401692?><pub-id pub-id-type="pmid">4401692</pub-id></mixed-citation></ref><ref id="pone.0212785.ref163"><label>163</label><mixed-citation publication-type="journal"><name><surname>Dongxiang</surname><given-names>H</given-names></name>. <article-title>Clinical trial of propranolol and amitriptyline in the treatment of migraine</article-title>. <source>Yunnan Medicine</source>
<year>2010</year>; <volume>31</volume>(<issue>5</issue>):<fpage>523</fpage>&#x02013;<lpage>525</lpage>.</mixed-citation></ref><ref id="pone.0212785.ref164"><label>164</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>Z</given-names></name>, <name><surname>Li</surname><given-names>X</given-names></name>, <name><surname>Xiong</surname><given-names>X</given-names></name>. <article-title>A clinical study of sibelium combining topiramate in prophylactic treatment of migraine</article-title>. <source>Chinese JMAP</source>
<year>2002</year>; <volume>19</volume>(<issue>5</issue>):<fpage>419</fpage>&#x02013;<lpage>421</lpage>.</mixed-citation></ref></ref-list></back></article>